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List of abbreviations 
 
  
HBA hop bitter acids 
AA α-acids 
BA β-acids 
IAA iso-α-acids 
DHIAA dihydro-iso-α-acids 
THIAA tetrahydro-iso-α-acids 
HHIAA hexahydro-iso-α-acids 
RF riboflavin 
MBT 3-methylbut-2-ene-1-thiol 
NaBH4 sodium boron hydride 
H2/Pd-C hydrogenation/ catalyzed by Pd on carbon substrate 
e.g. exempli gratia ("for example"). 
UV ultraviolet 
1
H-NMR proton nuclear magnetic resonance 
TLC thin layer chromatography 
GC gas chromatography 
HPLC high performance liquid chromatography 
Nm nanometer 
EBC European Brewing Convention 
ASBC American Society of Brewing Chemists 
EDTA ethylenediamine tetraacetate 
MeOH methanol 
MeCN acetonitril 
ESI electrospray ionisation 
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LC-MS liquid chromatography-mass spectrometry 
ESCOP European Scientific Cooperative on Phytotherapy 
ADME Absorption – distribution – metabolism - elimination 
HL-60 cells Human promyelocytic leukemia cells 
U937 cells 
Human leukemic monocyte lymphoma cell line; macrophage-
like cell line 
IC50 
concentration of an inhibitor where the response (or binding) is 
reduced by half 
Bcl-2 B-cell lymphoma 2; family of proteins regulate apoptosis by 
controlling mitochondrial permeability 
Bax, Bad, Bid pro-apoptotic Bcl-2-family proteins 
Fas the death receptor on the surface of cells that leads to 
apoptosis 
FasL ligand of Fas; transmembrane protein that belongs to the tumor 
necrosis factor (TNF) family. 
MDAMB- 231 type of human breast carcinoma cell line 
SK-MES type of human lung carcinoma cell line 
DNA deoxyribonucleic acid 
cytochrome c small heme protein associated with inner membrane of the 
mitochondrion;  part of the electron transport chain in 
mitochondria 
GADD153 growth arrest of DNA damage-inducible gene 153 
TNF tumor necrosis factor 
TRAIL tumor necrosis factor related apoptosis inducing ligand 
SW480 cells type of human colon adenocarcinoma cell line 
SW620 type of human colon adenocarcinoma cell line 
p53 type of tumor suppressor protein which regulates the cell cycle 
and is involved in preventing cancer.  
Mcl-1 induced myeloid leukemia cell differentiation protein. Bcl-2 
family protein, regulating cell apoptosis. 
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MAPKs mitogen-activated protein kinases 
JNK Jun N-terminal kinase 
ERK extracellular signal-regulated kinase 
p38 class of mitogen-activated protein kinases that are responsive 
to stress stimuli and are involved in cell differentiation, 
apoptosis and autophagy. 
PFT-α pifithrin-α. p53 inhibitor 
RNA ribonucleic acid 
G0 resting phase of cell-division cycle 
G1  cell increase growth phase of cell-division cycle 
TPA 12-O-tetradecanoylphorbol-13-acetate 
TNF-α tumor necrosis factor alpha 
K562 human immortalised myelogenous leukemia line 
HEL cells human erythroleukemia cell line 
KU812 cells human leukemic cell line 
THP-1 cells human acute monocytic leukemia cell line 
ML-1 cells human myeloblastic leukemia cell line 
CAMs chick embryo chorioallantoic membranes 
ED50 the median dose of a drug that produces a quantal effect (all or 
nothing) in 50% of the population that takes it. 
KOP2.16 cells murine endothelial cell line 
bFGF basic fibroblast growth factor 
VEGF vascular endothelial growth factor 
Co26 cells murine transplantable colon cancer model 
HUVEC Human umbilical vein endothelial cells 
NO nitric oxide 
iNOS inducible nitric oxide synthase 
LPS lipopolysaccharide 
IFN-γ interferon-γ cytokine, critical for innate and adaptive immunity 
against viral and intracellular bacterial infections and for tumor 
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control. important activator of macrophages. 
mRNA messenger ribonucleic acid 
COX-2 cyclooxygenase-2 or prostaglandin-endoperoxide synthase 2 
enzyme that converts arachidonic acid to prostaglandin 
endoperoxide H2. 
PGE2 prostaglandin E2 
RAW264.7 type of mouse macrophage cell line 
IKKβ subunit of the IκB kinase (IKK) enzyme complex that is involved 
in propagation of the cellular response to inflammation 
NF-κB the transcription factor nuclear factor-kappaB (NF-κB). Plays 
critical roles in inflammation, control of cell death pathways and 
cell proliferation. 
ERK1/2 extracellular signal-regulated protein kinases 1 and 2. Members 
of the mitogen-activated protein kinase super family that can 
mediate cell proliferation and apoptosis 
CRE cAMP response element for CREB  
cAMP Cyclic adenosine monophosphate. Is a second messenger 
used for intracellular signal transduction 
CREB  cAMP response element-binding protein. Is a cellular 
transcription factor. It binds to certain DNA sequences called 
CRE, thereby increasing or decreasing the transcription of the 
downstream genes 
GSK3 glycogen synthase kinase 3 (GSK-3). Is a serine/threonine 
protein kinase that mediates the addition of phosphate 
molecules onto serine and threonine amino acid residues. 
SB216763 synonym: 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-
pyrrole-2,5-dione. Is a potent and selective ATP-competitive 
inhibitor of the GSK-3 α and β isozymes.  
RANKL receptor activator of nuclear factor kappa-B ligand 
TRAP tartrate-resistant acid phosphatase 
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IL-1β interleukin-1 beta (IL-1β). Member of the interleukin 1 cytokine 
family. Is a cytokine protein. Important mediator of the 
inflammatory response, and involved in a variety of cellular 
activities, including cell proliferation, differentiation, and 
apoptosis.  
MMP-13 matrix metallopeptidase 13. Member of the matrix 
metalloproteinase (MMP) family which are involved in the 
breakdown of extracellular matrix in normal physiological 
processes. 
SW1353 cells human bone chondrosarcoma, fibroblast-like cell line 
IκB inhibitory kappaB binding proteins of mammalian NF-κB 
transcription factor  
p65 nuclear factor NF-kappa-B p65 subunit. Part of the p50/p65 
heterodimer, which is the most abundant form of NF-κB 
PI3K phosphatidylinositide 3-kinase. Member of a family of enzymes 
involved in cellular functions such as cell growth, proliferation, 
differentiation, motility, survival and intracellular trafficking, 
which in turn are involved in cancer. 
Akt protein kinase B. Is a serine/threonine-specific protein kinase 
that plays a key role in multiple cellular processes such as 
glucose metabolism, apoptosis, cell proliferation, transcription 
and cell migration. 
CYP-450 cytochrome P450 superfamily. Are the major enzymes involved 
in drug metabolism and bioactivation. 
ACF aberrant cryptic foci. Clusters of abnormal tube-like glands in 
the lining of the colon and rectum.  
DMBA 7,12-dimethylbenz[α]anthracene 
ID50 the median dose that causes 50% inhibition 
TxA2 thromboxane A2 
COX-1 cyclooxygenase-1. Constitutive isozyme of the cyclooxygenase 
14 
 
enzyme in the biosynthetic pathway to prostaglandins from 
arachidonic acid 
MC3T3-E1 cells osteoblast precursor cell line 
PBMC human peripheral blood mononuclear cells 
FCS fecal calf serum 
ip intraperitoneal 
PBS phosphate-buffered saline 
DMSO dimethylsulfoxide 
WOMAC Western Ontario and McMaster Universities Arthritis Index. 
Proprietary set of standardized questionnaires used by health 
professionals to evaluate the condition of patients with 
osteoarthritis of the knee and hip, including pain, stiffness, and 
physical functioning of the joints. The WOMAC has also been 
used to assess back pain, rheumatoid arthritis and 
fibromyalgia.  
VAS visual analog ue scale. Psychometric response scale which can 
be used in questionnaires. 
PPARs peroxisome proliferator-activated receptors. Group of nuclear 
receptor proteins that function as transcription factors 
regulating the expression of genes which play essential 
roles in the regulation of cellular differentiation, development, 
and metabolism, and tumorigenesis of higher organisms. 
PPAR-α α-subtype of PPAR 
PPAR-γ γ-subtype of PPAR 
HepG2 cells human liver carcinoma cell line. In vitro model for polarized 
human hepatocytes 
CV-1 cells normal African green monkey kidney fibroblast cells  
GAL-4 yeast transcription factor. Archetypal transcription factor 
isolated as an activator of the genes for galactose metabolism 
15 
 
in Saccharomyces cerevisiae  
PPRE PPAR response element 
COS1L2A cells transformed (Simian Virus 40) African green monkey kidney 
fibroblast cells; derived from CV-1 cells 
KK-A
y
 mice mice with non-insulin dependent diabetes. Widely used as an 
experimental model for type 2 diabetes mellitus. 
ACO acyl-coenzyme A oxidase. Enzyme participating in fatty acid 
metabolism, polyunsaturated fatty acid biosynthesis, and PPAR 
signaling pathway. 
FAT fatty acid translocase. Long chain fatty acid transporter present 
at the plasma membrane 
ADRP adipose differentiation related protein 
LPL lipoprotein lipase 
C57BL/6N mice diet-induced obese diabetic mice 
HDL high density lipoprotein.  Enables lipids like cholesterol and 
triglycerides to be transported within the water-based 
bloodstream 
ACS acyl-Coenzyme A synthetase. Involved in metabolism of carbon 
sugars, catalyzing the formation of  acetyl-coenzyme A 
FATP fatty acid transport protein 
hemoglobin A1c glycosylated hemoglobin 
BMI Body Mass Index 
CNS central nervous system 
GABA γ-aminobutyric acid 
EPM test Elevated Plus Maze test 
E. coli. Escherichia coli 
L. monocytogenes Listeria monocytogenes 
MIC minimum inhibitory concentration 
ROS reactive oxygen species 
DPPH 2,2-diphenyl-1-picrylhydrazyl 
16 
 
RSA radical scavenging activities 
LIA lipid peroxidation inhibitory activity 
FRAP ferric-reducing ability of plasma 
TRAP total radical trapping by anti-oxidants 
GRAS generally recognized as safe 
LD50 median lethal dose for 50% of subjects 
NOAEL no-observed-adverse-effect level 
8-PN 8-prenylnaringenin 
IsoX isoxanthohumol 
Cmax maximum concentration 
Tmax time to reach the maximum concentration 
AUC area-under-the-curve 
MDR1 multidrug resistance protein 1 also known as P-glycoprotein 1 
PXR human nuclear xenobiotics pregnane X receptor 
Caco-2 human epithelial colorectal adenocarcinoma cells 
P-gp phospho-glycoprotein 
SLC solute-carrier superfamily 
ABC ATP-binding cassette 
MRP multidrug resistance associated protein 
BCRP breast cancer resistance protein 
ATP Adenosine-5'-triphosphate 
Papp apparent permeability coefficient 
L-DOPA L-3,4-dihydroxyphenylalanine 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HBSS Hank’s balanced salt solution 
TEER transepithelial electrical resistance 
FBS fetal bovine serum 
DMEM Dulbecco’s Modified Eagle Medium 
HCOOH formic acid 
AP apical 
17 
 
BL basolateral 
EtOAc ethyl acetate 
EtOH ethanol 
AP-to-BL apical-to-basolateral transport 
BL-to-AP basolateral-to-apical transport 
CMFDA 5-chloromethylfluorescein diacetate 
H3PO4 phosphoric acid 
NaOAc sodium acetate 
H. pomatia Helix pomatia 
ER efflux ratio 
ANOVA one-way analysis of variance 
APCI atmospheric pressure chemical ionization 
UV/VIS ultraviolet/visible 
SIM selected-ion monitoring 
LOD limit of detection 
LOQ limit of quantification 
RSD relative standard deviation 
S/N signal-to-noise-ratio 
%RE percentage relative error 
logD octanol/water distribution coefficient 
clog P calculated log octanol/water partition coefficient 
PK pharmacokinetic 
ILVO Institute for Agricultural and Fisheries Research 
t1/2 half life 
HED human equivalent dose 
Km factor based on the ratio of the body weight (kg) and body surface 
area (m²) of a species. 
BSA body surface area 
S9 fraction defined by the U.S. National Library of Medicine's "IUPAC 
Glossary of Terms Used in Toxicology" as the "Supernatant 
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fraction obtained from an organ (usually liver) homogenate by 
centrifuging at 9000 g for 20 minutes in a suitable medium; this 
fraction contains cytosol and microsomes. 
Tris-HCl buffer buffer based on hydrogen chloride salt of 
tris(hydroxymethyl)aminomethane 
NADPH nicotinamide adenine dinucleotide phosphate  
NRS  NADPH-regenerating system  
G6P glucose-6-phosphate 
β-NADP
+
 nicotinamide adenine dinucleotide phosphate ion 
G6PDH glucose-6-phosphate dehydrogenase 
MgCl2 magnesium chloride 
MRM multimode reaction monitoring 
TIC total ion chromatogram 
EIC extracted ion chromatogram 
FDA US Food and Drug Administration 
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I. Literature Review 
 
1.1 History of hop and beer  
 
The history of farming and cultivation of the hop plant (Humulus lupulus L.) is highly 
connected to beer brewing and goes back to the ancient times. Historical artifacts of beer 
brewing date even back to 7000 B.C. in Babylon,1 the remains of the city present day known 
as Al-Hillah in Iraq. Even the ancient Egyptians prepared beer from malted barley and a 
primitive type of wheat.2 The first written proof on the use of hops dates back to the first 
century as depicted by Plinius the Elder (23-79 A.D.). In his encyclopedic collection 
“Naturalis Historia”, hop was mentioned as a garden plant that was used for the consumption 
of the young shoots. He described hop as “lupus salictarius” (or “the wolf of the willow”), 
because of the comparison of the strangling growth of wild hops among willows and the 
destructive behavior of wolfs towards sheep.3, 4 From this Latin term, the latter botanical 
name Humulus lupulus was derived.  
Although expertise on the brewery techniques passed on from the ancient 
civilizations to the Greeks and Romans, their preferred drink however was wine. In fact, beer 
and the development of brewing was more linked to the culture of the Celtic and Germanic 
agrarian population of Northern and Central Europe in the medieval and early modern 
period. Fortunately, following tradition, the medieval monks (8th - 9th century) kept a 
comprehensive collection of written proofs of their activities. As a result we now know that 
the cultivation of hops started in Germany (Freising, Bavaria), where monasteries and 
cloisters were often surrounded by large hop gardens and hops were principally used for 
medicinal purposes.5 In particular, hop preparations were mainly recommended for the 
treatment of sleeping disorders, as a mild sedative, liver/bile disorders, and for the activation 
of gastric function as bitter stomachic.6, 7  
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Since education and scientific research was only reserved for the monks, it was there 
that experimental use of hops in beer brewing started, as an antiseptic and flavoring agent. 
One of the first documented evidences was recovered in the statutes of the abbot from the 
monastery of Corvey on the river Weser (North Rhine-Westphalia, Germany).8 In fact, at the 
beginning, hop was utilized as an alternative to Myrica gale (bog myrtle or sweet gale), 
which at that time was the established beer additive in Europe, where it was native. The 
common name for this beer agent was called ‘gruit’ or ‘gruut’ in the Netherlands and 
Northern Germany, where the trade of ‘gruut’ was a royal business in the medieval time. 
Remarkably, Hildegard von Bingen (1098-1179) was against the use of hops for making 
beer and recommended the use of ‘gruut’ instead (in combination with other aromatic herbs) 
to flavor beer. During the medieval period, there was a strong competition between both 
types of beer (based on hops and on sweet gale), but due to its lower shelf life resulting from 
microbiological instability, beer made from sweet gale was not really suited for long-distance 
transportation. This important feature boosted the hop flavored beer and the use of H. 
lupulus overcame that of M. gale due to its better preserving property.9 As a consequence, 
hop beer export became more important but also hop cultivation followed this export through 
the whole of Europe for use in local brewing. From that moment, the decline of gruut beer 
was inevitable, while in the 18th century, it was even thought to be poisonous and production 
of sweet gale beer was forbidden in Germany.  
As a protectionism measure, William IV, Duke of Bavaria, adopted in 1516, the 
Reinheitsgebot (purity law), in which it was stipulated that the only allowed ingredients of 
beer were water, hops, and barley-malt.10 Later, when the knowledge on fermentation was 
established by Pasteur, yeast was added to this list. Although, this food-quality regulation 
was abandoned in 1987 following a European Commission decree, it is still in use until today 
among German brewers to maintain their position in the German market.  
In the time of the medieval monks, the fermentation of sugars to ethanol and carbon 
dioxide in the process of brewing took place spontaneously. The first observations of yeast 
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cells were reported in the 17th century by Antonie van Leeuwenhoek (1632-1723). Later, in 
the 19th century, a real breakthrough in this field was achieved by the publication of L. 
Pasteur’s “Etudes sur la bière”. Essential in this work was the discovery of yeast as a 
microorganism which applied fermentation of sugars as an energy source for growing 
(instead of sunlight).11 In addition to this, the progress of the brewing scientist Emil Christian 
Hansen from the Carlsberg brewery (Denmark) was crucial for modern brewing industry. In 
1883, he obtained several pure yeast cultures and selected especially the strain 
“Saccharomyces carlsbergensis” for the production of pilsner beers, which is still in use 
today.12 This concept was soon applied in practical brewing, proving of major importance in 
standardizing yeasts for reliable fermentations. By selection of the most appropriate yeast 
strains for beer brewing, reproducible beers could be produced.  
During the 19th century, the industrial revolution, and the related population growth, 
income rise and increased consumption provoked the transition of artisanal domestic 
brewing to industrial brewing. The development of hydrometers and thermometers 
introduced process control during brewing.13 During the 20th century, the scientific 
knowledge on malting and brewing flourished and, as a result, the modern brewing industry 
applies a whole spectrum of novel technical, biochemical, microbiological, and genetic 
inventions.14  
Today, the brewing industry is a global business, consisting of several dominant 
multinationals and many thousands of smaller regional and local breweries and brewpubs. 
The fusion between Interbrew (Belgium) and AmBev (Brazil) (2004) forming InBev and, more 
recently, the fusion with Anheuser-Bush to form AB InBev (2009), makes this company now 
the biggest  brewer in the world.  On the opposite hand, nowadays, there is an upcoming 
trend in the establishment of local breweries in many countries producing specific beers that 
increase consumer’s options. Despite the global success of InBev, beer consumption is 
decreasing in Belgium, as well as in most European countries.  
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This modern time, the hop plant (Humulus lupulus L.) is an essential ingredient in beer and 
about 95% of world-wide cultivated hops is destined for brewing purposes, while the 
remaining fraction is nowadays used in fully developing new markets, such as the domain of 
phytopharmaceuticals and dietary supplements. Also, particularly in Belgium, shoots of hop 
plants are served as a delicacy, though prices are expensive.5 
 
1.2 Phytogeography of hop 
 
The genus Humulus belongs to the Cannabinaceae family, which consists of three 
species: H. lupulus Linnaeus, H. japonicus Siebold & Zucc. And H. yunnanensis Hu.15, 16 The 
origin of the genus has been suggested to be in China, since all of the Humulus species 
were found in this area. From China, an advancing eastward migration to Japan and 
America and a migration to the west to Europe could be responsible for the actual 
distribution of the Humulus species.16-18 Successful cultivation of hops requires optimal 
growth conditions, especially with respect to the length of daylight, the summer temperature, 
the amount of rain, and the fertility of the soil. Therefore, hops are found in the moderate 
climatic zones of the Northern and Southern hemispheres, with Germany and the United 
States by far the largest producing countries.19-22 The farming of hops for long times has 
caused the existence of hundreds genetically close cultivars.16 The major reason was the 
need for hop plants delivering specific organoleptic properties to improve the flavor and the 
aroma of beer. As a result, cultivars with an increased content in volatile oil and bitter acids 
have been selected throughout the years.23 
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1.3 Botanical description of hop 
 
  
Figure 1.1 Humulus lupulus L. Figure 1.2 Hop field. 
 
 
The hop plant (Humulus lupulus L.) is a dioecious perennial climbing plant 
characterized by a very fast growth each spring from the rhizomes of an underground 
rootstock. Each autumn and winter, the annual parts from aboveground of the plant die, 
though the plant has a fair resistance to frost thanks to an extended root system which 
burrows deep into the ground. Every year in spring, numerous shoots sprout from the 
remaining expanding rootstock, from which new plants can develop. Hop can grow 
amazingly fast, sometimes growing up to 30 cm per day and can reach heights from 6 up to 
8 m. The climbing plant is grown in a hop field, trained up wires which support the plants and 
allow them significantly greater growth with the same sunlight profile. The stem is rough, 
hexagonal squared, and swings clockwise around trees and other supports, attached by fine 
two-pointed hairs. The leaves of the hop plant are rough, dark green, heart-shaped with a 
long stalk and finely toothed edges. The leaves can grow up to 15 cm long, are singular, 
cross-opposed, with a hand-shaped nervure and they possess little supportive leaves that 
are single-lobed.  
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Figure 1.3 Inflorescences on the male 
plant of Humulus lupulus L. 
Figure 1.4 Hop cones on the female plant of 
Humulus lupulus L. 
 
During the blooming period, in July and August, the flowers spring from the axils of 
the leaves. Although individual monoecious plants are frequently found in some wild North-
American hop populations, hop is known as a dioecious plant. Accordingly, unisexual male 
and female flowers grow on separate plants. The male plants carry small inflorescence, 
while the flowers of the female plants develop into greenish-yellow, hop cones called 
strobiles that are formed of membranous partially overlapping scales (bracts and 
bracteoles). This morphological difference between male and female flowers is the only 
morphological characteristic to distinguish and identify the sex of the plant.22  
At the end of the summer or the beginning of autumn, the female inflorescence has 
reached ripening and can be harvested as ovoid, greenish hop cones. The inside of the 
bract and the bracteoles contains oleoresin glands that appear as small yellow-orange 
granules and constitute lupulin,22, 24, 25 a resinous, yellow-orange powder. Lupulin contains 
numerous compounds that are of economic interest especially in the beer brewing industry 
and, therefore, only the female hop plants are being cultivated.  
In some hop growing areas, particularly in England, male plants are cultivated 
together with the females in order to produce seeds in the hop cones following pollination 
and to improve crop yields.  However, in other global parts, it is forbidden to cultivate a male 
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plant in vicinity of females. In Belgium, wild males must be removed within 5 km from a 
female plant, because fertilized hop cones contain hard greasy seeds which adversely affect 
beer quality.21, 26, 27 Especially the fats and fatty acids have a bad influence on the beer foam. 
At harvest, the hop cones have a moisture content of 75-80 %. In order to prevent 
deterioration during storage or processing, drying of the hop cones is necessary to reduce 
the water content below 12%. This step, achieved by hot air dryers, is very critical with 
respect to the hop quality, since higher temperatures, especially above 65°C, may 
accelerate oxidative decomposition of major constituents. Dried hops are recommended to 
be stored at low temperature prior to processing or further use.16, 22 
The bitter and aroma components in the hop cones are very sensitive to oxidation. 
For this reason, the hop plant is frequently processed into more stable products, such as 
non-isomerized supercritical or liquid carbon dioxide extracts, distilled hop oil fractions, and 
potassium solutions of pre-isomerized hop acids that can be directly added to the brewing 
kettle (non-isomerized and pre-isomerized non-purified products) or post-fermentation (hop 
oils and pre-isomerized purified products).1, 28, 29 Hop extracts and hop oil fractions are also 
used as flavoring products in non-alcoholic beverages and foods.24 
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1.4 Chemistry of hop 
 
Female hop cones contain glandular structures in which lupulin powder is secreted (a 
yellow and sticky powder), in which a variety of secondary metabolites can be identified. 
Nagel et al. used microscopic techniques to visualize the morphology of hop cones and 
lupulin glands (Figure 1.5).30 The typical composition of air dried hops is presented in Table 
1.1.21, 22  
 
 
Figure 1.5 Morphology of hop cones and lupulin glands. A: Cones of hop cultivar Taurus 
(cones are ∼5 cm in length). B: Longitudinal cross-section of a hop cone showing lupulin 
glands at the base of bracteoles. C: A light-microscopy image of ripe lupulin glands. D: 
Scanning electron micrograph of a ripe lupulin gland showing the peaked appearance of the 
filled subcuticular sac. 
30
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Table 1.1 Composition of air-dried hops. 
 
Compounds % (m/m) 
α-acids 2-19 
β-acids 2-10 
amino acids 0.1 
ash/salts 10 
cellulose-lignin 40-50 
monosaccharides 2 
oils and fatty acids 1-5 
pectins 2 
polyphenols and tannins 3-6 
proteins 15 
volatile oil 0.4-3.4 (v/m) 
water 8-12 
 
Among the hundreds of compounds, the bitter acids, the volatile essential oil, and the 
polyphenols can be classified as the most important constituents31 both as chemical markers 
to support type differences in hop varieties and for the commercial use of hops. A schematic 
description of the composition of hops is presented in Figure 1.6. 
 
Figure 1.6 Composition of hops. 
Hop 
Hop acids 
α-acids 
orhumulones  
β-acids or lupulones 
Hop essential oil 
hydrocarbon 
terpenoids 
oxygen- and sulfur- 
containing 
compounds 
Polyphenols 
phenolic acids, 
tannins, flavanols, 
prenylflavonoids 
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1.4.1 Hop essential oil 
 
The essential or volatile hop oil consists mainly of a hydrocarbon terpenoid fraction 
such as the monoterpene β-myrcene (30-50%), and the sesquiterpenes humulene, β-
caryophyllene, and farnesene (40-80%).16, 21, 32, 33 Some of the major compounds are 
depicted in Figure 1.7. Due to the susceptibility of terpenoids to oxidation, significant 
fractions of oxygenated products can be found as a result of post-harvest handling and 
storage.33 These include alcohols (linalool, geraniol), acids (2-methylbutyric acid, 3-
methylbutyric acid), and esters (2-methylpropylisobutyrate, 2-methylbutylisobutyrate) in 
combination with aldehydes, ketones, and epoxides.21 
 
Figure 1.7 Terpenoids and oxygenated derivatives in hop essential oil. 1. humulene, 2. β-
caryophyllene, 3. farnesene, 4. β-myrcene, 5. α-pinene, 6. limonene, 7. linalool, 8. geraniol, 9. 2-
methylbutyric acid, 10. 2-methylpropylisobutyrate. 
 
Among all constituents in hop essential oil, less than 1% accounts for organosulfur 
compounds including thiols, sulfides, polysulfides, thioesters, thiophenes, and episulfides. 
Either their origin is from the plant itself (for tissue repair purposes) or they can be formed 
as a result of the spraying of sulfur-containing fungicides during farming. Moreover, it is 
unclear how many of such organosulfur compounds are formed after harvest as a result of 
drying and storage.  
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1.4.2 Hop polyphenols 
 
Polyphenols (Figure 1.7) in hop include phenolic acids, flavonol glycosides, tannins, 
together with a number of prenylated chalcones, such as xanthohumol and 
desmethylxanthohumol. These latter ones are precursors of the isomeric flavanones 
isoxanthohumol (main prenylflavonoid present in beer) and 8-prenylnaringenin, along with 6-
prenylnarigenin, respectively. 
 
Figure 1.8 Hop-derived prenylflavonoids. 1’: xanthohumol; 2’: isoxanthohumol; 3’: 
desmethylxanthohumol; 4’: 8-prenylnaringenin; 5’: 6-prenylnaringenin. 
 
 
1.4.3. Hop bitter acids 
 
Hop bitter acids consist of two related series, the α-acids (or humulones) and the β-
acids (or lupulones), which are both characterized as prenylated phloroglucinol derivatives 
(Figure 1.8). These compounds occur as pale yellowish oils (or so-called soft resins) that are 
soluble in hydrocarbon solvents, such as hexane. Depending on the nature of the acyl side 
chain, five analogues can be identified: isovaleroyl in n-, isobutyroyl in co-, 2-methylbutyroyl 
in ad-, isohexanoyl in pre-, and propanoyl in post-bitter acids.  
1’ 2’ 
3’ 4’ 5’ 
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Figure 1.9 Chemical structures of hop α-acids (1’) and β-acids (2’). 
 
The relative amounts of α-acids and β-acids, as well as the concentrations of 
individual representatives, depend strongly on the hop variety and the conditions of growing. 
Hop bitter acids are very sensitive to oxidation, thus forming a mixture of ill-defined products 
that are soluble in diethyl ether, but no longer in hexane (this fraction of compounds is 
referred to as hard resins). Deterioration of hops as a function of time is accompanied by the 
development of a strong odor that is generally not welcomed by brewers.26  To prevent this, 
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hops are rapidly dried after harvesting, pelleted, and stored in airtight bags, preferably at low 
temperatures. Today, next to the use of pellets, many beers are rendered bitter-tasting with 
hop extracts, which leads to the benefits of an increased utilization of brewing principles, 
increased stability, improved uniformity, and easier handling.28 
The α-acids are the most important constituents of hops, that make up to 20%  of the dry 
weight of the hop cones (Table 1.1). The weak-acidic, salt-forming, and chelating properties 
of α-acids reside in their β-triketo system. It appears that only the R-configuration at C-6 
within a fully enolized β-triketo system is formed stereoselectively in nature (Figure 1.9).22  
Only recently, the absolute structure of humulone was fully established by Urban et al. by X-
ray crystallography: the chiral center at C-6 in humulone was unequivocally assigned to be 
6S,34 contradicting the reports of De Keukeleire and Verzele in the 70’s, who determined that 
the configuration at C-6 in humulone was the R-configuration using a combination of 
chemical, spectrometric, and chiroptical techniques.35  
Determination of the composition of the α-acids mixture is important, as high levels of 
cohumulone are generally associated with a lower hop quality, although several authors 
reported that the differential contribution of the individual α-acids to the bitterness seems 
negligible.36-38 In general, the analogues n-humulone, cohumulone, and adhumulone are the 
main constituents of the hop α-acids, representing 35-70%, 20-65%, and 10-15% of the total 
levels, respectively. The pre- and post-humulones represent only a minor part of the α-acids. 
The relative amounts of n-humulone and cohumulone are depending on hop variety, while 
the amount of adhumulone is fairly constant.21 For research purposes, α-acids can be 
isolated from a hop acids mixture (e.g., a liquid carbon dioxide extract) by pH-selective 
liquid-liquid extraction (isooctane, diethyl ether)31 or by precipitation upon addition of lead(II) 
acetate, thus forming yellow-colored highly stable lead salts that can be stored for years 
without deterioration.22 The exact structure of the salts is not known, but the tertiary alcohol 
function must be involved, as the β-acids cannot form such salts. From the mixture of α-
acids, n-humulone can be isolated by complexation with 1,2-diaminocyclohexane followed 
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by repeated crystallization,39 while isolation of cohumulone and adhumulone requires further 
preparative HPLC.  
During brewing, the concentration of α-acids remaining in the final product is 
drastically reduced to reach levels of few mg/L due to several reasons including 
isomerization or other chemical reactions during wort boiling, their limited solubility in 
aqueous solutions, and adsorption on yeast cells, trub, and filter materials.40 In dry-hopped 
beers, residual concentrations of α-acids up to 14 mg/L can be present.36 The α-acids 
improve foam stability, suppress gushing, and contribute to the preservation of beer. 
However, their main contribution to beer is the isomerization during the boiling of wort with 
hops, thereby forming the iso-α-acids, the largest contributor to beer bitterness (see 
below).41 
 
The β-acids are less acidic than the α-acids, because the tertiary alcohol function at 
C-6 is replaced by an extra prenyl side chain. This difference enables separation of β-acids 
and α-acids from a hop acids mixture by pH-selective liquid-liquid extraction from a solution 
in hexane. The α-acids (pKa ~ 5.4)42 can be extracted with sodium bicarbonate, while the 
less acidic β-acids (pKa ~ 6.1)22 require a stronger base, like sodium hydroxide. In contrast 
to α-acids, two different enolization patterns prevail for each β-acid (Figure 1.8). However, 
β-acids are mostly represented in the predominant conjugated dienolic form, which 
corresponds to that of the α-acids. Most hop varieties contain approximately equal levels of 
n-lupulone and colupulone (ca. 20-55%), next to less variable levels of adlupulone (10-15%). 
Prelupulone and postlupulone are only present in trace quantities. 
Hop β-acids are extremely sensitive to oxidation, which is initiated by air (auto-
oxidation), but also during wort boiling giving rise to a number of oxidized compounds and 
derivatives.40, 43, 44 One particular and most important oxidative reaction leads to formation of 
the highly stable hulupones (Figure 1.10). In contrast to the non-bitter β-acids, hulupones 
have a very bitter taste (threshold concentration of 7.9 µmol/L) and can be present in beer in 
quantities of few mg/L. Other oxidation products reported in the literature include 
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tricycloderivatives (Figure 1.10). In comparative sensory tests, these showed bitterness 
threshold concentrations in line with their precursors or higher (37.9 – 90.3 µmol/L).44   
 
     
 
Figure 1.10 Chemical structures of hop β-acids oxidation products. a: hulupones; b: 
nortricyclolupulones; c: dehydrotricyclolupulones; d: tricyclolupulones. 
  
During the brewing process, α-acids are converted via a thermal isomerization to the 
more water-soluble iso-α-acids via an acyloin-type ring contraction, thereby yielding 
concentrations ranging from 10 up to 100 mg/L of iso-α-acids in beers. The higher solubility 
in aqueous medium is associated to their higher acidity (pKa 3.0-4.0).22 Conversion of each 
iso-α-acid analogue results in an epimeric pair of cis- and trans-isomers, where the 
stereochemical notation refers to the relative orientation of the hydroxyl at C-4 and the prenyl 
group at C-5 (Figure 1.11). Consequently, six major iso-α-acids are present in beers, the cis- 
and trans- epimers of isocohumulone, isohumulone, and isoadhumulone. According to the 
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new discoveries by Urban and co-workers, the isomerization of α-acids into iso-α-acids 
proceeds by configuration-retention of the tertiary alcohol in (6S)-humulone to the α-hydroxy 
ketone on C-4 in isohumulones.34 This is in contrast with the proposed isomerization 
mechanism found in most reports, which assume that the conserved stereocenter is on C-5, 
while cis and trans differ stereochemically at C-4. Considering that the oxygen atoms 
possess negative charges during the isomerization, one might imagine the chelation of two 
vicinal oxygen atoms to a divalent cation, a process that is known to accelerate the rate of 
isomerization, while limiting decomposition. 
 
 
 
 
 
Figure 1.11 Chemical structures of hop-derived cis- and trans-iso-α-acids.  
 
 
The ratio of cis/trans depends on the reaction conditions, but is typically 68:32 under 
normal brewing settings. The cis-isomer is thermodynamically more stable in view of the 
least steric hindrance between the two large vicinal side chains.41 Iso-α-acids can be formed 
from α-acids under a variety of conditions. During the brewing process, α-acids are 
isomerized by boiling hops or hop extracts in the aqueous wort medium at a pH of 5.0-5.5. In 
6 
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practice, a final α-acid utilization yield of only 25-35% is reached in the beer. This is also 
subject to variations, even from brew to brew. Many kinetic studies have been carried out on 
the transformation of the hop α-acids into the corresponding cis- and trans-iso-α-acids during 
the wort boiling process. 22, 45-50 The wort-boiling of α-acids follows first-order kinetics and the 
rate is influenced by the temperature, the pH, and the concentrations of divalent cations. The 
reaction can be favored by boiling α-acids in alkaline media in the presence of divalent 
cations as catalysts. Alternatively, isomerization of α-acids can be achieved by irradiation of 
a solution in methanol of α-acids with UV-light. This photo-isomerization proceeds in a fully 
regio- and stereoselective way and produces exclusively trans-isomers.51 Inter-conversion of 
cis- into trans-epimers, as well as conversion of iso-α-acids into their parent compounds, is 
feasible.22 Iso-α-acids represent well above 80% of all hop-derived components in beer. The 
high concentrations of these five-membered ring compounds in the final beverage and their 
low bitter taste thresholds support their function as major bitter agents in beer.52-55 Besides, 
they possess tensioactive properties, thereby stabilizing the beer foam, and protect beer 
against micro-organisms (preservative role).56, 57  On the other hand, iso-α-acids are key 
ingredients in the formation of the so called “lightstruck flavor” in beer. When exposed to 
light, iso-α-acids decompose via a series of excited states and radical-type intermediates to 
unpleasant smelling “skunky” thiols, mainly 3-methylbut-2-ene-1-thiol (next to 
dehydrohumulinic acid) (Figure 1.12).58, 59 This reaction is initiated by riboflavin (vitamin B2) 
as a photosensitizer, since iso-α-acids cannot absorb visible light directly.  
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Figure 1.12 Formation of the “lightstruck flavor” in beer. RF: riboflavin. MBT: 3-methylbut-2-
ene-1-thiol. 
 
Enhanced resistance to the “lightstruck flavor” is provided by the use of reduced 
derivatives of iso-α-acids. Three major types can be considered depending on the number of 
added hydrogen atoms: dihydro-, tetrahydro-, and hexahydro-iso-α-acids (Figure 1.13). They 
are formed either by hydrogenation (H2/Pd-C) or by reaction with sodium boron hydride 
(NaBH4), or by a combination of both.
60 The reduced derivatives are light-proof, and also 
more stable with respect to oxidation, thus allowing brewers to bottle beers with an 
increased shelf life. The tetrahydro-iso-α-acids (THIAA) and hexahydro-iso-α-acids (HHIAA) 
have the extra-advantage of enhancing beer foam stability.29, 41, 61  
During formation of dihydroiso-α-acids (DHIAA) and HHIAA, an additional chiral 
centre on the acyl side chain is introduced, leading to two epimeric reaction products for 
each iso-α-analogue. As a result, theoretically, the group of DHIAA and HHIAA can consist 
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of twelve stereoisomeric products.1 THIAA are formed by hydrogenation of the double bonds 
present in the side chains of IAA, thus also consisting of cis- and trans- isomeric pairs, 
leading to six stereoisomers.62, 63 Iso-α-acids and reduced derivatives are commercially 
available as aqueous solutions of their corresponding potassium salts. They can be applied 
post-wort boiling, e.g., during lagering or even just prior to bottling, since isomerization is no 
longer required.28 
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Figure 1.13 Chemical structures of reduced derivatives of iso-α-acids. IAA: iso-α-acids; DHIAA: 
dihydro-iso-α-acids; THIAA: tetrahydro-iso-α-acids; HHIAA: hexahydro-iso-α-acids. 
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Besides the formation of off-flavors occurring during light-exposure of beer, molecular 
transformations of the hop-derived iso-α-acids during beer ageing have an essential impact 
on the overall bitter taste of beer.40, 64, 65  
A rapid degradation of trans-iso-α-acid is observed, whereas the corresponding cis-
stereomers were found to be relatively stable.66-68 Detailed investigations discovered tri- and 
tetracyclic molecules (Figure 1.14) that are formed via acid-induced cyclization of trans-iso-
α-acids.64, 69, 70 Also, additional degradation products independent of the cis-/trans-
stereochemistry were found, including hydroxy- and hydroperoxy-trans-/cis-
alloisohumulones produced upon auto-oxidation involving air oxygen,71 plus formerly 
described trans-/cis-humulinic acids formed by proton-catalyzed transformations (Figure 
1.14).72, 73   
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Figure 1.14 Chemical structures of oxidized derivatives of iso-α-acids in beer: tricyclohumols 
(a), tricyclohumenes (b), isotricyclohumenes (c), tetracyclohumols (d), hydroperoxy-trans/cis-
alloisohumulones (e, f), hydroxy-trans-/cis-alloisohumulones (g, h), trans-/cis-humulinic acids 
(i, j), tricyclohumolactol, (k), and scorpiohumol (l) 
 
 
1.5 Purification and Analysis of Hop Acids  
 
Hop acids can be separated from the vegetative material by extraction with solvents 
of different polarity. Extraction with supercritical or liquid carbon dioxide yields a dark-green 
or a yellow-golden paste containing high levels of α-acids and β-acids without the more polar 
tannins, hard resins, and salts.29 This type of extract serves as a suitable material for further 
manipulations. From this, α-acids can be purified by precipitation of their lead(II) salts or by 
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liquid-liquid extraction with aqueous sodium bicarbonate, whereas β-acids need a more 
alkaline environment to be extracted (for example sodium hydroxide).22  
Iso-α-acids and reduced derivatives are commonly purified from their commercially 
available potassium salt solutions. An efficient separation of trans- and cis-iso-α-acids by 
complexation with β-cyclodextrin has been described using a molar ratio of β-cyclodextrin to 
iso-α-acids from 1:1 to 1:4.74, 75 Individual hop bitter acids are obtained from extracts by 
(semi)-preparative HPLC coupled to  detection by UV, mass spectrometry, 1H-NMR 
spectroscopy, or a combination of techniques.76-82  
A number of variables determine the final composition of hop bitter acid preparations. 
There are substantial variations in the starting material, depending on the hop variety, the 
harvest time, the growing conditions, the processing, and the storage. Furthermore, hop 
bitter acids are very sensitive to oxidation and degradation. For research purposes, it is 
therefore essential that purification and storage of these compounds is well controlled and 
the relative composition of the extracts must be frequently monitored. However, researchers 
tend to underestimate this issue, making it hard to compare results from different studies 
with the “same” compounds. The specification of the exact composition of the hop extracts 
used should be included in the reports or individual compounds could be used. Further 
information on the chemistry, preparation, and purification of hop bitter acids can be found in 
reviews by Verzele and De Keukeleire, 22 and Ting and Goldstein.62 
Due to their importance for beer bitterness, various analytical approaches were 
undertaken in the past to measure iso-α-acids. Spectrometric analysis according to a 
method of the European Brewing Convention is the most common procedure.83 Bitter units 
are calculated from the total UV-absorption at 275 nm, but detailed information on the exact 
composition of the hop-derived bitter compounds in beer samples is lacking, since this 
method is incapable of distinguishing between the individual bitter acids. To overcome this 
limitation, specific analytical methods were developed based on separation techniques such 
as countercurrent distribution.84 It gives a good separation of bitter substances, but requires 
large amounts of organic solvents and is time-consuming. Others developed thin-layer 
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chromatography (TLC) separation techniques for detection of trans- and cis-isohumulone, 
together with hulupones.85 However, the sensitivity and the resolution are insufficient.  This 
problem can be solved by the use of high-performance liquid chromatography (HPLC) and 
gas chromatography (GC). HPLC with UV-detection has been intensively used for the 
analysis of hops and beer76, 86-90 next to other techniques such as capillary electrophoresis91 
and micellar electrokinetic chromatography.92 All hop-derived bitter substances are UV-
active and demonstrate maximum molar absorption coefficients of the same order of 
magnitude as simple aromatic compounds at appropriate wavelengths (i.e., of the order of 
104). The α- and β-acids show UV-maxima at wavelengths of around 310-340 nm, while the 
iso-α-acids and reduced derivatives show UV-maxima around 250-270 nm. Nowadays, 
chromatographic separation can also be combined with sophisticated detection techniques 
based on NMR analysis 80, 93 or mass spectrometry. 78, 94-96 The latter, being more and more 
the state-of-the-art in analytical detection, in different types and configurations (single quad, 
time-of-flight, tandem…) 
 
1.5.1 Considerations regarding complexity of hop acids mixtures 
 
The hop acids (α- and β-acids) occur as a mixture of homologues and structural 
isomers, with the three major components labeled as co-, n-, and ad-homologues. The co-
species have one methylene (CH2) group less than the n- and ad-compounds, being less 
polar and readily resolved from the n- and ad-counterparts. The n- and ad-variants are 
isomers which differ only in the location of the side chain branching point, which renders the 
separation more challenging.  For quantification purposes, it is assumed that these 
compounds (including co-, n-, and ad-) show the same response factor under the 
chromatographic conditions applied.  
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This issue is even more complex in the group of iso-α-acids and derivatives due the 
fact that each α-acid gives rise to two stereoisomeric cis- and trans-iso-α-acids, varying in 
the stereochemistry of one carbon. The resolution of the 3 cis-iso-α-acids from their 3 trans-
epimers requires strictly pH-controlled mobile phases. The same applies to the 
corresponding tetrahydro-iso-α-acids (with the double bonds hydrogenated), which also 
consist of three cis- and trans-pairs, totaling six congeners. The dihydro-iso-α-acids are 
derived from the borohydride reduction of the iso-α-acids. From each iso-α-acid, two epimers 
are formed upon reduction of the carbonyl moiety to the corresponding secondary alcohol, 
so there are theoretically 12 related compounds possible. However, the trans-dihydro-iso-α-
acids are mostly absent from a dihydro-iso-α-acid preparation, probably due to the steric 
hindrance experienced by the borohydride moiety when approaching the carbonyl along the 
isopentenoyl-side chain of the trans-iso-α-acids.62 An overview of the chemical structures of 
the major hop-derived bitter acids studied in this work are shown in Fig. 1.15. Pure 
calibration standards of individual hop acids for use as external standards are not 
commercially available. One of the reasons is the inherent instability of these compounds. 
Although isolation of pure analogues of α- and β-acids should be feasible, the calibration 
standard available (Labor Veritas, Switzerland) contains only a mixture of co-, n-, and ad-
analogues of α- and β-acids and are calibrated for these compounds on a percentage (w/w) 
basis. In the case of iso-α-acids, pure trans-isohumulones can readily be prepared by 
photoisomerization of humulone,97 but decomposition occurs even when stored under 
nitrogen atmosphere at low temperature. Instead, the mixture of dicyclohexyl-ammonium 
(DCHA) salts of trans-iso-α-acids has been widely used as a reference for the quantification 
of iso-α-acids and is commercially available. Until today, a standard including the cis-
isomers is not commercially available. For the tetrahydro-iso-α-acids, a mixture of cis-and 
trans-forms of co-, n-, and ad-homologues is commercially available, while, for the dihydro-
iso-α-acids, a purified preparation of the dicyclohexyl-ammonium salts of cis-dihydro-iso-α-
acids is commercialized. 
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Fig.1.15 Molecular structures of hop-derived bitter acids. AA: α-acids, BA: β-acids, IAA: iso-α-
acids, DHIAA: dihydro-iso-α-acids, THIAA: tetrahydro-iso-α-acids. 
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1.5.2 HPLC analysis of hop-derived bitter acids mixtures 
 
An overview of the methods described in literature for the determination of α- and β-
acids by HPLC for is given Table 1.2.  
 
Table 1.2 Recommended HPLC methods for the HPLC analysis of hop α- and β-acids. 
 
Mobile phase Stationary phase T (°C) Flow rate 
 (ml/min) 
Ref. 
Gradient: 
MeCN/ MeOH/ tris buffer pH  7.5 
Nucleosil C18 
250 x 3 mm, 5 µm 
40 0.55 
76
 
MeCN/ phosphoric acid buffer pH 2.8 
Alltima C18 
150 x 4.6 mm, 5 µm 
ambient 1.8 
90
 
Gradient: 
MeCN/ MeOH/ 5%HCOOH 
Nucleosil C18 
250 x 4.6 mm, 5 µm 
35 0.9 
31
 
MeOH/ H2O/ phosphoric acid 
C18 
250 x 4.6 mm, 5 µm 
ambient 0.8 ASBC, EBC 
 
The methods recommended by the European Brewing Convention (EBC) and the 
American Society of Brewing Chemists (ASBC) rely on the use of phosphoric acid to 
suppress the ionization of the acidic components and to enhance retention on the column. 
Others tried other acidic additives, such as formic acid, but needed higher concentrations for 
the same performance. Also, problems related with interaction of the solutes with trace 
metals in the chromatographic system resulting in poor resolution have been reported. 
Quenching of these metal ions may be achieved by the addition of both phosphoric acid and 
ethylenediamine tetraacetate (EDTA).88  
As for the α- and β-acids, methods are recommended for the HPLC analysis of iso-α-
acids (Table 1.3). Separation of the cis-isohumulone from trans-iso-adhumulone proved 
most challenging. Ionization suppression is usually achieved by phosphoric acid. The 
chromatography of iso-α-acids is considered more sensitive to trace metal ions.22 When 
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simultaneous analysis of iso-α-acids and its reduced derivatives is needed, citrate buffers 
were proposed to attain maximum resolution. 
 
 
Table 1.3 Recommended HPLC methods for the HPLC analysis of hop-derived iso-α-acids and 
reduced derivatives. 
 
Mobile phase Scope Stationary 
phase 
T (°C) Flow rate 
(ml/min) 
Ref. 
Gradient: 
MeCN/MeOH/citric acid buffer pH 
7 
Iso-α-acids (IAA),  
dihydro-iso-α-acids 
(DHIAA), 
Tetrahydro-iso-α-acids 
(THIAA), 
Hexahydro-iso-α-acids 
(HHIAA) 
Zorbax 
Eclipse XDB-
C8 
250 x 4.6 
mm, 5 µm 
 
25 1.0 
98
 
Gradient: 
MeCN/MeOH/ citric acid buffer pH  
7 
IAA, DHIAA, THIAA 
Nucleosil C18 
250 x 3.0 
mm, 5 µm 
40 0.55 
76
 
MeCN/ phosphoric acid buffer pH 
2.8 
IAA 
Alltima C18 
150 x 4.6 
mm, 5 µm 
ambient 1.8 
90
 
MeCN / water/ phosphoric acid IAA 
Hipersil C18 
250 x 4.6 
mm, 5 µm 
ambient 1.5 
99
 
 
 
1.5.3 LC-MS analysis of hop-derived bitter acids mixtures 
 
During the last two decades, the optimization of the chromatographic separation 
parameters as well as the advantage of mass spectrometric detection significantly improved 
selectivity and sensitivity of the analysis of hop-derived bitter acids. Most HPLC-methods 
presented above use non-volatile buffer additives, such as phosphate and citrate, for the 
separation of hop acids and its derivatives, but they are not compatible with mass 
spectrometry. Some reports have been published on the LC–MS analysis of hop acids. 
Using ammonium acetate or acetic acid as mobile phase additives (Table 1.4), hop acids 
47 
 
were analyzed in beers by electrospray ionization (ESI) in the negative mode, after direct 
injection.95 Vanhoenacker et al. described a LC-MS method for the simultaneous analysis of 
iso-α-acids and reduced derivatives using an ammonium acetate buffer at high pH (pH = 
9.95) in combination with a solid phase that is stable at such elevated pH levels.78 
 
Table 1.4 Recommended LC-MS methods for the HPLC analysis of hop-derived mixtures of α-
acids, β-acids, iso-α-acids, and reduced derivatives (dihydro-iso-α-acids, tetrahydro-iso-α-
acids, hexahydro-iso-α-acids).  
Mobile phase Scope Stationary 
phase 
T (°C) Flow rate 
(ml/min) 
Ref. 
MeOH / 0.01M sodium acetate buffer in 
20% MeOH without pH adjustment. 
IAA, DHIAA, 
THIAA, HHIAA 
Hypersil C18 
100 x 4.6 mm, 5 
µm 
ambient 1.0 
100
 
MeCN / 8% HCOOH AA, BA 
Inersil ODS3 
25 x 0.46 cm, 5 
µm 
ambient 0.8 
94
 
 
MeCN / MeOH / ammonium acetate pH 8 
IAA 
XTerra C18 
15 x 0.21 cm, 
3.5 µm 
40 0.23 
96
 
Gradient: 
MeCN/ EtOH/ Ammoniumacetate pH 9.95  
AA, BA, 
IAA, DHIAA, 
THIAA, HHIAA 
Two Zorbax 
Extend C18 
35 1.0 
78
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1.6 Biological activity of hop-derived bitter acids 
 
Since ancient times, hops have been used in folkloric medicine for their claimed anti-
inflammatory, antiseptic, antidiuretic, (an)aphrodisiac, hypnotic, sedative, and stomachic 
properties.5, 25, 101-103 Indian tribes drank hop tea to alleviate nervousness and heated a small 
bag of leaves to apply in cases of ear- or toothache.104 King George III slept on a pillow 
stuffed with hop cones to alleviate symptoms of porphyria.5, 19, 105 The German Commission 
E approved a monograph on hops for use in mood and sleep disturbances. Similar 
indications are described in an ESCOP (European Scientific Cooperative on Phytotherapy) 
monograph.19, 24, 106, 107  
Today, a wide range of over-the-counter preparations containing hop extracts or hop-derived 
products is available on the market, in particular for use in the phytotherapy of sleep 
disorders or pain relief and in alleviation of menopausal symptoms.20, 101, 108, 109 
In line with a growing interest in the health benefits of plants used in traditional 
medicine, researchers have been trying to identify the bioactive ingredients in hops and to 
elucidate the underlying molecular mechanisms by which they exert their activities.   
During the past decade, many pharmacological investigations in vitro and in vivo tried to 
produce scientific evidence of the reported traditional uses. 
In recent years the estrogenic properties as well as the potential chemopreventive 
activities of hops have been investigated, in which much attention has gone to the bioactivity 
of the polyphenolic content of hops. Among this group, especially 8-prenylnaringenin has 
been identified as one of the most potent phytoestrogens currently known, while 
xanthohumol showed to have an important function in several cancer-inhibiting 
mechanisms.110-112  Recently, increasing evidence reveals that the hop bitter acids, which 
represent up to 30% of the total lupulin content of hops, exhibit interesting effects on human 
health. A rising number of studies show bioactive concentrations in the lower micromolar 
range.  
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In the next section, a comprehensive overview of the current evidence for the 
bioactivities and pharmacological properties of hop-derived bitter acids is outlined, as a 
framework for the study on the aspects of the bioavailability (ADME; absorption – distribution 
– metabolism - elimination) of hop-derived bitter acids. The following segment is based on 
the review of Van Cleemput et al., and updated with recent data on this subject. 
 
1.6.1 Anticancer Potential of Hop Bitter Acids 
 
Several natural compounds, including hop bitter acids, have been identified as 
promising molecules for the use in cancer chemotherapy or cancer chemoprevention. Plant-
derived substances may lower the risk of developing cancer by preventing metabolic 
activation of pro-carcinogens, or alternatively, they can inhibit cancer development by 
arresting or reversing the processes of tumor initiation, promotion, and progression.113 
 
1.6.1.1  In vitro activity: induction of apoptosis 
 
Hop bitter acids target cancer via the induction of controlled cell death (or apoptosis) 
in fast-growing tumor cells. The first report dates from 1997, when Tobe and co-workers 
reported the apoptosis-inducing properties of humulone in promyeloid leukemia HL-60 cells. 
Humulone (1-100 μg/mL) induced DNA fragmentation into (oligo)-nucleosomal units, a 
characteristic for apoptosis, in a time- and dose-dependent manner. Interestingly, treatment 
with iso-α-acids (100 μg/mL) did not induce DNA breakdown, not even after overnight 
incubation.114  In later studies, scientists attempted to unravel the molecular targets of hop 
bitter acid-initiated apoptosis. Chen and Lin used a standardized hop extract, consisting of 
49.39% α-acids and 24.94% β-acids, which dose-dependently induced apoptosis in human 
leukemia HL-60 cells (IC50 8.67 μg/mL) and, albeit to a much lesser extent, in human 
histocytic lymphoma U937 cells (IC50 58.87 μg/mL). In this study, hop bitter acids activated 
the intrinsic mitochondrial apoptotic pathway by disrupting the mitochondrial membrane 
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potential and enhancing membrane permeability by altering the expression of the Bcl-2 
family of proteins, consisting among others of the anti-apoptotic Bcl-2 and the pro-apoptotic 
Bax. This eventually resulted in activation of a cascade of caspases, which function as 
cysteine proteases thereby causing proteolytic breakdown of structural cell proteins. 
Furthermore, hop bitter acids stimulated the extrinsic pathway, which involved increased 
expression of the death receptor Fas and its ligand, FasL.115  Recently, inhibition of 
proliferation by humulone and lupulone was confirmed by Tyrrell et al. in MDAMB- 231 
(breast cancer) and SK-MES (lung cancer) cell lines in a dose- and time-dependent manner. 
Exposure of SK-MES cells to humulone or lupulone induced significant DNA fragmentation 
suggesting cell death by caspase-dependent apoptosis. Also, treatment of SK-MES cells 
with hop bitter acids led to a significant inhibition of adhesion to both mineralized and non-
mineralized matrices, which has important implications for processes that control the 
development of metastases. 116 
Consistent with the above, Liu et al. examined the antiproliferative effects of β-acids 
(BA) and the structurally related compounds, hexahydro-β-acids on HL-60 cells. Hexahydro-
β-acids (IC50 0.71 µg/ml) and BA (IC50 2.31 µg/ml) displayed strong growth-inhibitory effects 
against HL-60 cells and were able to induce apoptosis in a concentration- and time-
dependent manner. Treatment with hexahydro-β-acids caused a rapid loss of mitochondrial 
trans-membrane potential, released mitochondrial cytochrome c into cytosol, increased 
levels of Bad and Bax, and promoted the up-regulation of Fas prior to activation of pro-
caspase-8 and cleavage of Bid, suggesting the involvement of a Fas-mediated pathway in 
HBA-induced cells. Moreover, these changes occurred upon HBA-induced irreparable DNA 
damage, and enhanced expression of (GADD153) protein (growth arrest of DNA damage-
inducible gene 153) in a concentration- and time-dependent manner, triggering apoptosis in 
HL-60 cells. 117 
In a next study of the same authors, lupulones (40 μg/mL) were reported to up-
regulate Fas and FasL expression in a human metastatic colon carcinoma-derived cell line 
(SW620 cells). Again, mitochondrial membrane permeability was augmented in association 
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with an altered expression of Bcl-2 and Bax proteins.118 More detailed investigation revealed 
that a crucial role was determined for the TNF (tumor necrosis factor)-related apoptosis-
inducing ligand (TRAIL)-R1 and -R2 receptors, which were up-regulated and activated by 
lupulones (40 μg/mL) in both TRAIL-sensitive (SW480) and TRAIL-resistant colon cancer 
cells (SW620).119 Because p53 plays a central role in the response to cellular stresses by 
up-regulating the transcription of several genes controlling apoptosis, the involvement of p53 
on lupulone-triggered apoptosis was studied in a successive investigation. Interestingly, both 
cell lines SW480 and SW620, which exhibit the same p53 mutations, showed opposing 
responses of p53 upon lupulone treatment (40 µg/ml). In SW620 cells, lupulone up-regulated 
p53 gene expression and caused a cloistering of p53 in the nucleus, allowing p53 to play a 
pro-apoptotic role by activating the TRAIL-death receptor pathway. In contrast, in SW480 
cells, p53 was translocated to the cytoplasm where it initiated a survival response with the 
up-regulation of anti-apoptotic Bcl-2 and Mcl-1 proteins in an attempt to preserve 
mitochondrial integrity. These pro-survival effects of p53 in lupulone-treated SW480 cells 
were inverted by pifithrin-α (PFT-α), p53 function inhibitor, which caused a blocking of p53 in 
the nucleus leading to the down-regulation of Bcl-2 and Mcl-1, the up-regulation of pro-
apoptotic Bax protein and TRAIL-death receptors leading to enhanced cell death.120 Since 
the mitogen-activated protein kinases (MAPKs) control fundamental cellular processes such 
as apoptosis, the role of Jun N-terminal kinase (JNK), extracellular signal-regulated kinase 
(ERK), and p38 inhibitors on lupulone-triggered apoptosis was determined. Data showed 
that only p38 played a major role in by activation of p53 and the TRAIL-death receptor 
apoptotic pathway in SW 620 cells.121 
 
1.6.1.2 Antiproliferative activity of hop bitter acids  
 
Hop bitter acids show antiproliferative activity, thus arresting cell growth of invasive 
cancer cells.118, 122 The β-acids, lupulone and colupulone, and a semi-synthetic derivative, 
hexahydrocolupulone, inhibited cell growth of several human cell lines: hexahydrocolupulone 
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was the most potent variant with a wide spectrum of activity against solid tumors and 
leukemia’s, as well as against drug-resistant cell lines (IC50 values of 0.85 and 2.19 μM, 
respectively). It caused cell cycle arrest (G0/G1 phases) and affected the incorporation of 
precursors into their macromolecules, resulting in disrupted DNA, RNA, and protein 
synthesis.122  
Humulone inhibited the proliferation of human leukemia U937 cells (IC50 3.4 μM) and 
slightly induced their differentiation, as concluded from higher nitroblue tetrazolium reducing 
and lysozyme activities, both typical differentiation markers.  Agents that inhibit proliferation 
and enhance the conversion of premalignant cells to differentiated cells are expected to 
reduce cancer development. Humulone enhanced the differentiation of U937 monocytes 
induced by vitamin D3, 12-O-tetradecanoylphorbol-13-acetate (TPA), all-trans-retinoic acid, 
and tumor necrosis factor alpha (TNF-α). These effects were similar in other myelogenous 
leukemia cells, such as K562, HEL, KU812 erythroleukemia cells, promyelocytic leukemia 
HL-60 cells, monoblastic THP-1 cells, and myeloblastic ML-1 leukemia cells.123 
 
1.6.1.3 Inhibition of Angiogenesis 
 
The formation of new capillary blood vessels for the supply of oxygen and nutrients, 
also named angiogenesis, plays a key role in the development of malignant tumors. 
Shimamura and co-workers reported that humulone dose-dependently prevented 
angiogenesis in chick embryo chorioallantoic membranes (CAMs), with an ED50 (the 
“effective dose” at which 50% of angiogenesis is inhibited) of 1.5 μg/CAM. Humulone (10 
μM) inhibited tube formation by vascular lung endothelial cells from rats and reduced cell 
growth of endothelial mouse KOP2.16 cells, stimulated by basic fibroblast growth factor 
(bFGF), by 20%. Furthermore, 100 μM humulone suppressed the expression of vascular 
endothelial growth factor (VEGF), which contributes to angiogenesis, more significantly in 
tumor cells (Co26s) than in endothelial cells (KOP2.16).124  
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Lupulone (2.5-50 μg/mL) induced a concentration-dependent inhibition of HUVEC 
endothelial cell proliferation and chemotaxis toward fibronectin. Furthermore, the formation 
of closed capillary-like structures was reduced in a Matrigel morphogenesis assay, indicating 
a strong inhibitory effect on neovascularization.125 Nitric oxide (NO) is a gaseous free radical 
involved in the production of VEGF, the overexpression of which induces angiogenesis and 
vascular hyperpermeability, and accelerates tumor development. The ethyl acetate-soluble 
fraction of hop cones, containing hop bitter acids, inhibited both NO-production and 
expression of inducible nitric oxide synthase (iNOS) in RAW 264.7 mouse macrophages, 
stimulated by a combination of lipopolysaccharide (LPS) and interferon-γ cytokine (IFN-γ). 
Within this fraction, the strongest effect was observed for xanthohumol, whereas lupulone 
and some of its oxidative degradation products inhibited NO-production, but without reducing 
iNOS-expression. The oxidation products, exhibited either much weaker inhibitory activities 
on NO-production than lupulone or false inhibitions with strong cytotoxicity, indicating that 
oxidation may reduce the inhibitory activity of lupulone on NO-production.126 
Hexahydro-β-acids, reduced derivatives of β-acids (BA), significantly inhibited protein 
and mRNA expression of iNOS and cyclooxygenase-2 (COX-2) in murine RAW 264.7 
macrophages activated with lipopolysaccharide (LPS). Both BA and hexahydro-β-acids 
inhibited concentration-dependently nitrite-production (indicator for NO), but the inhibitory 
effect of hexahydro-β-acids (IC50 3.3 µg/mL) was more significant, compared to the BA (IC50 
8.9 µg/ml).  For PGE2-production, hexahydro-β-acids inhibited PGE2- increase in LPS-
stimulated RAW264.7 cells in a dose-dependent manner, while the inhibitory effect for BA 
was only observed under higher concentration.127 
Several authors provided experimental support for the tumor promoting function of 
IKKβ and the classical NF-κB pathway in several distinct models of cancer [32, 45,47, 48, 
57], supporting the hypothesis that transcription factor NF-κB (nuclear factor kappa B) and 
the signaling pathways that control its activity provide a molecular link between inflammation 
and cancer. Inflammatory signaling is highly regulated by a network of transcription factors 
that modulate gene transcription in response to pro-inflammatory stimuli, such as cytokines, 
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pathogens, and oxidative stress. For example, when TNF-α triggers its cognate membrane 
receptor, an intracellular cascade of kinases is activated, which leads to the release of NF-
κB from its inhibitor in the cytoplasm. Released NF-κB can then translocate to the nucleus, 
where it initiates the formation of a functional transcriptome, leading to increased expression 
of cytokines, enzymes, and adhesion molecules. Furthermore, constitutive NF-κB-activation 
is often detected in cancer.  
In a mechanistic study in LPS-stimulated RAW 264.7 cells, DHIAA selectively 
inhibited the NF-κB pathway, while having no effect on ERK1/2, p38 and JNK 
phosphorylation, nor on the transactivation of CRE (a known transcriptional factor regulated 
by MAPK), demonstrating specifically inhibiting the NF-κB signaling pathway but not MAPK 
pathways. GSK3 (α and β) were inhibited by DHIAA and phosphorylation of a known GSK-3 
substrate, β-catenin, was inhibited by DHIAA in, showing similar mode of action to a known 
GSK-3 inhibitor, SB216763, which also inhibited β-catenin. In addition, DHIAA inhibited NF-
κB-mediated inflammatory markers in various cell models, including NO in LPS-stimulated 
RAW 264.7 cells, RANKL-mediated tartrate-resistant acid phosphatase (TRAP) activity in 
transformed osteoclasts, and TNF-α/IL-1β-mediated MMP-13 expression in SW1353 human 
chondrosarcoma cells.128 
 
Hexahydro-β-acids inhibited the transcriptional activity of NF-κB in LPS-stimulated 
murine macrophages by blocking phosphorylation of inhibitor κB (IκB) α and p65. Also, 
hexahydro-β-acids inhibited LPS-induced activation of PI3K/Akt, extracellular signal-
regulated kinase (ERK) 1/2 and p38 MAPK. Independently, our research group established a 
dose-dependent reduction of NF-κB-dependent gene transcription by α-acids, β-acids (0.5-
10 μM), and iso-α-acids (25-200 μM).129  
 
It was observed that dihydro-iso-α-acids (DHIAA) and tetrahydro-iso-α-acids (THIAA) 
dose-dependently reduced NF-κB nuclear translocation and abundance in LPS-stimulated 
RAW 264.7 macrophages. Also, a commercially available extract, consisting of DHIAA 
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(META060) dose-dependently inhibited prostaglandin E2-and NO-formation, inducible but 
not constitutive COX-2 abundance, and NF-κB activation in LPS-stimulated RAW 264.7 
macrophages.  
 
 
1.6.1.4 Induction of CYP-450 Enzymes 
 
Several compounds induce the expression of detoxification enzymes of the 
cytochrome P450 system, which are very important in the metabolism and subsequent 
activation and/or inactivation of many xenobiotics including pro-carcinogens. As a part of a 
mouse diet, colupulone (0.18%) increased the P-450 content of the liver microsomes and 
stimulated various phase I enzyme activities, such as those responsible for demethylation of 
ethylmorphine and aminopyrine and the hydroxylation of aniline and benzo[a]pyrene.130 An 
up-regulation of multiple CYP-450 enzymes, in particular of CYP3A and CYP2B, was 
detected independently by western and northern blotting.130, 131 Similar results were obtained 
after administration of a hop hexane extract (0.33%) and crude hops (1%).130  
If hops and colupulone, in particular, are able to induce CYP-450 enzymes in species 
other than the mouse, then ingestion might have a significant impact on the bioactivation 
and/or detoxification of food-borne pro-mutagens. However, short-term administration of 
colupulone to the rat (0.36%) did not alter the ex-vivo CYP450-mediated conversion of the 
pro-mutagens alfatoxin B1 and benzo[a]pyrene to their mutagenic forms, as measured in 
Salmonella typhimurium and mammalian microsomal assays.131 In two comparative studies, 
published by Foster and co-workers, several brands of beer were examined for their 
potential to affect human cytochrome P450-mediated biotransformation. Initial findings were 
confirmed that some beers had a potential to affect the safety and efficacy of medications 
and supplements metabolized by CYP2D6, CYP3A4, or CYP2C9 isozymes. Moreover, 
dose-dependent inhibition of CYP3A4, CYP3A5, CYP3A7, and CYP19 (aromatase) by β-
acid content was significant. Further studies are required to determine the clinical 
significance of these findings.132, 133 Up to the present, no further studies addressing the 
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effects of long-term administration of hops, or individual hop constituents, on in vivo CYP-
450 enzyme activity have been carried out. 
Hall and co-workers presented a study probing the potential inhibition of cytochrome P450 
(CYP) catalytic activity of six isozymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 
and CYP3A4, collectively involved in the metabolism of approximately 85% of all phase I-
metabolized drugs and other xenobiotics,134 by a commercial mixture of dried magnesium 
salts of dihydro-iso-α-acids (DHIAA). Results showed CYP2C9 was the most strongly 
inhibited CYP isozyme (IC50 of 0.30 µg/mL DHIAA), while CYP2C19 was moderately 
inhibited (IC50 6.3 µg/mL). CYP3A4 was weakly inhibited by DHIAA. No inhibition was noted 
at the highest concentrations of DHIAA tested for 1A2 (>100 µg/ml), CYP2D6 (>100µg/ml) 
and CYP2E1 (>50 µg/ml).135 
 
1.6.1.5 In vivo activity 
 
 
In rats, adding lupulone (0.001% and 0.005%) to the diet reduced the development of 
colon carcinogenesis, initiated by azoxymethane, in a dose-dependent way. Both the 
number of pre-neoplastic lesions (aberrant cryptic foci, ACF) and the total number of tumors 
in the colon were dramatically reduced.118 In a similar experimental protocol, oral 
administration of an isomerized hop extract containing 30% iso-α-acids (0.01% or 0.05%) 
proved to reduce the number of ACF in the colon, as well as the prostaglandin E2 (PGE2) 
levels in the mucosa.136 Topical application of humulone (1 mg/mouse) protected against 
tumor formation in mouse skin, initiated by 7,12-dimethylbenz[α]anthracene (DMBA) and 
promoted by 12-O-tetradecanoylphorbol-13-acetate (TPA).137  
Humulone significantly inhibited TPA-induced epidermal cyclooxygenase-2 (COX-2) 
expression, for which the levels are up-regulated during carcinogenesis and inflammation.138 
Additionally, orally administered lupulone (0.01% in drinking water for 21 days) inhibited new 
vessel formation in mice by 50%. Neovascularization was determined by measuring the 
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hemoglobin content of Matrigel plugs, implanted under the mouse skin, and was 
standardized for control plugs of mice receiving tap water containing excipient.125 
 
1.6.2 Hop Bitter Acids in Inflammatory Disorders 
 
Since long ago, the hop plant has been known for its anti-inflammatory properties, as 
American Indians (the Delaware) used hops traditionally to relieve toothache and earache.104 
Yasukawa and co-workers screened 100 edible plant extracts against TPA-induced 
inflammation in mice in an attempt to find new herbal anti-inflammatory compounds. They 
identified a hop methanolic extract as a potent inhibitor of TPA-induced ear edema and 
identified humulone as the active compound. In comparison with standard drugs, humulone 
(ID50 0.2 mg/ear) was a less effective inhibitor than the steroid hydrocortisone (ID50 0.03 
mg/ear), but compared well with the inhibition potency of the nonsteroidal indomethacin (ID50 
0.3 mg/ear).139 Similarly, humulone was found to inhibit ear edema in mice, induced by 
arachidonic acid.137 
1.6.2.1 In vitro activity 
 
Cyclooxygenases (COX) are key enzymes required for the transformation of 
arachidonic acid to a wide range of prostanoids, including PGE2 and thromboxane A2 
(TxA2). The COX-2 isoform is highly up-regulated by cytokines at sites of inflammation, 
whereas, in contrast, COX-1 is constitutively expressed in many cell types, where it has 
homeostatic functions in gastric cytoprotection and platelet activation.140 The so-called 
“COX-2 hypothesis” assumes that the gastroduodenal toxicity of traditional nonsteroidal anti-
inflammatory drugs (NSAIDs), which block both COX isoforms, is mainly related to their 
inhibition of COX-1-dependent PGE2- and TxA2-formation in the gastric epithelium and 
platelets, while COX-2 has a major role in pain mediation, inflammation, and pyresis.141 
Specific inhibitors for the COX-2 isoform, including celecoxib (Celebrex), are used for the 
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treatment of osteoarthritis and rheumatoid arthritis, particularly in patients at high risk of 
developing gastrointestinal complications.142 
From several studies, individual hop acids demonstrated interesting anti-
inflammatory therapeutic properties, by selectively inhibiting COX-2 up-regulation by pro-
inflammatory mediators. Humulone suppressed the TNF-α-dependent release of PGE2 in 
murine osteoblastic MC3T3-E1 cells (IC50 0.030 µM) and reduced COX-2 enzyme activity, 
mRNA-expression, and promoter activity. These effects were similar for the glucocorticoid 
dexamethasone, but, for humulone, the glucocorticoid receptor was not involved. Results 
from in vitro enzymatic assays showed inhibition of the catalytic activity of COX-2 by 
humulone with an IC50 value of 1.6 μM, whereas COX-1-activity was not inhibited below 10 
μM.143 On screening hop bitter acid-containing formulations for COX-2-inhibition in LPS-
induced mouse macrophages RAW 264.7, a number of these emerged as strong anti-
inflammatory agents with no effects on PGE2 originating from the constitutive form of the 
enzyme. Furthermore, the hop acids studied left constitutively secreted COX-1 in human 
gastric mucosa cells unaffected, which is predictive of a low gastrointestinal toxicity.144 
Interestingly, in a study presented by Liu and co-workers, hexahydro-β-acids significantly 
blocked protein and mRNA expression of COX-2 (but not COX-1) and iNOS in LPS-induced 
RAW264.7 macrophages in a dose-dependent manner.  
Also, reduced iso-α-acids (dihydro-iso-α-acids and tetrahydro-iso-α-acids) (1-20 
μg/mL) inhibited PGE2-release from LPS-stimulated RAW 264.7 macrophages in a dose-
dependent manner by inhibiting inducible COX-2 protein expression.135, 145  
Furthermore, after an interferon-γ-combined stimulation with LPS, iso-α-acids 
inhibited PGE2-production in a dose-dependent way.
136 Independently, a standardized 
carbon dioxide extract from hops dose-dependently inhibited PGE2-production in LPS-
stimulated human peripheral blood mononuclear cells (PBMC) without compromising 
metabolic activity (IC50 3.6 μg/mL). Using human blood (whole blood assay), PGE2 
production was not decreased after selective activation of COX-1 by calcimicin. 
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In contrast, the hop extract inhibited PGE2-concentrations in blood, pretreated with aspirin to 
inactivate COX-1 and supplemented with LPS to induce COX-2. Thus, the hop extract was 
concluded to inhibit COX-2 selectively with a calculated IC50 of 20.4 μg/mL. The large 
differences in IC50 (PBMC vs. WBA) was explained by different experimental conditions: in 
whole blood assays, using 50% blood, a larger concentration of plasma proteins is present, 
which might interfere with the hop extract when compared to the PBMC, cultured in 10% 
FCS.146 
 
1.6.2.2 In vivo activity  
 
Our research group studied the effects of hop bitter acids in mice, in which acute 
inflammation was induced by subcutaneous injection of zymosan in the paw. Intraperitoneal 
(ip) administration of 250 μg of iso-α-acids or α-acids effectively inhibited paw edema, a 
characteristic symptom of inflammation, and this effect was similar for administration as 
potassium salts in phosphate-buffered saline (PBS) or as neutral acids in dimethylsulfoxide 
(DMSO), suggesting that both formulas are equally well absorbed from the peritoneal 
cavity.129  
 
In contrast, Hougee and co-workers administered a carbon dioxide hop extract orally 
to mice (1.25 mg by oral gavage for 10 days) in which acute arthritis was induced by 
injection of zymosan into the knee, but failed to detect a reduction of inflammation-related 
symptoms. The orally administered hop carbon dioxide extract neither inhibited joint 
swelling, nor restored the inhibited proteoglycan synthesis in the arthritic cartilage.  
On the other hand, upon stimulating the blood of mice with LPS ex vivo, PGE2-production 
was 24% lower in samples from mice treated with the hop extract, compared to vehicle-
treated mice, thus suggesting that the extract does become bioavailable. These 
contradictory findings can be explained by the low bioavailability of hop bitter acids after oral 
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intake. It was suggested, therefore, by the authors that the dose of 1.25 mg of hops extract 
be increased in order to lead to a detectable reduction of parameters for inflammation.146  
Mice with collagen-induced arthritis were orally dosed with 10, 50, or 250 mg/kg of 
DHIAA, and symptoms of joint swelling and the arthritic index were evaluated. It was found 
that DHIAA and THIAA dose-dependently reduced the arthritis index and, at 250 mg/kg, their 
efficacy was similar to that of 20 mg/kg of celecoxib, the positive control.147, 148 Analyses of 
individual markers revealed that, compared to the diseased controls, DHIAA (250 mg/kg)-
treatment significant reduced joint destruction, cartilage degradation, and bone erosion.128 
Similar results were obtained by oral administration of META060, a commercially available 
extract consisting of dihydro-iso-α-acids, in mice with carrageenan-induced acute 
inflammation.149 
 
Next to these results in animal studies, proof of effectiveness of anti-inflammatory activity of 
hop-derived bitter acids in humans is limited and suggestive: in an 6-week, open-label trial of 
human subjects exhibiting knee osteoarthritis, the anti-inflammatory activity of DHIAA (1000 
mg/day for 6 weeks) was assessed using the validated WOMAC and visual analog scale 
(VAS) questionnaires. In all questionnaires, a reduction in score was due to a reduction in 
symptoms, such as pain and stiffness. After 6 weeks, RIAA administration led to a 54% 
reduction in the WOMAC global score.135 
 
1.6.3 Hop Bitter Acids Improve Markers for Metabolic Syndrome 
 
In modern western society, the prevalence of metabolic diseases is taking on 
epidemic proportions and implicates a high risk of mortality due to cardiovascular 
complications. The so-called “metabolic syndrome” is defined as a cluster of abnormalities 
covering insulin resistance, central obesity, impaired glucose tolerance or type 2 diabetes, 
dyslipidemia, hypertension, hypercoagulability, atherosclerosis, and elevated rates of 
inflammatory blood markers.150 Current treatment is based on diet, exercise, and specific 
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lipid-altering drug therapy, supplemented with anti-diabetic agents that improve some of the 
associated complex atherogenic parameters. Plants, as extracts or isolated pure 
compounds, have already been shown to play a valuable role in the prevention or treatment 
of lifestyle-related disorders.151 Iso-α-acids have been shown to improve health by positively 
influencing lipid metabolism, glucose tolerance, and body weight. 
 
1.6.3.1 In vitro activity 
 
Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear receptors 
that are essentially involved in the regulation of fatty acid and carbohydrate metabolism. 
Fibrates, agonists of the PPAR-α subtype, are clinically used for the treatment of 
dyslipidemia, whereas the glitazones, PPAR-γ agonists, improve insulin sensitivity in type II 
diabetes. Positive results of hop iso-α-acids on the lipid profile in rodents suggested a direct 
agonistic effect on PPARs. Indeed, these compounds dose-dependently (1-30 μM) activated 
PPAR-α and PPAR-γ in HepG2 and CV-1 cells, respectively. Using chimeric expression 
plasmids in which the ligand-binding domain of PPAR-α or PPAR-γ was fused to the DNA-
binding domain of the yeast transcription factor GAL-4, iso-α-acids bound to PPAR-α as well 
as PPAR-γ, thereby increasing the transcription of a co-transfected reporter gene, containing 
five GAL-4 binding sites coupled to the luciferase-encoding sequence.152 However, this 
result could not be substantiated in our research group when transfecting full-length 
receptors together with a PPRE (PPAR response element) containing luciferase reporter in 
COS1L2A cells.129  
 
1.6.3.2 In vivo activity 
 
In a mouse model of non-insulin-dependent diabetes (KK-Ay mice), co-administration 
of iso-α-acids improved hyperglycemia and hyperlipidemia, similar to the PPAR-γ agonist 
pioglitazone, but, without a concomitant increase in body weight. In the liver, genes for acyl-
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CoA oxidase (ACO) and fatty acid translocase (FAT) were highly up-regulated, resulting in 
an enhanced lipid metabolism. Unexpectedly, iso-α-acids increased only moderately the 
expression of the adipose differentiation related protein (ADRP) and lipoprotein lipase (LPL) 
genes, involved in lipid uptake and storage in white adipose tissue. Similar effects were 
observed in diet-induced obese diabetic C57BL/6N mice. Co-administration to C57BL/6N 
mice of a high-fat diet and an isomerized hop extract, containing high amounts of iso-α-
acids, dose-dependently reduced body weight gain, improved glucose tolerance, and slightly 
reduced insulin resistance, compared to the control group. In white adipose tissue, apoptosis 
of hypertrophic adipocytes was induced, next to an increased number of small adipocytes, 
thus improving insulin sensitivity.152 
 
When feeding the mice an iso-α-acid-rich diet, supplemented with high amounts of 
cholesterol, a drastic improvement of atherosclerotic clinical parameters was observed. 
Indeed, an increase in plasma HDL-cholesterol and a reduction in the liver content of 
cholesterol and triacylglycerol were observed. Similar results were obtained feeding the 
animals a standard diet containing only hop iso-α-acids.153 In general, lipid metabolism in the 
liver was enhanced by up-regulated levels of acyl-CoA oxidase (ACO), acyl-CoA synthetase 
(ACS), and fatty acid transport protein (FATP) mRNA, which control cellular fatty acid uptake 
and peroxisomal β-oxidation, next to elevation of apoprotein CIII and lipoprotein lipase (LPL) 
content, crucial for the metabolism of triacylglycerol.153-155 The changes in lipid metabolism 
correspond to those of the PPAR-α agonist, fenofibrate, and were not found in PPAR-α-
deficient mice, thus suggesting that iso-α-acids operate via an analogous mechanism.154, 155 
Iso-α-acids also inhibited absorption of dietary fat in rats, which further supports a negative 
effect on body weight gain. As a possible target, isomerized hop extract decreased the 
pancreatic triacylglycerol lipase activity in a dose-dependent manner, thus elevating the 
undigested lipid content in the feces.153 
Concerning cardiovascular parameters, rats on a high-salt regimen did not develop a 
higher mean blood pressure when iso-α-acids were incorporated into the diet (0.3%). It was 
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proposed that these compounds reduce oxidative stress and restore the lower levels of 
bioavailable nitric oxide (NO) caused by the high-salt diet. As NO is a critical messenger 
molecule for the kidney to maintain salt and water homeostasis, increased bioavailable NO 
could protect against developing hypertension.156 
One pilot study in humans has been carried out in which oral iso-α-acids ameliorated 
insulin sensitivity in mild type 2 diabetic patients by decreased blood glucose and 
hemoglobin A1c levels.152 Above results were confirmed in a 12-week double-blind human 
study in which pre-diabetic subjects ingested capsules with iso-α-acids (16 mg, 32 mg or 48 
mg p/day). Next to a decrease in blood glucose and hemoglobin A1c, treatment resulted in a 
decreased body mass index (BMI) and total fat area.157  
 
1.6.4 Role of Hop Bitter Acids in Osteoporosis 
 
Osteoporosis develops when the balance between bone formation and bone 
resorption is disturbed, and, consequently, it is considered feasible to prevent osteoporosis 
by promoting bone formation or by inhibiting bone resorption. Humulone inhibited the 
formation of osteoporotic lesions in dentine slices (pit formation assay) with an IC50 value of 
5.9 nM.  The ad-homologue was equally active, while cohumulone showed no inhibitory 
activity. Also, lupulone was reported to be a strong inhibitor of bone resorption.158, 159 
However, the question remains as to what extent these in vitro data are valuable in 
the in vivo setting. It was reported that long-term administration to rats of a hop powder-
enriched diet (further undefined), either alone or combined with isometric strength training, 
did not improve bone parameters. However, the authors concluded that the body weights 
were significantly lower in those rats fed with the hop diet than in the control group. 
Therefore, it might have been difficult to detect positive effects of hops on bone, because 
lower body mass is associated with lower bone mass.160 It should also be mentioned that 
recent studies have established an unequivocal relationship between osteoporosis and 
inflammation.161 For example, elevated serum levels of systemic inflammation markers such 
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as interleukin-6, TNF-α, and high-sensitivity C-reactive protein are correlated significantly 
with a lower bone mineral density.162, 163 Therefore, the direct anti-inflammatory effects of 
hop acids could also contribute in the prevention and treatment of osteoporosis. 
 
 
1.6.5 Effects of Hop Bitter Acids on the Central Nervous System 
 
For quite a long time, from when it was observed that hop pickers tired easily, the 
hop plant has been reputed to possess sedative properties.20, 164 At present, hop-based 
preparations, mostly in combination with valerian, are marketed widely as a natural remedy 
for sleeping disorders, nervousness, and insomnia.165-167 
Already by the beginning of the 20th century, the sedative activity of various hop 
extracts and components was shown using frogs. In general, hop extracts reduced the 
excitability of the striated muscles and motor nerve endings, diminished the irritability of the 
nervous system, and induced narcosis.168, 169  However, the effect seemed to be highly 
species-dependent, since in rabbits, hops caused opposite effects such as increases in body 
temperature and dyspnea.169 
  As both hop extract, freed from hop acids, and hop essential oil were devoid of 
activity, as early as 1938, Sikorski and Rusiecki pointed to the hop bitter acids humulone and 
lupulone as active compounds for the observed sedative activity upon administration of hops 
to pigeons and small birds.170 Later on, Hänsel and co-workers suggested that it was not the 
hop bitter acids but rather a degradation product produced during storage that is responsible 
for the tranquilizing properties of hops.171-173 They reported that degradation of humulones 
and lupulones can result in the formation 2-methylbut-1-en-3-ol, a C5-alcohol, by a radical-
type auto-oxidation in the presence of atmospheric oxygen.174 Both in rats175 and mice,176 ip 
administration of this decomposition product showed sedative activity at low doses and 
induced transient deep narcosis at higher doses.  
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However, only hop teas and balneotherapeutic preparations were found to contain effective 
amounts of 2-methylbut-1-en-3-ol, whereas its content in “sedative dragees” was negligible. 
Therefore, their effectiveness could be questionable. Still, these dragees contain high 
amounts of hop acids, which, according to Hänsel et al., could act as precursors of the active 
compound via a similar radical-type degradation reaction in vivo.173 
Over the past decade, the neuropharmacological activity of hops has been 
reinvestigated in more detail using recent techniques including receptor binding assays. Both 
a carbon dioxide hop extract and an isolated α-acid fraction proved to modulate CNS activity 
in rats.177 It was found that both products dose-dependently enhanced pentobarbital-induced 
sleeping time without influencing locomotor activity, a marker for motor behavior. In addition, 
anti-depressant activity similar to the reference drug imipramine was observed for both hop 
preparations (forced swimming test), whereas no anxiolytic effects could be observed 
(Elevated Plus Maze test). 
In contrast, oral administration of a β-acid fraction increased locomotor activity and 
caused a reduced percentage of animals falling asleep on pentobarbital administration. It 
was shown that β-acids can interfere with the GABAergic system (GABA; γ-aminobutyric 
acid), leading to a general reduced neurotransmission in CNS.178 Negri et al. investigated the 
anxiolytic properties [Elevated Plus Maze (EPM) test and Neophobia test] of a 
hydroethanolic hop extract in male Wistar rats, which received orally doses of 250, 500, 750 
and 1000 mg/kg of a hop extract. Results showed that the extract of significantly increased 
the time of permanence on the open arms of the EPM with all doses tested. The extract also 
increased significantly the amount of food intake during the 60 min of evaluation in the 
Neophobia test.179 
In contrast to the work by Zanoli et al., reduced locomotor activities on administration 
of either carbon dioxide or ethanolic hop extracts to mice were observed by Schiller et al., 
albeit using much higher dosages. Interestingly, they did observe an increased sleeping time 
on treatment with a narcotic drug and, moreover, they observed a reduced body 
temperature, another parameter indicating sedative activity. Furthermore, by using a range 
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of different enriched fractions, it was indicated that various components including α-acids, β-
acids, and hop oil all contribute to the overall sedative activity of hops.180 
 
1.6.6 Bactericidal Activity of Hop Bitter Acids 
 
Initially, hops were used for prolonged storage of beer. Adding hops reduces the 
growth of Lactobacillus, the main beer contaminant, which otherwise would affect yeast 
performance, cause losses in ethanol yield, and form undesirable off-flavors.181 The 
preservative properties of hops have been investigated for many years and, despite some 
reports on the anti-bacterial activity of hop oil,182 the bitter acids seem to be the main active 
compounds. The target bacteria are Gram-positive species, such as Lactobacillus, 
Streptococcus, Staphylococcus, Micrococcus, and Bacillus.25, 183-189 In contrast, Gram-
negative bacteria, such as Escherichia coli, are either resistant or only affected at very high 
concentrations of hop acids. However, the combination of hop resins with sodium 
hexametaphosphate showed strong antimicrobial activity against E. coli.190   Yeast is not 
inhibited, which is very important for the use of hops in beer production.187, 191 Some 
inhibitory activity has also been reported for certain fungi, such as Penicillium and 
Aspergillus species.185, 192, 193  
In general, lupulone has greater antimicrobial activity than humulone, which is, in 
turn, more active than isohumulone.194 It appears that the more prenyl groups (three in the β-
acids) are present, the stronger the bacteriostatic action is. However, the role of iso-α-acids 
in beer preservation is of great value, since they represent quantitatively the main 
contribution of hops to beer. In all studies, hop acids may behave as either bacteriostatic 
substances or bactericides, depending on the conditions employed.  
Growth of Listeria monocytogenes was inhibited in culture media and in certain foods 
by hop extracts containing varying concentrations of α- and β-acids. The lowest inhibitory 
concentrations were observed for extracts containing the highest concentrations of β-acids. 
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In food matrix, these hop extracts showed varying magnitudes of inhibition, but, overall, the 
anti-microbial activity in food appeared to increase with acidity and lower fat content.194  
 
In bacteriological broth, the addition of β-acids (1.0-5.0 µg/mL) inhibited growth of L. 
monocytogenes, with inhibition being more pronounced at higher concentrations and at 
lower storage temperature (4°C).  Moreover, the anti-listerial activity of β-acids (0.5 to 3.0 
µg/mL) was enhanced when combined with sodium diacetate, acetic acid, or potassium 
lactate. 195 In a succeeding study on the storage of frankfurters, dipping of L. monocytogenes 
inoculated-frankfurters in solution of β-acids (0.03-0.10 w%), before low-temperature storage 
for up to 90 and 48 days, caused L. monocytogenes reductions and complete suppression of 
pathogen growth for 30 to 50 days (4°C) or 20 to 28 days (10°C), with anti-listerial effects 
increasing with higher concentrations. Further analysis revealed that the presence of β-acids 
resulted in an extension of the lag-phase duration of the pathogen, and decreased growth 
rate. 196 It was also found that a low level of iso-α-acids in beer wort is sufficient to inhibit 
growth of L. monocytogenes.197 It has to be mentioned that food preservation with hop acids 
requires quite high levels, which may impart undesirable flavors and aroma characteristics.  
Shimwell noted that the anti-septic potency of hops increased at low pH, which was 
attributed to changes in permeability of the bacterial cell wall.186 This hypothesis was 
confirmed in Bacillus subtilis, in which lupulone, humulone, and isohumulone caused cell 
wall lesions by incorporation into the cytoplasmic membrane. This activity resulted in 
inhibition of active transport of sugars and amino acids and, subsequently, led to inhibition of 
cellular respiration and synthesis of proteins, RNA, and DNA.191 
Later on, Simpson identified the mechanism by which trans-isohumulone inhibits the 
growth of the beer-spoilage bacterium Lactobacillus brevis. Apparently, the iso-α-acids act 
as mobile carrier ionophores, catalyzing electroneutral influx of undissociated molecules, as 
well as their internal dissociation and efflux of their complexes with divalent cations such as 
Mn2+. Consequent loss of the proton gradient inhibits the uptake of sugars and causes 
starvation in bacterial cells. The properties of other hop acids are similar to those of trans-
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isohumulone, confirming a similar mechanism.57 Since hop acids are weak acids and only 
undissociated forms are active, the antibacterial properties fall with higher pH-values. 
Furthermore, the potency is enhanced by increasing the hydrophobicity of the molecules, as 
determined by the acyl side chain length and the number of prenyl groups.57, 187 In a 
comparative study on the antibacterial activity of iso-α-acids (IAA), dihydroiso-α-acids 
(DHIAA), and tetrahydroiso-α-acids (THIAA) against some Gram-positive bacteria 
(Lactobacillus and Pediococcus), it was observed that the minimum inhibitory concentration 
(MIC) decreased when the degree of hydrogenation of the analyzed compounds increased, 
[MIC]THIAA < [MIC]DHIAA < [MIC]IAA. This confirms the former observation that increased 
hydrophobicity (lipophilicity) leads to a greater anti-microbial activity. The authors stated that 
the increased hydrophobicity renders a compound more prone to interaction with the cell 
membrane, thus explaining the observed effects.198 
Varying applications have been examined to exploit the bacteriostatic activity of the 
β-acids, for example, to control and reduce bacterial activity in the sugar industry. Pollach 
and co-workers presented a study on the application of lupulones as bacteriostatic in the 
sugar industry in order to potentially replace formaldehyde as disinfectant. It was found that 
addition of hop β-acids could help reducing the formation of lactic acid. 199 Also, addition of a 
commercially available alkaline solution of hop β-acids, named BetaStab® 10A, (0 – 160 
mg/L), to a thick juice (a concentrated intermediate product in the production of beet sugar) 
delayed acidification which is related to bacterial growth and the development of fastidious 
bacteria in a concentration-dependent manner. The addition of β-acids extended the lag time 
of colony formation, thus leaving the number of colonies unaffected.  In this way, β-acids do 
not prevent the thick juice from deteriorating, but they could significantly delay its 
degradation.200 
 
In a study on the evaluation of the anti-bacterial properties of hop bitter acids (α-
acids, β-acids, iso-α-acids, and reduced derivatives) against different strains of bacteria 
involved in primary or secondary skin and soft tissue infections (Propionibacterium acnes, 
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Staphlylococcus epidermidis, Staphylococcus aureus, Kocuria rhizophila and, 
Staphylococcus pyogenes), all hop acids tested showed inhibitory effects, though lowest 
MIC-values were observed for lupulones; 0.1 mg/ml against Propionibacterium acnes and 
Staphylococcus pyogens and 1 mg/ml against S. epidermidis, K. rhizophila, and S. aureus, 
respectively.  These low MIC values are comparable to the most commonly prescribed 
antibiotics for topical acne treatment (e.g. clindamycin and erythromycin).201 
Also, there are a few reports on the antibiotic properties of hops in relation to 
tuberculosis infection. Chin et al. demonstrated that lupulone inhibits the growth of a virulent 
strain of Mycobacterium tuberculosis in vitro and considerably suppressed the development 
of tuberculotic lung lesions in mice when administrated either intramuscularly or 
intragastrically.184, 202 Humulone also proved to be effective, although to a lesser extent, 
while the iso-α-acids were negative.  
A detailed study of influencing parameters showed that lupulone remains active, 
regardless of experimental variations in pH, NaCl-concentration, and serum content.203 
Indeed, in a small-scale study in tuberculosis patients, daily oral administration of 5 g of 
lupulone for 3 months was considered therapeutically active, without toxicity.204 However, the 
most suitable method of administration and the possible development of drug resistance 
have not been investigated.  
Limited evidence is available on the anti-viral activity of hop acids. The iso-α-acids 
were shown to have a low to moderate anti-viral activity against several DNA and RNA 
viruses (IC50 in low µg/ml range), whereas no anti-viral activity was detected for the hop β-
acids.205  
 
 
 
 
1.6.7 Hop Bitter Acids as Potent Antioxidants 
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Various health-promoting effects of plant compounds can be attributed to their 
intrinsic anti-oxidant activities: they neutralize cell damage caused by reactive oxygen 
species (ROS) and reactive nitrogen species such as free radicals, singlet oxygen, and 
hydroperoxides. Cell damage caused by free radicals appears to be a major contributor to 
ageing and degenerative diseases of ageing such as cancer, cardiovascular disease, 
immune system decline, diabetes mellitus, inflammation, brain dysfunction, and stress, 
among others. Phytochemicals may assist the body’s own defense enzymes, such as 
superoxide dismutase and glutathione peroxidase, to scavenge or quench free radicals to 
protect the body against deleterious effects. There are many in vitro assays available for 
determining anti-oxidative activities, including measuring 2,2-diphenyl-1-picrylhydrazyl 
(DPPH), hydroxyl, superoxide, or peroxynitrite radical scavenging activities (RSA), lipid 
peroxidation inhibitory activity (LIA), the ferric-reducing ability of plasma (FRAP), total radical 
trapping by anti-oxidants (TRAP), xanthine oxidase activity, and determination of hydrogen 
peroxide hemolysis. Often, a combination of methods is applied to characterize a compound 
as an anti-oxidant.  
Humulone inhibited hydrogen peroxide-induced hemolysis (IC50 28 μM).
114 
Furthermore, humulone and lupulone were shown to be radical scavengers in the DPPH-
RSA assay with IC50 values of 32 and 25 μM, respectively. Both compounds also inhibited 
lipid peroxidation (IC50 7.9 μM for humulone and 39 μM for lupulone). Interestingly, hop acids 
were more potent than the natural anti-oxidants α-tocopherol and ascorbic acid in this assay. 
The β-triketone moiety seems pivotal in view of its radical stabilizing property.206 Ting et al. 
suggested that the β-triketo group and the fully conjugated cyclic dione of α-acids can lead 
to stable phenoxyl radicals, which can act anti-oxidatively.207 In this investigation on the 
radical scavenging capacity of pure hop compounds and their derivatives, components 
having a 6-membered ring configuration (semi-quinone or quinoid) had the strongest radical-
suppression activity.207  
This is consistent with Mikyska et al., who reported that hop α- and β-acids showed 
significant radical-quenching abilities, while iso-α-acids displayed a negligible effect. 
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Moreover, iso-α-acids may be slightly pro-oxidative by acting as electron donors and thereby 
leading to the formation hydrogen peroxide.208 Another report gave the following order of 
decrease in OH-RSA: α-acids > β-acids > dihydroiso-α-acids > hexahydroiso-α-acids > 
tetrahydroiso-α-acids (IC50: 0.21, 0.96, 1.36, 1.40, and 1.78 mg/mL, respectively). α-Acids 
and β-acids are potent scavengers of free radicals, whereas iso-α-acids and reduced 
derivatives show decreased activities in this regard. However, in terms of lipid peroxidation, 
the order of potency was as follows: α-acids > β-acids > iso-α-acids > tetrahydroiso-α-acids 
> dihydroiso-α-acids > hexahydroiso-α-acids.209 
In vivo anti-oxidative effects can be determined by the in situ fluorescent detection of 
ROS and NO in tissues or by indirect assays, such as measuring urinary NOx excretion and 
quantifying ROS-production in the blood. Iso-α-acids have been reported to inhibit oxidative 
damage in rats fed a high-salt diet, thus preventing renal tissue damage. They decreased 
the production of ROS in renal tissues and increased bioavailable NO to basal levels. 
Increased ROS inactivates NO, critical for maintaining salt and water homeostasis in the 
kidney, thereby generating peroxynitrites, which, in turn, modify tyrosine residues of proteins 
to produce nitrotyrosine. Iso-α-acids in a high-salt diet, indeed, reduced the levels of renal 
nitrotyrosine, as detected by western blotting.156 
 
1.6.8 Effects of Hop Bitter Acids on the Gastrointestinal Tract 
 
Hops are used as over-the-counter products to improve gastric function. The 
bitterness of the hop acids is supposed to stimulate gastric secretion, similar to other bitter 
plant substances such as quinine. Only one study has addressed the effect of hops on 
gastric function, which uses the rat pylorus-ligated model. Oral administered hops clearly 
increased gastric juice volume without affecting acidity, which was not the case for intra-
gastric administration. The effects after oral administration were similar to those obtained 
with carbachol, a cholinergic agonist, whereas they were completely blocked by the 
cholinergic antagonist atropine. It was concluded that the increase in gastric juice volume by 
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hops could be mediated by the cholinergic nervous system. However, since this study was 
carried out with an undefined hop extract, suspended in physiological saline at pH 4.5, it is 
not clear as to what extent these effects were caused by the bitter acid content of hops.210 
 
 
1.6.9 Conclusions 
 
Through their wide range of biological and pharmacological effects, hop acids have 
proved being interesting candidates for the treatment and/or prevention of several human 
disorders, including cancer, diabetes mellitus, osteoarthritis, osteoporosis, and 
cardiovascular disease. Hop acids may accounts at least partially for some of the health-
beneficial effects of moderate beer consumption, as reported by a battery of epidemiological 
studies.211-221 
In conclusion, hop bitter acid research has led to a better understanding of the effects of 
these compounds on health and this knowledge has already been translated into the 
production of hop-derived phytomedicines and dietary supplements. 
 
 
 
 
 
 
 
 
 
1.7 Toxicology of Hop Bitter Acids  
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In general, skin contact with hops is well tolerated. Occasional hop allergy has been 
reported, most frequently after long-term exposure by direct contact or inhalation, for 
example by hop-pickers. Allergic reactions, mostly mild, include skin symptoms, such as 
urticaria, dermatitis, erythema, and pruritus of the uncovered skin, as well as respiratory 
disorders, including rhinitis, conjunctivitis, and asthma.5, 26, 101, 222-224  Due to long-term uses 
in brewing and herbal medicine, hops are generally recognized as safe (GRAS) for oral 
intake.225 
In vivo toxicity studies showed that only very large doses of hop intake are toxic, 
causing respiratory irregularities and central respiratory depression terminating in paralysis, 
in frogs, pigeons, small birds, rabbits, and mice.168, 169, 171 Regarding individual hop acids, 
intravenous injection of small doses of lupulone stimulated respiration in rabbits and cats.184 
In mice, oral doses of 10 to 100 mg/kg body weight of lupulone did not cause any adverse 
effects.171  Repeated intravenously injected humulone, at doses of 1-10 mg/kg, caused 
hyperventilation and hyperthermia in cats. In rabbits, the effects were much weaker and also 
of shorter duration. Lethal doses of humulone caused an abnormally severe rigor mortis, 
which appeared rapidly after death, suggesting that humulone affects muscular 
metabolism.226 
A safety study of pre-isomerized hop acids revealed that the LD50-values of iso-α-
acids and dihydroiso-α-acids are approximately 1000 mg/kg body weight in the rat, when 
administered as single doses in a 50% corn oil solution. Long-term addition of iso-α-acids, 
dihydroiso-α-acids, tetrahydroiso-α-acids, or hexahydroiso-α-acids to the diet (1% for 90 
days) caused a reduction in body weight gain in rats, without behavioral and 
histopathological changes. A dose of 150 mg/kg body weight was considered to be the no-
observed-adverse-effect level (NOAEL). Furthermore, tetrahydroiso-α-acids, hexahydroiso-
α-acids, and dihydroiso-α-acids did not cause mutagenic or genotoxic effects. In the dog, 
subchronic oral administration of tetrahydroiso-α-acids and hexahydroiso-α-acids was well 
tolerated with NOAEL values of 50 and 100 mg/kg body weight, respectively. Undigested 
material could be retrieved in the feces, suggesting a poor gastrointestinal absorption. In 
74 
 
general, toxic effects of high doses of pre-isomerized hop acids were limited to the 
gastrointestinal tract, most probably due to irritation by these bitter compounds.227 
There are only a small number of reports addressing the safety of hop bitter acids in 
humans. A daily oral administration of 5000 mg of lupulone for three months was not toxic 
for the liver, kidney, bone marrow, or myocardium. However, each patient experienced some 
degree of gastrointestinal irritation, ranging from epigastric burning pain, abdominal 
cramping, diarrhea, nausea, and vomiting.204  
A formula containing dihydroiso-α-acids (Meta050) (440 mg daily for eight weeks) did 
not result in clinically relevant changes in blood pressure, complete blood counts, or liver 
and kidney function. Furthermore, there was no negative impact on gastrointestinal markers 
normally affected by selective COX-2 enzyme inhibitors, as concluded from normal fecal 
calprotectin excretion.228, 229 Similar data were obtained after administration of pure 
dihydroiso-α-acids (450 mg daily for 2 weeks).228, 229 
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II. State-of-the-art and Objectives 
 
 
2.1 Background on bioavailability of hop-derived bitter acids 
 
There is increasing scientific evidence that the health-beneficial properties of 
moderate beer consumption not only relate to the presence of alcohol (ethanol),230-232 but, in 
particular, to unique biological activities of hop-derived constituents111, 124, 233 - in analogy to 
the health-protective activity of red wine-that is associated with the presence of anthocyanins 
and stillbenoids-.  
During the last 50 years, first the department of organic chemistry and later the lab 
for pharmacognosy and phytochemistry at Ghent University has gained a lot of experience 
on the chemistry, purification, stability, and analysis of substances present in hops and beers, 
including the photo-stability of beer-bittering substances, and the bioactivity and 
bioavailability of hop-derived prenylflavonoids and derivatives.  
A number of studies report on the phytoestrogenic and cancer-chemoprotective 
activities of hop-derived prenylflavonoids. Some beers contain quite a lot of isoxanthohumol 
(IsoX), the pro-phytoestrogen for 8-prenylnaringenin (8-PN); in the range of 3-4 mg/L. This 
could in principle provide estrogenic activities in specific persons (low natural estrogen level 
and high conversion of IsoX to 8-PN by microbiota).  
On the other hand, current investigations focus on highly interesting health-beneficial 
effects by hop-derived bitter acids (α-acids, β-acids) and derivatives (iso-α-acids, dihydro-
iso-α-acids, tetrahydro-iso-α-acids). As presented in the previous chapter, a steadily growing 
number of publications have been reporting bioactive concentrations with IC50-values in the 
lower micromolar range (anti-inflammatory and anti-angiogenic properties, improving lipid 
profiles, and counteracting diabetes type 2).6, 128, 157, 229, 234, 235 
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Surprisingly, until recently, only little was known on absorption, distribution, 
metabolism, and excretion (ADME) of iso-α-acids and derivatives, a topic that is highly 
relevant when assessing the usefulness of these compounds for either preventive or 
therapeutic uses. Insights into the bioavailability and the effective bioactivity of these 
compounds are essential to support, on a sound scientific basis, any health-related claim 
associated to nutraceuticals based on hop-derived bitter acids. In both the US and Europe, 
Metagenics Inc commercializes hop-based nutraceuticals and medical foods that contain 
hop-derived bitter acids varying from a few 100 mg up to 1000mg.236 In beer, typical 
concentrations of α-acids are low, but techniques such as “dry hopping” can introduce levels 
of α-acids up to 14 mg/l.36 The β-acids are generally not present in beer. On the other hand, 
iso-α-acids and reduced derivatives can be present in  beer in much larger quantities, 
varying from 10 up to 100 mg/l, depending on the bitterness.67, 68, 237 The presence of such 
high concentrations of hop-derived bitter acids could possibly explain the positive health 
effects associated with ingestion of preparations containing these products. Below, an 
overview of the limited knowledge on the ADME of hop bitter acids is presented.  
In the evaluation for anti-inflammatory efficacy of a defined mixture of dihydroiso-
alpha-acids (DHIAA), support for its bioavailability was determined by administration of a 
single oral dose of 1000 mg DHIAA to 2 normal healthy subjects. The bioavailable DHIAA 
was determined by the measurement of 2 separate diastereomers of the n-analog of DHIAA: 
trans-(6R)-n- and cis-(6S)-n-dihydroisohumulones. Both diastereomers were present in the 
plasma following oral administration and a reached maximum concentration (Cmax was 1-3 
μg/ml) at 4 h after dosing. The AUC0–8h for the trans-(6R)-n- and cis-(6S)-n-diastereomers 
was 18.8 and 7.15 µg*h/ml, respectively.135  
In another study, presented by Desai et al., reporting on the anti-inflammatory 
properties of a tetrahydro-iso-α-acids mixture, META060, its bioavailability was determined 
in a small human trial, as part of a study to address its therapeutic efficacy to treat chronic 
inflammation. META060 is a mixture of n- (45%), co-(39%), and ad-(8%) analogues of 
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tetrahydroiso-α-acids. Four healthy volunteers consumed 5 softgel capsules delivering 940 
mg of META060 as the free acid. META060 was detected in the plasma of 4 human subjects 
within 1 h following a single oral dose of 940 mg; peak levels were observed in 3 of the 4 
subjects at 4 h. While inter-subject variability was evident, Cmax ranged from 4–15 μg/ml and 
Tmax from 2–4 h. In the absence of data from systemic administration of META060, it was not 
possible to determine the absolute bioavailability, but the area-under-the-curve (AUC0–8 h) 
ranged from 15–98 μg*h/ml when normalized to a dose of 10 mg/kg. 238 
Recently, induction of the quinone reductase activity by α-acids and iso-α-acids and 
activation of CYP3A4, CYP2B6, and some MDR1 levels in human hepatocytes have been 
reported.233, 239 It appears that hop acids stimulate both phase I and phase II detoxification 
processes. Activation of CYP3A4 is noteworthy because this gene product is the most 
abundant of all the cytochromes P450, clearing more than half of all prescription drugs.240 
This may be relevant with respect to the bioavailabilities as enhanced activities stimulate 
metabolism and excretion, resulting in lower overall bioavailabilities on repeated ingestion.  
In one of the studies cited above, conducted by Teotico and co-workers, data 
indicated that hop bitter acids induced CYP3A4 and other drug-metabolizing genes by 
activating the human nuclear xenobiotics pregnane X receptor (PXR). PXR has a key role in 
the transcriptional regulation of genes that encode multidrug resistance efflux pumps and 
xenobiotic metabolism enzymes including cytochromes P450, glutathione transferases, UDP 
glucuronosyltransferases, sulfotransferases. The β-bitter acid colupulone was demonstrated 
to be a direct activator of (PXR).241 The crystal structure of the ligand binding domain of 
human PXR in complex with colupulone was elucidated, and colupulone was observed to 
bind in a single orientation stabilized by both van der Waals and hydrogen bonding contacts. 
The crystal structure also indicated that related hop-derived α- and β- acids have the 
capacity to serve as PXR agonists as well.239  
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2.2. Objectives 
 
The goal of this PhD project is the characterization of the factors governing the absolute 
bioavailability of hop-derived bittering substances using both in vitro and in vivo approaches, 
in combination with state-of-the-art analytical techniques. Furthermore, given the subtle 
differences in molecular structure between the compounds under investigation in this work, 
comparison of the results allows identification of possible structure-activity relationships.  
 
To achieve this objective, the following topics were addressed in this research project: 
 
1) As a first approach to study the bioavailability, we have investigated the in vitro 
intestinal permeabilities of hop α-acids, β-acids, iso-α-acids, dihydro-iso-α-acids and 
tetrahydro-iso-α-acids using Caco-2 cell monolayers (a commonly used screening 
tool for the prediction of intestinal absorption). Because of the wide use of hops as 
main ingredient for beer brewing and the increasing amount of hop-based food 
supplements, the in vitro absorption of both hop-derived α-, β-, iso-α-acids, 
dihydroiso-α-acids, and tetrahydroiso-α-acids using Caco-2 cell monolayers was 
investigated.  
 
2) In addition, in vivo experiments have been carried out in which various hop acids and 
derivatives (α- and β-acids, iso-α-acids, dihydro- and tetrahydro-iso-α-acids) were 
administered to rabbits (oral vs. intravenous administration). The pharmacokinetic 
profiles of the compounds were used to calculate the absolute bioavailability of these 
substances in rabbits. In addition, in a second type of experiments, the different types 
of hop acids were administered orally to rabbits and urine and feces were collected 
over a period of 24h to elucidate elimination pathways for these compounds. 
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3) As a final part of the investigations, hop bitter acids were incubated with liver 
microsomes as an in vitro model to investigate phase-I and phase-II metabolism. In 
addition, the urine samples of the in vivo experiments were evaluated for the 
presence of possible metabolites and/or degradation products. 
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III. Transport of hop-derived bitter 
acids across Caco-2 cell 
monolayers 
 
 
 
This chapter is based on:  
 
Cattoor, K.; Bracke, M.; Deforce, D.; De Keukeleire, D.; Heyerick, A., In vitro transport of 
hop bitter acids across Caco-2 monolayers, Journal of Agricultural and Food Chemistry  
2010, 58 (7), 4132-4140 
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3.1 Introduction 
 
In drug development, oral ingestion is the most common -or most desired- way of 
intake. Knowledge on the absorption and metabolism of xenobiotics at the intestinal mucosal 
level is of high importance, since the oral bioavailability is defined as the fraction of an oral 
dose reaching the systemic circulation in an unchanged form. Typically in vivo trials of potent 
bioactive molecules are preceded by in vitro screening methods and in silico computer 
simulations, based on ethical considerations and/or because of cost control issues. The 
most important advantage of in vitro work is that it permits an enormous level of 
simplification of the system under study, so that scientists can focus on a small number of 
components. Other possible advantages include options for high throughput research, 
mechanistic studies, etc.  The primary disadvantage of in vitro experimental studies lies in 
the translation from the in vitro results back to the biology of the intact organism and/or 
humans. Care must be taken to avoid over-interpretation of the in vitro results.  
In this chapter, the intestinal absorption of hop-derived bitter acids was studied using 
an in vitro approach. This study focuses on hop α- and β-acids as pure cohumulone and 
colupulone, respectively, and a mixture of n-humulone + adhumulone and n-lupulone + 
adlupulone, respectively. Also, the intestinal absorption of iso-α-acids (IAA), dihydroiso-α-
acids (DHIAA), and tetrahydroiso-α-acids (THIAA) was studied. For the exact molecular 
structure of all the investigated compounds, see Figures 1.9; 1.15. The concentrations of 
hop acid chosen (30-120 μM) in the presented study can be reasoned by taking into account 
that an intestinal exposure to 30-120 μM hop bitter acid is in line with moderate consumption 
of a dry-hopped beer or a single oral dose of a food supplement containing about 10-20 mg 
of hop acids, while commercially available hop-based food supplements may contain up to 
1000 mg of hop-derived bitter acids.236The results provide first insights into the intestinal 
absorption of hop acids. 
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During the past decade, numerous in vitro screening techniques have been 
developed to predict human intestinal absorption. One of the most intensively applied assays 
for permeability assessment has been the Caco-2 monolayer system.242, 243 Less laborious 
methods with assays utilizing artificial membranes244, 245 have also gained popularity, but the 
Caco-2 monolayers are regarded as the best model in terms of reliability.246-250 
 
3.2 The Caco-2 cell monolayer system 
 
The human epithelial Caco-2 cell monolayer model using differentiated Caco-2 cells 
is commonly applied as a screening tool for the prediction of intestinal absorption of 
compounds and for mechanistic studies of drug transport across epithelial layers.250  
Notably, in vitro permeability coefficients measured for reference compounds obtained in the 
Caco-2 cell model have shown good correlation with results based on in vivo studies.251, 252  
Although derived from a colon carcinoma, Caco-2 cells can differentiate 
spontaneously, when grown on a suitable substrate, into a monolayer to exhibit the 
morphological characteristics of small intestinal cells including the formation of intercellular 
tight junctions and apical microvilli. The adjacent cells adhere through tight junctions formed 
at the apical side of the monolayer and form a clear separation of the apical compartment 
from the basolateral compartment. These compartments correspond to the intestinal lumen 
side and serosal side (bloodstream), respectively. A schematic picture of the Caco-2 cell 
monolayer set-up is shown in Figure 3.1. 
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Fig 3.1 Schematic view of a Caco-2 cell monolayer set-up using a Transwell insert with a 
microporous filter. 
 
3.2.1 Expression of phase-I enzymes  
 
The first studies on the Caco-2 cell line demonstrated that these cells, upon 
differentiation, express small intestine hydrolase enzyme activities (i.e. sucrose-isomaltase, 
lactase, aminopeptidase N, dipeptidylpeptidase IV) on the apical membrane.253 Certain 
cytochrome P450 enzymes are abundant in the human small intestine, such as CYP3A4, 
which accounts for ≈50% of all CYP isozymes in this tissue.254 The specific expression of 
CYP1A1 in Caco-2 cells was proven by Boulenc et al.255, while expression of CYP3A4 has 
been reported in Caco-2 cell monolayers by Gan and co-workers,256 albeit at low levels. 
However, others have reported neither immunological nor functional evidence of phase-I 
enzymes in Caco-2 cells.257 The under-expression of CYP enzymes compared to human 
small intestine, limits the use of Caco-2 cells as a model for intestinal phase-I metabolism of 
orally administered compounds. Investigators have tried to overcome this by treating Caco-2 
cell monolayers at confluence with 1α,25-dihydroxyvitamin D3, resulting in an increase of the 
CYP3A4 mRNA expression, next to increased levels of NADP cytochrome P450 
reductase.258 Confirmation was obtained by studying metabolic kinetics of midazolam by 
CYP3A4 enzymes, giving results that were similar to those observed in vivo.259 
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3.2.2 Expression of phase-II enzymes  
 
Although CYP enzymes are poorly expressed in Caco-2 cells, many other drug 
metabolizing enzymes are expressed at levels, useful for intestinal metabolism studies.260, 261 
For example, hydrolases, carboxylesterases, glucuronyltransferases, glutathione-S-
transferases, sulfotransferases, and catechol-O-methyltransferase are present and 
functional in Caco-2 cells. Among these, the phase-II sulfotransferases and 
glucuronyltransferases are particularly significant in the determination of bioavailability of 
orally administered compounds, since conjugation usually results in reduction or elimination 
of their biological activity. Caco-2 cells have been shown to produce sulfate and glucuronide 
conjugates of resveratrol,262 flavonoids, like chrysin263 and epicatechin,264 and also of hop-
derived prenylated flavonoids, such as 8-prenylnaringenin.265  
 
3.2.3 Expression of Efflux transporters 
 
Efflux transporters play an important role in disposition and elimination of many 
substances including metabolites, pharmacological drugs, dietary compounds, and other 
xenobiotics.  The known intestinal efflux transporters responsible for carrier-mediated 
transport are divided in two categories: the solute-carrier superfamily (SLC) and the ATP-
binding cassette (ABC) transporter superfamily. ABC transporters involve P-glycoprotein (P-
gp, multidrug resistance protein 1 (MDR1)), multidrug resistance-associated proteins (MRPs), 
and the breast cancer resistance protein (BCRP). These ABC transporters function to 
suppress the intracellular accumulation of their substrates by preventing the influx and 
facilitating the efflux out of cells. In intestinal epithelia, P-gp, MRP2, and BCRP are 
expressed on the apical membrane and MRP3 is expressed on the basolateral membrane. 
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P-glycoprotein 
The apical efflux transporter P-gp is responsible for the trans-membrane transport of 
different compounds by an ATP–depending process. P-gp mainly recognizes a variety of 
structural and pharmacologically unrelated neutral and positively charged hydrophobic 
compounds.266 Caco-2 cells possess an elevated activity of P-gp, compared to human 
intestine, which is important to consider when using these cells as a model for intestinal 
bioavailability. Also, P-gp expression in Caco-2 cells was observed to be influenced by 
culture conditions and drug exposure.253 This implies that the purpose of Caco-2 cell assays 
must be focused mainly to screen whether a compound interacts with P-gp, but not to 
quantify the interaction.267 
MRP 
The MRP’s belong to the same ABC-superfamily as P-gp and transport relatively 
hydrophilic substrates, including glucuronide, glutathione, and sulfate conjugates, 
endogenous and exogenous compounds.268 Thus, the substrates are predominantly anionic 
substances. MRP1 to MRP6 are known to be expressed both in humans and Caco-2 cells at 
medium to low levels. Also, MRP-2 and MRP-3 may have greater roles than other MRP’s 
due to their higher expression levels.269 It was shown that MRP-2 was only present at the 
apical membrane of Caco-2 cells270 and similarly it is localized at the luminal membrane of 
the small intestine. In contrast, MRP-3 is located at the basolateral membrane in Caco-2 
cells and various epithelia.271 
BCRP 
BCRP is a third member of the ABC-superfamily with wide substrate specificity and is 
expressed in many normal human tissues.272 BCRP can transport a structurally and 
functionally diverse range of organic substrates including both hydrophobic and hydrophilic 
agents.266 In Caco-2 cells, BCRP was found to be located on the apical membrane.273, 274 
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3.2.4 Transport mechanisms across Caco-2 monolayers 
 
The intestinal absorption (see Figure 3.2) of various compounds across the intestinal 
epithelia into the blood circulation is mediated primarly by two routes: the paracellular (route 
A) and the transcellular route. Transcellular transport is carried out by either of the following 
three mechanisms: simple passive diffusion across the lipid bilayer (route B), carrier-
mediated uptake for compounds which can act as substrates for intestinal transporters (route 
C), and endocytosis (transcytosis) (route D). Efflux pumps localized at the apical side, such 
as P-gp and MRP-2, serve as a protective barrier to intestinal transport by exporting 
xenobiotics back into the intestinal lumen (E). Absorption via the paracellular route is 
typically restricted by the relatively small pore size of the paracellular canal and the presence 
of tight junctions acting as a barrier to absorption,275 reducing the pore radius to a few 
Ångstrom (1 Å = 0.1 nm). Moreover, the relative total surface area of the intercellular space 
is negligible compared to the total area of the epithelium, hence this paracellular pathway is 
only significant for chemicals showing slow transport across the cell membrane. In general, 
the more lipophillic compounds are rapidly transported across cells, while the most 
hydrophilic compounds have lower permeability coefficients.276 For hydrophilic compounds 
that exhibit poor membrane permeability, and which do not serve as substrates for 
membrane uptake carriers,242 the paracellular route may be an important absorption 
mechanism.  
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Fig 3.2 Schematic representation of routes and mechanisms for intestinal transport of 
molecules. Following oral intake, a compound can be absorbed into the systemic circulation 
by passive diffusion via paracellular transport between cells (A), transcellular transport across 
the cell membrane (B), or via active transport by carrier-mediated uptake (C) and transcytosis 
(D). Compounds can also be pumped back to the intestinal lumen by apical localized efflux 
pumps like P-gp, MRP-2, or BCRP-types (E). 
 
 
Carrier-mediated uptake is possible for compounds having a molecular structure 
resembling those of actively transported nutrients. Often, transport is mediated partly by the 
carrier and partly by passive routes. Since, carrier-mediated transport is saturable, the 
contribution of the passive route will increase with increasing dose.  If the compound has a 
low passive permeability, saturation of the carrier will result in a decreased absorbed fraction. 
Endocytosis is mainly considered for compounds which are excluded from other transport 
ways due to their large size. 
Permeability data from former research with Caco-2 monolayers revealed that 
compounds known for complete human absorption were found to have a high apparent 
permeability coefficient (Papp ≥ 1 x 10
-6 cm/s), while poorly absorbed substances had a low 
permeability coefficient (Papp ≤ 0.1 x 10
-6 cm/s). It has been shown, from in vivo absorption 
data, that the usefulness of Caco-2 systems is appropriate for relative ranking of 
permeability of compounds (for example, classification in low and high absorption), but not 
for exact quantitative prediction of human absorption.277 Lennernäs et al. investigated the 
effective permeability of different classes of drugs in Caco-2 monolayers and in human 
jejunum in situ.  
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The permeabilities of the rapidly and completely absorbed compounds (transported by a 
passive transcellular route) differed only 2- to 4- fold between the two models, whereas the 
correlation of the permeabilities of the slowly and incomplete absorbed drugs (transported by 
a passive paracellular route) were transported at a 30- to 80-fold slower rate in the Caco-2 
monolayers than in the human jejunum. The permeability for the drug L-DOPA (L-3,4-
dihydroxyphenylalanine), which is normally completely and rapidly absorbed, mainly via the 
carrier for large neutral amino acids in the human jejunum, was transported at a >100-fold 
slower rate in Caco-2 monolayers than in the jejunum in the investigated concentration 
interval.278 Thus, it seems possible that the strength of the Caco-2 monolayers vs. in vivo 
correlations may vary for different groups of compounds. 
 
3.3 Materials  
 
Atenolol, propranolol, verapamil hydrochloride, indomethacin, sulfatase type H1 (from 
Helix pomatia), sodium fluorescein, 4–(2-hydroxyethyl)–1–piperazine-ethane sulphonic acid 
(HEPES) sodium salt 99%, D-(+)-glucose, and all HBSS buffer constituents were purchased 
from Sigma-Aldrich (Bornem, Belgium). Glutamine, non-essential amino acid solution, 
penicillin G, fungizone, amphotericin B, and fetal bovine serum (FBS) were purchased from 
Gibco (Invitrogen, Merelbeke, Belgium). The liquid/supercritical CO2 extract was obtained 
from Hopsteiner (Mainburg, Germany). Isohop®, Redihop®, and Tetrahop Gold® were 
obtained from the Barth-Haas Group (Botanix, Kent, UK).  International calibration standards 
for α- and β-acids (ICE-2), iso-α-acids (DCHA-iso, ICS-I3), dihydroiso-α-acids (all cis-
dihydro-iso, ICS-R2), and tetrahydroiso-α-acids (ICS-T3) were all obtained from Labor 
Veritas (Zürich, Switzerland). HPLC/LC-MS solvents (analytical grade) were purchased from 
Biosolve (Valkenswaard, The Netherlands). 
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3.4 Methods 
 
Caco-2 cell culture  
 
Caco-2 cells (American Type Culture Collection (ATCC), Rockville, Maryland, USA) 
originating from a human colorectal carcinoma were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) containing GLUTAMAXTM, supplemented with 10% fetal bovine serum, 1% 
non-essential amino acids, 1% L-glutamine, 100 U/ml penicillin, and 100 μg/mL 
streptomycin. Cells were grown in 25 cm2 culture flasks (Corning Costar, New York, USA) in 
an atmosphere of 10% CO2 and 90% relative humidity at 37°C (Forma Scientific, Marietta, 
Ohio, USA). Cells were passaged every 7 days (90-95% confluence) at a split ratio of 1:10. 
For transport studies, Caco-2 cells were seeded at a density of 1 x105 cells/insert on 
Transwell® membrane inserts (0.4 μm pore diameter, 6.5 mm diameter, Corning Costar, 
Corning, New York, USA) and cultured until late confluence. In the experiments with iso-α-
acids, dihydro-iso-α-acids, and tetrahydro-iso-α-acids, membrane inserts with 0.4 µm pore 
diameter and 24 mm insert diameter were used. The cell culture medium was changed every 
other day. Monolayers were investigated, 18 to 24 days post-seeding. Cells with passage 
numbers 25-50 were used. The integrity of each monolayer of differentiated cells was 
monitored by measuring the transepithelial electrical resistance (TEER) with a Millicel-ERS 
volt-ohmmeter (Millipore, Bedford, Massachusetts, USA). TEER is a measure for the 
presence of tight junctions between adjacent cells. Volumes amounted to 200 μl at the apical 
side and 750 μl at the basolateral side of the monolayer (or 1.5 ml and 2.6 ml at the apical 
and basolateral side in case of 6 well plates). 
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Purification of α-acids and β-Acids  
 
Individual hop α- and β-acids were separated on the basis of a pH-dependent liquid-
liquid extraction, followed by semi-preparative HPLC. The hop CO2 extract (10 g) was 
dissolved in diethyl ether (50 mL) in a separation funnel. α-Acids (pKa 4.7-5.6) were 
extracted with Na2CO3 (0.15M, 3 x 50 mL) and β-acids (pKa 6.7-7.6) with NaOH (0.1 mol/l, 3 
x 50 mL).279 The aqueous phases containing either the deprotonated α-acids or β-acids were 
acidified with HCl (12 M, pH 2) and extracted with diethyl ether (3 x 200 mL). The fractions 
enriched in either α-acids or β-acids were further purified by preparative HPLC (Gilson, 
Villiers-le-bel, France). The injection volume of a concentrated solution (300-400 mg/mL in 
MeOH) was 200 μL. A Varian C-18 column (250 x 21.4 mm, 10 μm) was used. Isocratic 
elution with a flow rate of 15 ml/min was applied with a mobile phase consisting of 30:70 
(v/v) H2O/CH3CN + acidified with 0.025% HCOOH. The residues of the respective fractions 
after evaporation (cohumulone, n-humulone + adhumulone, colupulone, n-lupulone + 
adlupulone) were extracted with diethyl ether after acidification with HCl (12 M, pH < 2). 
Purities (> 98%) were confirmed by LC-MS and were stored at -20°C.  
 
Caco-2 control measurements  
 
The low-permeability standard atenolol (50 μM) and the high-permeability standard 
propranolol (20 μM) were added to the monolayers simultaneously (in the same well) with 
the test compounds. TEER was measured before and after the experiments. Monolayers 
with low TEER-values assumed to exhibit extensive leakage through imperfect occluding 
junctions or holes in the monolayer were discarded. After the transport studies, sodium 
fluorescein was used as a paracellular leakage marker. HBBS (200µl) containing 1 mg/mL 
sodium fluorescein was added to the AP chamber of each monolayer. After 1 h of 
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incubation, the amount of fluorescein transported to the BL chamber was measured by 
fluorescence spectrophotometry (λexc = 480 nm, λem = 530 nm).  
 
Bidirectional Transport Studies of α-acids and β-acids 
 
The transport medium was Hanks’ buffered saline solution (HBSS) containing 10 mM 
HEPES + 25 mM D-(+)-glucose, adjusted to pH 7.4. The osmolarity was ± 0.35 Osm/l, 
verified with an osmometer (Knauer, Berlin, Germany). Prior to the experiments, the cell 
culture was removed from both AP and BL chambers of the Transwell plate. The cells were 
washed three times and preincubated (37°C, 10% CO2) with transport medium for 30 min. 
TEER was measured before the experiments. Only cells with initial TEER-values >300 Ω x 
cm2 were used. Stock solutions (20 mM in EtOH) of cohumulone, n-humulone + 
adhumulone, colupulone, and n-lupulone + adlupulone were diluted in the transport medium 
to a final concentration of 50 μM. Due to co-elution of ad- and n-analogues in the preparative 
HPLC method, these compounds were applied as a mixture (n-humulone + adhumulone and 
n-lupulone + adlupulone, respectively). Final EtOH contents were <0.5%.  
The transport experiment was initiated by adding 50 μM hop sample to either the AP 
chamber (for absorptive transport study AP-to-BL) or the BL chamber (for secretive transport 
study BL-to-AP). Blank transport medium was added to the other (receiving) chamber. Each 
experiment was performed in triplicate (three sequential wells with Caco-2 monolayers were 
tested, in correspondence with methodologies described elsewhere).275, 280 Samples from the 
receiving compartment were collected after 10, 20, and 30 min, respectively. During the 
experiments, each sampling volume was replaced by an equal volume of blank transport 
medium. Samples (apical (200 μl) and basolateral (750 μl) taken from the Caco-2 assay at 
different incubation times were spiked with the internal standard (IS) (1.0 μg). 4-
hydroxybenzophenone was applied as internal standard in case of samples containing α-
acids and β-acids. Next, samples were acidified (pH 2) with H3PO4 (0.1 mol/l; 1.5 volumes) 
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followed by extraction with ethyl acetate (EtOAc; 4 volumes; extraction was repeated once). 
Collected organic phases were evaporated (N2) and residues were reconstituted in 100 μl 
methanol (MeOH). Samples were stored at -20°C until LC-MS analysis.  
 
Cellular Uptake Experiments of α-acids and β-acids 
 
The same pre-incubation protocol was followed as described under ‘Bidirectional 
Transport Studies of α-acids and β-acids’. In cellular uptake studies, the hop acids (final 
concentration of 50 μM) were added to the AP chambers. Blank transport medium was 
added to the BL chamber. Different monolayers were incubated with hop acids for 15, 30, 
and 60 min, respectively. Each experiment was performed in triplicate. At the end of the 
experiment, samples were withdrawn from the AP (200µl) and the BL (750µl) chambers, 
followed by EtOH extraction of the cell monolayers. For this, excessive transport medium 
was removed and monolayers were extracted with EtOH (200 μl AP; 750 μl BL) during 30 
minutes. Afterwards, EtOH samples from both the AP and BL chambers were combined and 
stored at -20°C until LC-MS analysis. 
 
Inhibitor Studies of transport of α-acids and β-acids 
 
 In transporter inhibition studies, either verapamil (100 μM) or indomethacin (100 μM) 
was added into both AP and BL chambers. After a pre-incubation period in the presence of 
specific inhibitors, the same experimental protocol was followed as described under 
‘Bidirectional Transport Studies of α-acids and β-acids’. Furthermore, the transport of probe 
substrates rhodamine 123 (as substrate for P-gp) and 5-chloromethylfluorescein diacetate 
(CMFDA) (as substrate for MRP-2) was monitored as positive controls. 
 
Bidirectional Transport Studies of iso-α-acids and reduced derivatives  
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The same pre-incubation protocol was followed as described under ‘Bidirectional 
Transport Studies of α-acids and β-acids’. Different donor concentrations (30, 60, and 120 
μM) were applied by adding a solution of IAA, DHIAA, or THIAA to either the AP 
compartment (for absorptive transport study; AP-to-BL) or to the BL compartment (for 
secretive transport study; BL-to-AP). Donor solutions were diluted from commercially 
available solutions of potassium salts of hop-derived bitter acids at pH 8-10 (Isohop®, 
Redihop®, and Tetrahop Gold® containing 200, 300, and 90 mg/ml of IAA, DHIAA, and 
THIAA, respectively) in HBSS (dilution factor > 4000). Blank transport medium was added to 
the other (receiving) compartment. After 1, 2, and 4 hours of incubation, samples were taken 
out from the basolateral (2600 µl) (for AP-to-BL transport) or apical (1500µl) (for BL-to-AP 
transport) side and the volume was replaced with blank transport medium. At the last 
sampling point (4 h), an aliquot of the donor compartment was included as a sample 
(respectively 1500 µl from the AP chamber or 2600 µl from the BL chamber).  
In order to quantify the absorbed intracellular amounts, excessive transport medium 
was removed and monolayers were extracted with EtOH (1500 μl AP; 2600 μl BL) during 30 
minutes. Afterwards, both EtOH fractions (1500µl; 2600 µl) of both sides were combined. 
Each experiment was performed in triplicate (three sequential wells with Caco-2 monolayers 
were tested). Samples (apical (1500μl) and basolateral (2600 μl)) taken from the Caco-2 
assay at different incubation times were spiked with the internal standard (IS) (1.0 μg). 
THIAA were applied as internal standard in case of samples containing IAA and DHIAA. In 
samples following dosing of THIAA, DHIAA were used as internal standard. Next, samples 
were acidified (to pH < 2) with H3PO4 (0.1 mol/l; 1.5 volumes) followed by extraction with 
ethyl acetate (EtOAc; 4 volumes; extraction was repeated once). The collected organic 
phases were evaporated (N2) and residues were reconstituted in 100 μl methanol (MeOH). 
Samples were stored at -20°C until LC-MS analysis.  
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Enzymatic Hydrolysis of Caco-2 monolayer extracts  
 
Conjugated levels of hop-derived acids were quantified by enzymatic hydrolysis 
based on a method validated by Wyns et al.281 Cell fraction extract aliquots (EtOH; 375 μl) 
were evaporated until dryness. Afterwards, residues were re-dissolved in 5 volumes NaOAc 
buffer (0.1 mol/l, pH 5) and 30 μl of a solution in NaOAc buffer (0.1 mol/l, pH 5) containing 
both β-glucuronidase and sulfatase (activities of 10,000 units/ml and 330 units/ml, 
respectively) H. pomatia from was added. Samples were incubated for 2 h at 37 °C. 
Subsequently, samples were acidified with H3PO4 (200 µl; 1.0 mol/L, pH 2) and extracted 
with EtOAc (4 volumes, extraction was repeated once). The collected organic phases were 
evaporated (N2) and residues were reconstituted in 100 μl methanol (MeOH). Samples were 
stored at -20°C until LC-MS analysis. Replicate control samples were included in absence of 
enzyme treatment to determine the extent of glucuronidation and/or sulfation. Cellular levels 
of conjugated hop-derived acids were calculated by subtracting the amount of free hop acid 
(no enzyme treatment) from the amount of total hop-derived acids (+ β-glucuronidase/ 
sulfatase). Similarly, aliquots of the medium from the basolateral (300 μL) and the apical 
(100 μL) compartments were combined with the mixture of β-glucuronidase/sulfatase and 
further processed as described above. 
 
 
Data Presentation of Caco-2 Experiments  
 
The results of the transport experiments are expressed as an apparent permeability 
coefficient Papp (cm/s), calculated as described by Artursson et al.
252 
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with δQ/δt (nmol/s): transport of the compound in the receiving chamber over time, A (cm²): 
the membrane surface area of the cell monolayer, C0 (nmol/cm³): the initial compound 
concentration in the donor compartment. Other important parameters are the percent 
amount transported to the receiving chamber compared with the amount added to the donor 
compartment (%T) and the efflux ratio (ER), which is used  to determine the extent of efflux, 
calculated according the following equation:  
 
with PappBA and PappAB, being the apparent permeability coefficients for transport from the 
basolateral to apical compartment and from the apical to basolateral compartment, 
respectively. 
 
Statistical Analysis 
SPSS release 17.0 for Windows (SPSS, Chicago, Illinois, USA) was used for all 
statistical analyses. All experiments had a minimum of 3 independent observations for each 
test group. Each experiment was replicated at least once such that N=6, unless indicated 
otherwise. Data were expressed as means ± SEM when applicable. Normality of distribution 
was investigated using the Shapiro-Wilk test and the homogeneity of variances was 
evaluated using the Levene’s test. Comparison of means between more than 2 groups was 
performed using one-way analysis of variance (ANOVA) followed by Bonferroni post-hoc 
comparison of statistical significance. Linear regression was performed when correlation 
analysis was warranted. Results were considered to be statistically significant when P < 
0.05. 
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Purity of donor solutions of IAA, DHIAA, and THIAA 
 
The purity of the donor solutions from commercially available Isohop®, Redihop® 
and Tetrahop Gold® was evaluated by dilution with methanol at a concentration of 0.1 and 
1.0 μg/ml and analyzed by LC-MS to determine quantities of IAA, DHIAA, and THIAA in 
each solution. A purity > 98% was confirmed for each of the class of hop acids. 
 
Stability of Hop Bitter Acids  
 
The stability of hop-derived bitter acids in the experimental conditions was evaluated. 
Stock solutions of 20 mM (EtOH) of α- and β-acids and commercial available solutions of 
IAA, DHIAA, THIAA were diluted to a final concentration of 50 μM for each class of hop 
acids, and incubated at 37°C for 4 h. Afterwards, samples (500 μL) were extracted as 
described in the sections ‘Bidirectional Transport Studies of α-acids and β-acids’ and 
‘Bidirectional Transport Studies of iso-α-acids and reduced derivatives’.  
 
LC-Analysis of Samples 
 
Extracted samples from the Caco-2 experiments were analyzed using LC/MS 
analysis (Agilent 1200 LC-MS, Agilent, Waldborn, Germany). MS analysis was performed 
using an AT multimode ionization source coupled to a single quadrupole detector (MSD), SL 
version. The Agilent Chemstation software package (Rev.B.02.01) was used to control the 
analytical system as well as for data acquisition as for processing.  For the analysis of 
atenolol and propranolol, a Zorbax SB C-18 column, was used. The mobile phase consisted 
of 10 mM ammonium acetate pH 5.0 + 2% CH3CN (A) and methanol (B). The initial mobile 
phase, 10% B, was increased linearly to 90% B over 8 min, maintained for 4 min, and further 
increased to 100% B in 1 min and maintained during 4 min. Finally, the mobile phase was 
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adjusted to 10% B in 1 min and re-equilibrated at 10% B for 4 min prior to the next injection. 
In case of samples containing α- and β-acids, iso-α-acids, dihydroiso-α-acids, and 
tetrahydroiso-α-acids, an Xbridge C18 column (150 x 30 mm; 3.5 µm) (Waters, Zellik, 
Belgium) was used. The mobile phase consisted of 10 mM ammonium acetate pH 9.75 + 
20% MeOH (A) and 100% MeOH (B). The flow rate was 0.5 ml/min and the column 
temperature 40°C. The initial mobile phase, 27% B, was increased linearly to 60% B over 24 
min, maintained for 5 min, and further increased to 95% B in 5 min and maintained during 4 
min. Finally, the mobile phase was re-adjusted to 27% B in 1 min and re-equilibrated at 27% 
B for 6 min prior to the next injection.  The MS-parameters in the negative atmospheric 
pressure chemical ionization (APCI) mode were tuned to maximize formation of the 
deprotonated analyte. Interface settings were as follows: N2 drying gas temperature 250 °C, 
N2 drying gas flow 5 l/min, APCI vaporizer temperature 150 °C, nebulizer pressure 0.1 MPa, 
capillary voltage 1000 V, corona current 6 μA, and charging voltage 1000 V. In each 
analysis, qualitative identification was performed in the negative ion scan mode (m/z 150–
700) and quantitative data were obtained by construction of the extracted-ion chromatogram 
following measurement in the selected-ion monitoring (SIM) mode. Quantitative analysis of 
atenolol and propranolol was operated in the SIM positive-ion mode using target ions at [M-
H](+) m/z 260.3 and 267.3 for propranolol and atenolol, respectively. The values of the target 
ions [M-H](-) m/z, used for quantification of the different hop acid compounds, are presented 
in Table 3.1. Calibration curves were established by linear least squares regression analysis 
using the ratio of the peak area of total hop acid versus IS against the concentration of hop-
derived acids in 6 standards (blank HBSS medium) covering the range of 0.5 to 200 μM. 
Daily prepared calibration curves were constructed by injecting calibration standards at the 
beginning and at the end of each batch of samples.  
To evaluate the accuracy and precision of the method, recovery experiments were 
carried out on three consecutive days by adding 2 different concentrations of AA, IAA, 
DHIAA, and THIAA (10 and 50 µM) to blank transport medium. The accuracy was expressed 
in terms of relative error, and the precision was evaluated in terms of the relative standard 
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deviation (RSD). The limit of detection (LOD) and the limit of quantification (LOQ) of the 
method were defined as the lowest concentration with a signal-to-noise ratio of 3 and 10, 
respectively, in spiked samples, where the noise data were taken from the analysis of blank 
matrices. 
 
 
Table 3.1 Molecular ions used for selected-ion monitoring (SIM) mode for the various 
compounds in LC-MS analysis.
a
  
Compound m/z (negative ionization)  
AA  
cohumulone 347 
n-humulone +adhumulone 361 
BA  
colupulone 399 
n-lupulone +adlupulone 413 
IAA   
cis-isoco  
trans-isoco  
347  
cis-isoad  
cis-iso-n+ trans-isoad  
trans-iso-n  
361  
DHIAA   
cis-DHisoco  
cis-DHisoco  
349  
cis-DHisoad  
cis-DHiso-n  
cis-DHisoad  
cis-DHiso-n  
363  
THIAA   
cis-THisoco  
trans-THisoco  
351  
cis-THisoad  
cis-THiso-n  
trans-THisoad  
trans-THiso-n  
365  
a 
AA: α-acids; BA: β-acids; IAA: iso-a-acids; DHIAA: dihydroiso-α-acids; THIAA: tetrahydroiso-
α-acids. 
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3.4 Results & Discussion 
 
LC-MS analysis of hop-derived bitter acids in Caco-2 samples 
 
In this study, an LC-MS method is described that enables simultaneous analysis of, 
in total, 24 hop-derived bitter acids. A mobile phase with a high pH is used based on the 
work of Vanhoenacker and co-workers.78  This study showed that an alkaline mobile phase 
demonstrated improved peak shape and efficiency, implying better resolution. As buffer 
additive, the volatile ammonium acetate was chosen at pH 9.75, thus requiring selection of a 
stationary phase, stable at high pH. The column, an Xbridge C18 is stable in the pH range 1-
12. In accordance with the study by Vanhoenacker et al., APCI was used in this work, 
instead of ESI. Figure 3.3 shows an LC-MS analysis of a mixure of all hop-derived hop acids 
in MeOH. The chromatograms of each group of compounds are reconstructed by the 
extracted-ion function. Peak identification was based on the  retention time and elution order 
of detected MS-ions, UV-spectra, and literature data.76, 98 
For the α-acids, full separation can be observed for all 3 homologues; while for the β-
acids, n- and ad-compounds are co-eluting. Generally, in routine analysis of iso-α-acids not 
all individual iso-α-acids are resolved. Mostly 2 peaks appear, the first peak representing the 
cis- and trans-isocohumulones and the second peak the cis- and trans-isomers of 
isohumulone and isoadhumulone. In the method presented in this study, full separation of 
the 6 major iso-α-acids can be observed (Fig 4.1). Also for the tetrahydroiso-α-acids, all 6 
constituents were separated with this method. In case of the cis-dihydroiso-α-acids, 
separation of five of the 6 constituents could be obtained. The small unassigned peaks in the 
chromatogram could be assigned to minor presence of trans-dihydroiso-α-acids. 
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Figure 3.3 Representative LC-MS chromatograms of various hop-derived bitter acids in MeOH. 
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The standard curves for the determination of α-acids, β-acids, iso-α-acids, dihydro-
iso-α-acids, and tetrahydro-iso-α-acids in blank transport medium were all linear over the 
concentration range of 0.5-200 μM. The correlation coefficients were always higher than 
0.995. The limits of detection (S/N = 3) for all compounds are listed in Table 3.2. The LODs 
ranged from 0.010 µM to 0.015 µM.  
 
Table 3.2 Limit of detection (LOD) in Caco-2 transport medium (HBSS) 
 HBSS LOD (µM) 
AA 0.014 
BA 0.010 
IAA 0.012 
DHIAA 0.015 
THIAA 0.012 
 
The accuracy and precision, expressed as the percentage relative error (%RE) and 
relative standard deviation (RSD), was within the acceptable ranges of 15% for all 
compounds (Table 3.3). The accuracy ranged from 6.7% to 12.5%. The intra-assay precision 
ranged from 2.6% to 5.7%. The inter-assay precision ranged from 6.9% to 10.7%.   
 
Table 3.3 Accuracy (%RE) and precision (RSD) (intra- and inter-assay) in Caco-2 transport 
medium (HBSS) 
compound accuracy 
precision 
intra-assay inter-assay 
AA 12.0 3.1 8.7 
BA 6.7 4.3 6.9 
IAA 7.1 5.4 10.7 
DHIAA 10.7 5.7 8.5 
THIAA 12.5 2.6 7.4 
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Bidirectional Transport of Marker Compounds and Monolayer Integrity 
 
The Caco-2 cell monolayers were assessed with respect to their barrier properties 
using the model compounds atenolol (paracellular transport) and propranolol (transcellular 
transport), known for passive diffusion. Propranolol and atenolol showed Papp values of 53.1 
± 5.0 x 10-6 and 0.45 ± 0.18 x 10-6 cm/s, respectively, which is in correspondence with 
reported data.249, 251, 252, 282, 283  Reference values for the atenolol flux are usually lower than 
1.0 x 10-6 cm/s while the propranolol flux is typically higher than 10 x 10-6 cm/s.275  The 
results indicate that the monolayers can be used to discriminate between compounds with 
low and high permeabilities. Final concentrations did not affect TEER or transepithelial 
transport, hence the transport of compounds did not influence TEER, which was confirmed 
by preservation of the integrity of the monolayers, also shown by fluorescein transport values 
< 1%/h for Transwell membrane inserts with 6.5 mm diameter and < 0.3%/h for inserts with 
24 mm diameter.284  
 
Stability of Hop-derived Bitter Acids in HBSS 
 
To investigate the stability of hop-derived bitter acids, control experiments with 
various classes of compounds were carried out. After 4 h of incubation in blank transport 
medium, recoveries were all >98%, indicating that no significant degradation was observed 
for all hop-derived bitter acids during the experimental conditions applied. 
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3.4.1 Caco-2 studies with hop α-acids and β-acids  
 
3.4.1.1 Bidirectional Transport of α-acids and β-Acids across Caco-2 Cell Monolayers 
 
The present study was undertaken to investigate the in vitro transport of hop bitter 
acids as cohumulone and n-humulone + adhumulone (α-acids) and colupulone and n-
lupulone + adlupulone (β-acids) using Caco-2 cell monolayers. The transport characteristics 
were determined for two directions, apical-to-basolateral (AP-to-BL) and basolateral-to apical 
(BL-to-AP). The cumulative amounts transported into the receiving chamber as a function of 
time are shown in Figures 3.4 and 3.5.  
 
 
Fig. 3.4 Apical (AP)-to-basolateral (BL) and basolateral (BL)-to-apical (AP) transport of α-acids 
(cohumulone and n-humulone + adhumulone) across Caco-2 monolayers. Hop α-acids (50 μM) 
were added to either the apical (AP-to-BL) or the basolateral (BL-to-AP) compartment of 
monolayers at time zero. Samples from the receiving compartment were collected at 10, 20, 
and 30 min, and analyzed by LC-MS as described under Materials and Methods. Data are 
means ± SEM for three replicates. Trendlines from linear regression analysis fitted through 
zero show good linearity (R
2
 > 0.95). 
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Fig. 3.5 Apical (AP)-to-basolateral (BL) and basolateral (BL)-to-apical (AP) transport of β-acids 
(colupulone and n-lupulone + adlupulone) across Caco-2 monolayers. Hop β-acids (50 μM) 
were added to either the apical (AP-to-BL) or the basolateral (BL-to-AP) compartment of 
monolayers at time zero. Samples from the receiving compartment were collected at 10, 20, 
and 30 min, and analyzed by LC-MS as described under Materials and Methods. Data are 
means ± SEM for three replicates. Trendlines from linear regression analysis fitted through 
zero show good linearity for AP-to-BL transport (R
2
 > 0.95). BL-to-AP transport showed 
enhanced transport upon longer treatment periods. 
 
Significantly higher amounts of α-acids were transported to the basolateral chamber 
compared with the β-acids. For the α-acids, the fractions transported into the receiver 
chambers increased linearly within 30 min in both absorptive and secretive directions. For 
the β-acids, the transport in the absorptive direction also showed a linear relationship, but, in 
efflux transport, a different relationship was observed. Table 3.4 presents the transport 
parameters Papp and efflux ratios (ratio of efflux versus influx) for the hop acids in the AP-to-
BL as well as in the BL-to-AP direction. 
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Table 3.4 Apparent permeability coefficients (Papp) and efflux ratios in the absence and 
presence of the specific inhibitors verapamil and indomethacin.
a 
 COH 
 (50 µM) 
N-HUM + ADHUM 
(50 µM) 
COL  
(50 µM) 
N-LUP + ADLUP 
(50 µM) 
PappAB (x 10
-6
 cm/s) 
 
41 ± 2 14 ± 2 2.1 ± 0.9 0.9 ± 0.1 
PappBA (x 10
-6
 cm/s) 
 
16 ± 2 7.2 ± 0.6 21 ± 3 8.9 ± 1.0 
efflux Ratio 
 
0.4 ± 0.1 0.5 ± 0.1 10 ± 4 10 ± 4 
PappAB  (x 10
-6
 cm/s) 
+verapamil  
37 ± 3 18 ± 3 2.5 ± 0.6 1.4 ± 0.3 
PappBA (x 10
-6
 cm/s) 
+ verapamil  
16 ± 1 10 ± 2 10 ± 2 10 ± 2 
PappAB (x 10
-6
 cm/s) 
+indomethacin  
41 ± 3 17 ± 2 27 ± 1 14 ± 5 
PappBA (x 10
-6
 cm/s) 
 +indomethacin  
15 ± 1 10 ± 1 5.6 ± 0.4 2.7 ± 0.5 
Efflux ratio  
+ verapamil 
0.4 ± 0.1 0.5 ± 0.2 4.2 ± 2.0
*
 7.0 ± 1.7 
Efflux Ratio 
+ indomethacin 
0.4 ± 0.1 0.5 ± 0.1 0.2 ± 0.1
**
 0.2 ± 0.1
**
 
 
a
Hop α-acids (50 μM) (cohumulone = COH and (n-humulone + adhumulone) = N-HUM + 
ADHUM) and β-acids (colupulone = COL and (n-lupulone + adlupulone) = N-LUP + ADLUP) 
were added to the apical (AP-BL) or basolateral (BL-AP) compartment of monolayers at time 
zero. After 10, 20, and 30 min, samples were withdrawn from the receiving compartment and 
analyzed by LC-MS as described under Materials and Methods. Data are means ± SEM for 
three replicates. Comparison of efflux ratios (in the absence and presence of inhibitors) 
between more than two groups was performed using one-way analysis of variance (ANOVA) 
followed by Bonferroni post-hoc comparison of statistical significance. Statistically significant 
differences versus the efflux ratios in the absence of inhibitors are indicated: *p < 0.05; **p < 
0.005. 
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The PappAB values ranged from 0.9 ± 10
-6 to 40.9 ± 10-6 cm/s. The highest membrane 
permeability was determined for cohumulone (40.9 ± 10-6 cm/s), being about 3-fold higher 
than the PappAB values of (n-humulone + adhumulone) and 20-40 times higher than the 
transport rates of the β-acids.  
In secretive transport, the PappBA of the α-acids in the BL-to-AP direction was 15.7 ± 
10-6 cm/s for cohumulone and 7.2 ± 10-6 cm/s for (n-humulone + adhumulone). Cohumulone 
and (n-humulone + adhumulone) showed higher absorption than secretion with efflux ratios 
of 0.4 for cohumulone and 0.5 for (n-humulone + adhumulone). Notably, colupulone and (n-
lupulone + adlupulone) exhibited substantially different bidirectional Papp values with efflux 
ratios of 10.3 and 9.7, respectively.  
 
3.4.1.2 Effect of Inhibitors on the Transport of α-acids and β-Acids 
 
To confirm the expression of efflux pumps in the Caco-2 cells, the transport of the 
probe substrates rhodamine 123 (as substrate for P-gp) and CMFDA (as substrate for MRP-
2) was monitored as positive control. The transport of rhodamine 123 showed a substantial 
efflux with an efflux ratio of 3.0, which was significantly reduced to 0.98 in the presence of 
verapamil as a P-gp inhibitor. For CMFDA, the presence of indomethacin as a MRP-inhibitor 
caused reduction of the efflux ratio from 6.4 to 0.91. The results confirmed that P-gp and 
MRP-2 were both present in the Caco-2 monolayers. To identify involvement of efflux 
transporters in the bidirectional transport of colupulone and (n-lupulone + adlupulone) across 
Caco-2 monolayers, their transport properties were examined in the presence and the 
absence of specific transport inhibitors. As a control experiment, bidirectional transport of α-
acids in the presence of verapamil and indomethacin was also examined. As expected, the 
transport of cohumulone and (n-humulone + adhumulone) was not influenced.  
 
The amounts transported in bidirectional transport of α-acids and β-acids in the 
presence of selective inhibitors (P-gp influence) and indomethacin (MRP-2 influence) are 
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shown in Figure 3.6 and the corresponding efflux ratios are listed in Table 3.2. For β-acids in 
the presence of verapamil (100 μM), a significant decrease of the efflux ratio was observed 
compared to the data in the absence of the P-gp-inhibitor (from 10.3 and 9.7 to 4.2 and 7.0, 
respectively). The presence of indomethacin (MRP-2-inhibitor) (50 μM) caused almost 
complete inhibition of the efflux of colupulone and (n-lupulone + adlupulone) (Table 3.2, 
Figure 3.6). A significant decrease in the efflux ratio from 10.3 and 9.7 to 0.2 for colupulone 
and (n-lupulone + adlupulone), respectively, was observed. The results suggest that both 
MRP and P-gp are involved in the efflux of hop β-acids. 
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Figure 3.6 Apical (AP)-to-basolateral (BL) transport of hop bitter acids across Caco-2 
monolayers in the presence/ absence of verapamil and indomethacin. Hop α- acids and β-
acids (50 µM) were added to either the apical (AP-to-BL) or the basolateral (BL-to-AP) 
compartment of monolayers at time zero. Samples from the receiving compartment were 
collected at 10, 20, and 30 min, and analyzed by LC-MS as described under Materials and 
Methods. Data are means ± SEM for three replicates.  
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3.4.1.3 Cellular Uptake of α- and β-Acids 
 
 
The amounts of α- and β-acids recovered in the AP chamber, BL chamber, and cell 
monolayer are shown in Figure 3.7.  
 
 
 
Fig. 3.7 Distribution of α-acids and β-acids in the apical compartment, the basolateral 
compartment, and the cell fraction. Hop α- acids and β-acids (50 µM) were added to the apical 
compartment of monolayers at time zero. After 60 min, samples were withdrawn from the 
apical compartment, basolateral compartment and cell fraction and analyzed by LC-MS as 
described under Materials and Methods. Data are means ±SEM for three replicates.  
 
 
After 60 min of incubation of the α-acids with the Caco-2 cells, the amount absorbed 
in the cell fraction was 60%, whereas 30% was transported to the BL-chamber. A residual 
amount of 10% was still present at the AP-chamber. After 60 min of incubation of the β-acids 
with the Caco-2 cells, the amount recovered in the cell fraction was only 8%, whereas 2.1% 
was present unchanged at the BL-chamber. A residual 4.0% was recovered in the AP-
chamber. More than 95% of the administered amount of α-acids was recovered unchanged.  
The formation of phase-II metabolites of α-acids seems unlikely within the duration of the 
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experiments.  The recovery of the β-acids was <15%. These observations suggest formation 
of phase II metabolites and/or degradation products of β-acids in the Caco-2 cells within the 
duration of the experiment (60 min). 
 
3.4.1.4 Enzymatic Hydrolysis of Cellular Uptake Samples of β-acids 
  
As a consequence of the low recovery of the β-acids (<15%), enzymatic hydrolysis of 
fractions from apical and basolateral compartments, and cell monolayers was carried out 
with a mixture of sulfatase and glucuronidase to determine the amount of sulfate and/or 
glucuronide conjugates (Fig 3.7, Table 3.5).  
The total amount(%), quantified after deconjugation, rendered a recovery of 97.5 ± 13.6%. 
Therefore, about 81-90% of the total amount of β-acids present in the apical compartment, 
the basolateral compartment, and cell fraction was present as conjugated sulfate or 
glucuronidated products. Following apical supplementation, 38.7 ± 2.5% of the total amount 
of the β-acid + conjugates were present in the apical compartment and 11.6 ± 1.4% in the 
basolateral compartment, whereas 47 ± 10% remained in the cell fraction. 
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Table 3.5 Amounts (%) of free and conjugated β-acids (as sulfates and glucuronides) in the 
apical compartment, basolateral compartment, and cell fraction
a 
 
 
% β-acid 
conjugated 
% β-acid non-
conjugated 
SUM   
% β-acid conjugated + 
non-conjugated 
Relative amount (%) 
Conjugated β-acids / Total β-
acids 
AP 34.7 ± 2.3 4.0 ± 0.2 38.7 ± 2.5 90 
BL 9.4 ± 0.9 2.2 ± 0.5 11.6 ± 1.4 81 
CF 38.5 ± 9.1 8.7 ± 0.6 47.2 ± 9.7 82 
SUM  
β-acids 
(%) 
82.6 ± 12.3 14.9 ± 1.3 97.5 ± 13.6 85 
 
a
Hop β-acids (50 µM) were added to the apical (AP) compartment of monolayers at time zero. 
After 60 min, samples were withdrawn from the apical compartment, the basolateral (BL) 
compartment and cell fraction (CF). Enzymatic hydrolysis with a mixture of sulfatase and β-
glucuronidase was carried out in order to determine the amount of conjugated β-acids. Control 
samples without addition of the enzyme mixture were included. Samples were analyzed by LC-
MS as described under Materials and Methods. Data are means ±SEM for three replicates. 
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3.4.1.5 Discussion 
 
Oral bioavailability is one of the most important pharmacokinetic properties of drugs. 
Various intestinal processes such as permeation, efflux, and intestinal metabolism may 
affect the bioavailabilities of hop acids. As a first aspect of the study of the bioavailability of 
hop acids, permeability experiments of hop acids in both absorptive (AP-to-BL) and secretive 
(BL-to-AP) modes were carried out to determine whether a carrier-mediated transport or a 
carrier-mediated efflux mechanism is involved. The Papp-values determined for the α-acids 
approximate the Papp-value of propranolol. Propranolol is a lipophillic compound, which is 
known for its high permeability across epithelial membranes. Rapidly and completely 
absorbed compounds are generally lipophillic and distribute readily into the cell membranes. 
Because the surface area of the brush border membranes is >1000-fold larger than the 
paracellular surface area,285 it is suggested that the hop α-acids are quickly and efficiently 
transported exclusively by the transcellular route286 in the absorptive direction.  
The absorptive transport of both α-acids and β-acids shows a linear increase during 
30 min, indicating the absence of saturation characteristics under the experimental 
conditions applied,280 which may suggest passive transport, although AP-to-BL and BL-to-AP 
permeabilities with a wider concentration range (for example, 5-200 μM) on the initial side 
are necessary to confirm this observation.  The vast majority of well-absorbed drugs are 
transported passively across cell membranes.250 Active transport of dissociated forms with 
anionic transporters or facilitated diffusion would rather lead to a sigmoid-like relationship. 
Even though, this would be observed only at sufficiently high concentrations, due by 
saturation of the carrier-mediated transport. If a compound has a low passive permeability, 
saturation of the carrier will result in a decreased absorbed fraction.242, 262 
There was no significant difference between transport in the absorptive direction and 
transport in the secretive direction of the α-acids, since PappAB and PappBA are comparable. 
Influx exceeded efflux, albeit with small differences. It may be derived that α-acids show a 
bidirectional transport by passive diffusion (i.e., not transporter-mediated). This observation 
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suggests that passive diffusion of α-acids could play a role in permeation across intestinal 
cells, not only in the Caco-2 monolayers, but possibly also in vivo. The Papp-values of the β-
acids (≤1 x 10-6 cm/s) were comparable to the Papp of atenolol, which is a marker for low 
permeability. This observation suggests that intestinal absorption of β-acids is predicted to 
be poor, which might be associated with a low bioavailability. Factors influencing diffusion 
include physico-chemical properties of molecules including molecular weight, lipophilicity, 
molecular surface polarity, hydrogen bonds, and charge.242 In a study reported by Hou et al., 
lipophilicity is recognized as one of the key descriptors governing permeability across Caco-
2 cells, reporting that measured logD explains ~50% (i.e. r2 ~0.5) of the total variance in a 
dataset of 77 permeability measurements.287 The extra isoprenyl moiety present in the β-
acids compared to the α-acids contributes to a higher lipophilicity and increased steric 
hindrance, resulting in lower absorption. Differences in lipophilicity are also demonstrated by 
the corresponding clog P-values (calculated using “Molinspiration MiTools”, based on ZINC 
database)288 of α-acids ranging from 3.2 to 3.9 for cohumulone and n-humulone, respectively 
in contrast with 6.2-6.9 for colupulone and n-lupulone, respectively. Furthermore, Gleeson et 
al. reported clogP values 3-5 for good permeability based on an analysis of > 50000 
compounds with measured artificial membrane permeability data. Weak acids can indeed 
cross cytoplasmatic lipophilic membranes in undissociated form.289, 290 Knowledge on the pH 
value of the transport medium and the pKa value of the hop acid under consideration allows 
to calculate the concentration of undissociated molecules at any pH value because 
[undissociated acid] = [total acid administered]/[ 10(pH-pKa) + 1 ] by rearrangement of the 
Henderson-Hasselbalch equation. Under the experimental conditions of pH 7.4, the ratio of 
dissociated/undissociated molecules was approximately 100. The presence of a high 
percentage of the dissociated forms seems contradictory with the high absorption of α-acids. 
Presumably, fast transport of the undissociated species from the apical compartment into the 
cell compartment, followed by a fast transport further to the basolateral compartment, is 
maintained by significant protonation of ionized α-acids due to rebalancing of the shifted 
acid/conjugated base equilibrium at the apical compartment. Therefore, it would be 
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interesting to study the effects of the pH of the transport medium on the epithelial transport 
of hop acids. 
Often, transport of compounds across the intestinal epithelial is accompanied by 
phase-II conjugation reactions, which may affect drug absorption. Enzymatic hydrolysis of 
samples following a 60 min-incubation of β-acids with Caco-2 cells indicate that the largest 
fraction of the β-acids is present as sulfate and/or glucuronide conjugates, suggesting that 
intestinal absorption of the lipophillic β-acids is limited by substantial glucuronidation and/or 
sulfation by the enterocytes. For Caco-2 cells derived from human colon carcinoma, 
expression of human phase II metabolizing enzymes has been confirmed.291 Therefore, the 
β-acid-derived phase-II metabolites found in the present study indicate that similar types of 
metabolites of β-acids might also be found in the human small intestine. It is also interesting 
to notice that the intracellular formed sulfated and glucuronidated β-acids were highly 
abundant in the apical compartment, whereas only low levels of those metabolites were 
found in the basolateral compartment. This suggests that a certain type of active transporter 
is involved in the selective efflux of the metabolites formed in the Caco-2 cells. Membrane 
transporters, especially the efflux transporters P-gp and MRP-2, are known to affect 
absorption and oral bioavailability of drugs. Previous studies demonstrated that P-gp- and 
MRP-type efflux pumps are capable of transporting phase-II metabolites such as glutathione, 
and glucuronide and sulfate conjugates.292  
Verapamil and indomethacin are representative inhibitors for in vitro screening and 
appropriate standards for such experiments. In drug discovery, for the P-gp-substrate 
specificity, the so-called “Rule of Four”, can be applied as an aid in predicting whether or not 
a test compound is likely to be a candidate for P-gp-involvement. The rule can be 
summarized as follows: a compound is more likely to be a P-gp-substrate when it has (N + 
O) ≥ 8 and a molecular weight (MW) > 400 with weak acidic character (pKa > 4). Most P-gp-
substrates can be defined as lipophillic and neutral species, while MRP-2 is directly 
responsible for the intestinal elimination of organic anions, complementing the substrate 
specificity of P-gp.  
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The bidirectional transport of colupulone and (n-lupulone + adlupulone) exhibited 
efflux ratios of 10.3 and 9.7, respectively, suggesting the involvement of carrier-mediated 
transport for β-acids (active efflux pathway by P-gp-, BCRP-, and/or MRP-2-type efflux 
pumps). Co-administration of verapamil or indomethacin did not modify the transport of hop 
α-acids, as expected.  In contrast, in the current study, both P-gp and, to a larger extent, 
MRP-2 decreased the efflux of β-acids to the apical compartment and increased the 
disposition of the β-acids to the basolateral compartment. Further study is needed to 
determine the possible interference of verapamil and indomethacin with phase-II 
conjugation, since several phase-II metabolites of verapamil and indomethacin have been 
reported.293, 294 
For the α-acids as well as for the β-acids, the different nature of the side chain at C-1 
(isopentanoyl in n- and ad-, isobutyroyl in co-analogues) resulted in different absorption 
efficiencies. The co-analogues seemed to be more efficiently absorbed than the (n- + ad)-
analogues. The different nature of the side chain is reflected by differences in diffusion and 
transport rates. The above observations suggest that the dissimilarity in the molecular 
structure and corresponding lipophilicity between the investigated α-acids and β-acids is 
sufficiently high to result in substantial differentiated absorption efficiencies, substrate affinity 
for efflux transporters, and metabolizing enzymes.  
Although no substantial degradation in the experimental setup was observed, 
experiments including the stability of these acids during gastrointestinal digestion by ex vivo 
studies in the stomach and intestinal fluid could be a great contribution to the discussion of 
the findings of this study in a broader context. 
 
In conclusion, the present study demonstrates fast and efficient absorption of hop α-
acids. Cohumulone showed higher absorption than (n-humulone + adhumulone). On the 
basis of the low apparent permeability coefficient of β-acids, the in vivo absorption of orally 
administered β-acids is predicted to be low. The limiting factors in the absorption of β-acids 
could be the involvement of P-gp- and MRP-2-type efflux transporters and/or substantial 
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phase-II metabolism reactions. The results from the Caco-2 cell culture model must be 
interpreted with caution because clearance and toxicity have not been measured, although 
they should have an impact in vivo.  
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3.4.2 Caco-2 cell experiments of iso-α-acids and reduced derivatives  
 
3.4.2.1 Bidirectional transport of iso-α-acids and reduced derivatives across Caco-2 
monolayers 
 
In this study, the absorption of IAA, DHIAA, and THIAA was investigated using an in 
vitro model system based on Caco-2 cell monolayers. The transport characteristics were 
determined in both the apical-to-basolateral (AP-to-BL) and the basolateral-to-apical (BL-to-
AP) direction. In Figure 3.8A (AP-to-BL) and 3.8B (BL-to-AP), the cumulative amounts 
(pmol/cm²) transported into the receiving chamber after 4h of incubation as a function of the 
donor concentration of IAA, DHIAA, and THIAA is presented.  
Significantly higher amounts (P < 0.0001) of IAA and THIAA were transported to the 
receiving compartment compared with DHIAA, both in absorptive (15.1 ± 0.8 nmol/cm² and  
16.4 ± 2.2 nmol/cm² for IAA and THIAA versus 7.8 ± 0.6 nmol/cm² for DHIAA for a 
concentration of 120 µM in the apical compartment) and secretive (28.9 ± 7.2 nmol/cm² and 
32.4 ± 3.4 nmol/cm² for IAA and THIAA versus 9.5 ± 2.6 nmol/cm² for DHIAA for a 
concentration of 120 µM in the basolateral compartment) directions. All transport results 
showed a linear dose-dependent relationship. The cumulative amounts (nmol/cm²) 
transported into the receiving compartment for a concentration of 120 μM as a function of 
time are shown in Figures 3.9A (AP-to-BL) and 3.9B (BL-to-AP) 
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Fig. 3.8 Cumulative amounts (nmol/cm²) of IAA, DHIAA, and THIAA transported across Caco-2 
monolayers in absorptive (A) (AP-to-BL) and secretive (B) (BL-to-AP) directions in function of 
different donor concentrations for 4 h of incubation. Each point was the mean ± standard 
deviation of three independent experiments. Trend lines fitted through zero show good 
linearity for AP-to-BL and BL-to-AP transport (r
2
 > 0.95). IAA: iso-α-acids; DHIAA: dihydroiso-α-
acids; THIAA: tetrahydroiso-α-acids. 
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Fig. 3.9 Cumulative amounts (nmol/cm²) of IAA, DHIAA, and THIAA transported across Caco-2 
monolayers in absorptive (A) (AP-to-BL) and secretive (B) (BL-to-AP) directions in function of 
time for a donor concentration of 120 µM. Each point was the mean ± standard deviation of 
three experiments. Trend lines fitted through zero show good linearity for AP-to-BL and BL-to-
AP transport (r
2
 > 0.97). IAA: iso-α-acids; DHIAA: dihydroiso-α-acids; THIAA: tetrahydroiso-α-
acids. 
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For all the hop-derived acids, the amount transported into the receiver chambers increased 
linearly with time, in both absorptive and secretive directions. The rates of transport are 
presented in Table 3.6, which shows the values for the apparent permeability coefficients 
Papp and efflux ratios for the hop-derived acids in the AP-to-BL, as well as in the BL-to-AP 
direction. The PappAB-values ranged from 1.58 x 10
-6 to 5.57 x 10-6 cm/s. Both IAA and THIAA 
showed similar absorption transport rates, since differences in their PappAB-values were not 
statistically significant. In secretive transport, the PappBA of the hop-derived acids varied from 
5.68 x 10-6 to 16.28 x 10-6 cm/s. Efflux ratios of IAA and THIAA were similar around 3, 
slightly lower than the value for DHIAA which was around 3.5.  
 
 
 
Table 3.6 Permeability in the AP-to-BL and BL-to-AP directions and efflux ratio of IAA, DHIAA, 
and THIAA across Caco-2 monolayers. Values are presented as mean values ± standard 
deviation.  IAA: iso-α-acids; DHIAA: dihydroiso-α-acids; THIAA: tetrahydroiso-α-acids
a 
 
Compound 
Papp (x 10
-6
 cm/s) 
Efflux ratio AP-to-BL BL-to-AP 
IAA 4.62 ± 1.29 13.02 ± 3.13 2.8 ± 1.4 
DHIAA 1.58 ± 0.22
*
 5.68 ± 0.87
**
 3.5 ± 1.0 
THIAA 5.57 ± 1.22 16.28 ± 2.71 2.9 ± 1.1 
*Significant difference in Papp (AP-to-BL) of DHIAA versus IAA and THIAA. P < 0.0001 
**Significant difference in Papp (BL-to-AP) of DHIAA versus IAA and THIAA. P < 0.0001 
a 
Comparison of Papp between IAA, DHIAA, and THIAA was performed using one-way analysis 
of variance (ANOVA) followed by post-hoc Bonferroni. Statistically significant differences 
versus the Papp between IAA, DHIAA, and THIAA are indicated. 
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3.4.2.2 Intracellular accumulation of iso-α-acids and reduced derivatives in Caco-2 cells  
 
The mass balance was determined from the sum of the cumulative amount 
transported, the amount remaining in the donor compartment, and the amount accumulated 
in the cells during the transport experiment in relation to the initial amount in the donor 
compartment. The total amount of IAA and THIAA recovered was 85-90 % in all experiments 
indicating that there was no significant breakdown, metabolism, nor sorption to the surface of 
the Transwell® microplates and inserts.  
In contrast, recovery of DHIAA was lower than 45%. The percentages of hop-derived 
acids associated to the cells with respect to the initial dose were found to be 1.5% with IAA, 
0.9% DHIAA, and 2.0% with THIAA. This showed that hop-derived acids were not 
significantly accumulated in the cells during the transport experiment. In contrast, a 
substantial amount was transported across the monolayer. 
To probe possible phase-II metabolism of IAA, DHIAA, and THIAA, enzymatic 
hydrolysis of fractions from cell monolayers was carried out with a mixture of sulfatase and 
glucuronidase (sulfatase from H. Pomatia with secondary β-glucuronidase activity). The 
presence of conjugates could not be demonstrated in samples of IAA and THIAA. The 
amounts, quantified after deconjugation, were not significantly different from the non-
hydrolyzed levels, indicating that formation of phase-II metabolites of IAA and THIAA seems 
unlikely. However, enzymatic hydrolysis of cellular fractions of DHIAA showed that up to 60 
% of the intracellular amount was conjugated as glucuronides and/or sulfates. 
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3.4.2.3 Discussion  
 
Hop-derived bitter acids, have been reported to show important bioactive properties, 
including anti-inflammatory, anti-angiogenic properties, lipid metabolism enhancement, and 
counteracting diabetes type 2. However, a review of the literature shows that data on 
bioavailability of these compounds are lacking. In this study, the in vitro transport 
characteristics, of IAA, DHIAA, and THIAA were assessed. The doses of hop acid applied in 
the present Caco-2 assay (30-120 μM) are relevant, as beer may contain up to 100 mg/l (or 
equal to 250 µM) hop-derived bitter acids (depending on beer type and brand).90 The dose 
solutions used in the experiments are diluted from commercially available Isohop®, 
Redihop® and Tetrahop Gold®, which are stable solutions (pH 8-10) of potassium salts of 
IAA, DHIAA, and THIAA, respectively. For optimal stability and solubility, dose formulations 
were obtained by dilution with HBSS buffer at pH 7.4. Results from the Caco-2 experiments 
showed that permeability (AP-to-BL) mechanisms other than passive diffusion seem unlikely, 
as indicated by the linear dose-transport and time-transport relationships, and the lack of 
saturation effects. A passive diffusion transport mechanism occurs most probably 
transcellularly, since the paracellular pathway is restricted by the tight junctions of intestinal 
epithelium.295 Also, the surface area of the luminal cell membrane of the intestinal epithelium 
is 1000-fold larger than that of the paracellular space.285 For the concentration range used in 
this study, the linear dose-transport relationship indicated that Papp values were independent 
of the dose applied for all hop-derived bitter acids.  
Based on the PappAB of IAA, DHIAA, THIAA in combination with the results of the α-
acids (AA) and β-acids (BA) of the previous subsection, a ranking in absorption is suggested 
as follows, AA > THIAA ≈ IAA > DHIAA > BA. In studies attempting to correlate passive drug 
permeability in Caco-2 experiments with drug absorption in 5 humans after oral 
administration, it was observed that moderately to well-absorbed compounds (20-80% 
fraction absorbed) had permeability coefficients of 1 x10-6 <Papp<10 x 10
-6 cm/s, whereas 
poorly absorbed drugs had Papp < 0.1 x 10
-6 cm/s (< 20 % fraction absorbed).252, 296 Taking 
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this into account and based on the values obtained in this study, a fair to good intestinal 
absorption of this range of compounds could be expected. 
For all hop-derived acids examined, secretion (BL-to-AP) showed a linear 
relationship between dose and amount transported suggesting that secretion is also 
expected to occur by passive diffusion. Efflux would only become important, when 
concentrations at the luminal side attain 20-50% of that at the blood side, independent of the 
involvement of active transporters (since diffusion is forced by a concentration gradient). 
Most likely, this is only reached just before complete absorption. However, efflux 
permeability coefficients (BL-to-AP) PappBA ranged from 6 to 16 x 10
-6 cm/s and efflux ratios 
(around 3-3.5) were substantial, hence additional experiments using specific inhibitors for 
efflux pumps (Pgp, MRP-2, and BCRP) providing proof of possible active efflux mechanism 
involvement would be important. In earlier work (results presented in subsection above),297 
the in vitro transport of hop α-acids and β-acids across Caco-2 monolayers has been 
investigated, showing efficient epithelial transport of hop α-acids (Papp > 10 x 10
-6 cm/s), 
whereas the permeability of β-acids was limited by the involvement of Pgp and MRP-2 type 
efflux transporters and phase-II metabolism.  
The lower PappAB-value of DHIAA compared to the values for IAA and THIAA could be 
explained by a substantial conjugation of DHIAA, following absorption in the Caco-2 cells, 
from where the major fraction being conjugated can transfer to the BL-compartment, or back 
into the AP-compartment, whether or not with the involvement of active transport 
mechanisms, most often of the MRP-type family.272 The absence of conjugation of IAA and 
THIAA provides an indication for conjugation via the accessible alcohol group in the 
molecular structure of DHIAA. The enolic group, present in the molecular structures of IAA 
and THIAA, may be inactive for conjugation in view of its acidity or due to intramolecular 
hydrogen bonding with the adjacent carbonyl group in the acyl side chain. 
Although the Caco-2 cell model is recognized rather as a model for human intestinal 
absorption than for studying phase-II intestinal metabolism, there are examples of 
conjugation reactions of xenobiotics by Caco-2 cells in the literature,263, 264, 298 including 
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flavonoids originating from hops, which are known to be extensively conjugated by Caco-2 
cells.265   
 
In conclusion, the present study demonstrates fast and efficient intestinal absorption 
of hop iso-α-acids and reduced derivatives. In the next chapter, the tissue culture data 
obtained in these Caco-2 studies will be compared with pharmacokinetic data generated in 
vivo. 
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IV. Bioavailability of hop-derived bitter 
acids using the rabbits as an in 
vivo model 
 
 
4.1 In vivo studies on the bioavailability 
 
 
 
This subchapter is based on:  
 
Cattoor K.; Remon J.P.; Boussery K.; Van Bocxlaer J.; Bracke M; De Keukeleire D.; 
Deforce D.; Heyerick A., Bioavailability of Hop-Derived Iso-α-acids and Reduced Derivatives, 
Food and Function  2011, 2 (7), 412-422 
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4.1.1. Introduction 
 
To express the efficacy of a compound to enter the systemic circulation, the term 
‘bioavailability’ is used. Bioavailability can be described as a numerical parameter which 
reflects the unchanged fraction of a compound that reaches the systemic circulation 
following administration. Following intravenous dosing, bioavailability is 100%. For every 
other way of administration, the bioavailability varies between 0 and 100%. Factors affecting 
an incomplete bioavailability can be numerous, including incomplete dissolution, intestinal 
instability, or metabolism.  
Oral dosage dominates contemporary drug therapy, as it is regarded to be safe, 
efficient and easily accessible with minimal discomfort compared to other routes of 
administration, such as sublingual, rectal, subcutaneous, intramuscular, transdermal, ocular, 
or intranasal dosing. However, despite the advantages of oral administration compared to 
alternatives, many of the mechanisms of drug uptake following oral administration remain to 
be fully characterized. Previously, for example, drug development projects were frequently 
terminated on grounds of poor gastrointestinal absorption and bioavailability.299 Today, 
however, it is fully accepted that it is important to consider the total biopharmaceutical (e.g. 
solubility, permeability, first pass effect) and pharmacokinetic variables (clearance, half-life, 
volume of distribution) in pharmaceutical drug development.  
The bioavailability is determined from the corresponding pharmacokinetic (PK) 
profiles obtained by in vivo research. Pharmacokinetics (PK) is the study of a drug and/or its 
metabolite kinetics in the body. More precisely, it refers to the temporary evolution of a 
compound and its metabolites in plasma, (or whole blood), and target tissues/ organs over 
time. The body is a very complex system and a compound undergoes many steps as it is 
being absorbed, distributed through the body, metabolized, and/ or excreted (ADME). In 
general, pharmacokinetics can be divided into two categories of study: absorption and 
disposition. Disposition is further subdivided into the study of distribution and elimination. 
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The term elimination includes both metabolism and excretion, since a compound is 
considered being eliminated when it is no longer in its original chemical structure, even if the 
resulting metabolites remain in the body. The dynamic relationship between ADME and PK-
properties provide the basis for drug discovery. Usually, ADME studies by in vitro, in situ 
(e.g. perfusion of specific organ), in vivo, or in silico techniques are focused solely in one 
specific pharmacokinetic aspect (Absorption, Distribution, Metabolism, Excretion) whereas 
the name ‘pharmacokinetics’ is normally reserved to in vivo studies where an approach of all 
the ADME processes together is taken. 
In the present study, different aspects of the bioavailability of the hop-derived bitter 
acids were investigated. The pharmacokinetic parameters for AA, BA, IAA, DHIAA, and 
THIAA were investigated upon both intravenous and oral dosing in New Zealand white 
rabbits. From these values, the absolute bioavailability of the different HBA was determined. 
Knowledge on the bioavailabilities and the pharmacokinetic parameters of hop-derived AA, 
BA, IAA, DHIAA, and THIAA is essential to understand possible health benefits associated 
to preparations containing hop-derived compounds such as beer and hop-based food 
supplements. 
 
4.1.2 Materials and methods 
 
4.1.2.1 Materials 
 
Isohop® (20% w/v iso-α-acids), Redihop® (35% w/v dihydroiso-α-acids), and Tetrahop 
Gold® (10% w/v tetrahydroiso-α-acids) were obtained from Barth-Haas Group (Botanix, Kent, 
UK). LC-MS solvents (analytical grade) were from Biosolve (Valkenswaard, the 
Netherlands). 
International calibration standards for α-acids and β-acids (ICE-2; 49.39% α-acids (w/w), 
24.94% β-acids (w/w)), iso-α-acids (DCHA-Iso, ICS-I3; 62.3% trans-iso-α-acids), dihydroiso-
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α-acids (all cis-dihydroiso, ICS-R2; 65.3 % w/w cis-dihydroiso-α-acids), and tetrahydroiso-α-
acids (ICS-T3; 99.4% w/w tetrahydroiso-α-acids) were all obtained from Labor Veritas 
(Zurich, Switzerland). Sulfatase type H1 (from Helix pomatia), was purchased from Sigma-
Aldrich (Bornem, Belgium).  
 
4.1.2.2 Methods 
 
In vivo evaluation 
 
The protocol of the animal experiments was approved by the Ethics Committee of the 
Institute for Agricultural and Fisheries Research (ILVO) (Merelbeke, Belgium). New Zealand 
white rabbits (3.0 ± 0.5 kg) were fasted 16 h prior to the experiment. Water was available ad 
libitum. In accordance with the regulations that apply to animals in laboratories in the ‘Guide 
for the Care and Use of Laboratory Animals’,300 the rabbits were sedated with an 
intramuscular injection of 0.05 ml kg-1 Placivet® (Codifar, FL, USA) immediately after either 
intravenous (i.v.) or oral administration.  
 
Collection of plasma samples  
 
A first group of 12 rabbits was divided in 4 groups of 3 animals. Each group (n = 3) 
received an i.v. dose in the marginal ear vein of 25 mg kg-1 (dose volume 1 ml) of AA + BA, 
IAA, DHIAA, or THIAA, respectively. Donor solutions containing 75 mg ml-1 of (AA + BA) 
(containing 75 mg ml-1 of a mixture of AA and BA) were prepared in ammonium acetate 
buffer (0.1 mol/l, pH 10) by dilution of a methanolic solution made up by dissolving a define 
amount of calibration standard.  
Donor solutions containing 75 mg ml-1 of IAA, DHIAA, or THIAA were prepared in 
ammonium acetate buffer (0.1 mol/l, pH 10) by dilution of commercially available aqueous 
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solutions (potassium salts) of hop-derived bitter acids at pH 8–10 (Isohop® 30%, Redihop® 
35%, Tetrahop Gold® 9%). The pH of the solution was increased to allow solubility of the 
compounds of interest. It is not expected that this significantly influences the 
pharmacokinetics upon both intravenous and oral intake as the total dosed volume was low 
(1 ml) and the recipient compartments (blood or stomach) have sufficient buffering capacity. 
Blood samples were collected from the ear vein at 0.5 min before and at 0.5, 2, 5, 10, 15, 30, 
45, 60, and 120 min after i.v. dosing; (in case of α-acids + β-acids, samples up to 60 min. 
were collected). A second group of 24 rabbits was randomly divided in 4 groups of 6 
animals. Each group (n = 6) was administered, via oral gavage using a syringe, an oral dose 
of 25 mg kg-1 (dose volume of 1 ml) of AA + BA, IAA, DHIAA, or THIAA, respectively. Similar 
to the i.v. administration, dosing solutions were diluted in ammonium acetate buffer (0.1 
mol/l, pH 10) to a final concentration of 75 mg ml-1 from commercially available Isohop® 30%, 
Redihop® 35%, and Tetrahop Gold® 9%. Blood samples were collected at 0.5 min before and 
at 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 h after oral dosing. After addition of heparin (LEO Pharma, 
Wilrijk, Belgium) to the blood samples, plasma was separated by centrifugation (700 x g, 5 
min) and samples were stored at -20 °C until further processing. 
 
Collection of faeces and urine  
 
In a separate experiment, 12 rabbits were divided in 4 groups of 3 animals. Each 
group was either administered a single oral dose or single i.v. dose in the marginal ear vein 
of 25 mg kg-1 solution of AA + BA, IAA, DHIAA, or THIAA, respectively. Donor solutions were 
diluted in ammonium acetate buffer (0.1M, pH 10) from commercially available solutions of 
potassium salts of HBA at pH 8–10 (Isohop® 30%, Redihop® 35%, and Tetrahop Gold® 9%, 
respectively). 
Urine and faeces were collected over a period of 24 h after oral and i.v. dosing. All samples 
were immediately frozen at -20°C and analyzed within 2 months. 
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Sample extraction  
 
The total volume of urine was determined and a sample of the total urine (500 µl) 
was diluted with 2.5 ml sodium acetate (NaOAc) buffer (0.1 mol/l; pH 5.0). Faecal material 
was lyophilized, weighted and grinded. Samples of total faeces (1.0 g) were diluted with 3 ml 
H2O and homogenized. To 1.0 g of this homogenate, 5 ml NaOAc buffer (0.1 mol/l; pH 5.0) 
was added. Subsequently, the urine, faecal, and plasma samples (300 µl) were spiked with 
internal standard (IS) (1.0 mg). THIAA were applied as internal standard in case of samples 
containing AA + BA, IAA, and DHIAA. In plasma samples following dosing of THIAA, DHIAA 
were used as internal standard. After addition of IS, samples were acidified (pH 2) with 
H3PO4 (0.1 mol/l; 1.5 volumes) followed by extraction with EtOAc (4 volumes). The EtOAc 
phase was evaporated (N2) and residues were reconstituted in 100 µl MeOH. Samples were 
stored at -20 °C prior to LC-MS analysis. 
 
Stability  
  
The short-term stability of (AA + BA), IAA, DHIAA, and THIAA in rabbit plasma and 
urine was evaluated. Blank plasma (500 µl) and urine (300 µl) were spiked with (AA+BA), 
IAA, DHIAA, or THIAA at concentrations of 0.1 and 1.0 mg ml-1 and left at room temperature 
for 12 h. Next, the samples were extracted following the procedure described in the section 
‘‘Sample extraction’’ and analyzed using LC-MS.  The concentration of each compound was 
compared to that of fresh samples and expressed in terms of degradation. 
 
Enzymatic hydrolysis of samples 
 
The extent of phase-II conjugation of the HBA as sulfate or glucuronide in the 
different samples (plasma, urine, faeces) was determined by enzymatic hydrolysis, based on 
a method validated including by Wyns et al.281 In this study, a bioanalytical method for the 
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detection of 13 phytoestrogens and their conjugates (including xanthohumol and 8-
prenylnaringenin) has been fully validated. Plasma samples (300 µl) and a sample of total 
urine (500 µl) were diluted with 5 volumes NaOAc buffer (0.1 mol/l; pH 5.0). A sample (1.0 g) 
of total faeces was diluted with 3 ml H2O and homogenized. To 1.0 g of this homogenate, 5 
ml NaOAc buffer (0.1 mol/l; pH 5.0) was added. To each of these mixtures, a preparation 
containing both β-glucuronidase (10000 units ml-1) and sulfatase (330 units/ml) from H. 
pomatia (30 µl) from a solution in NaOAc buffer (0.1 mol/l, pH 5) was added. Samples were 
incubated for 2 h at 37 °C. Afterwards, samples were extracted as described in the section 
‘Sample extraction’. Replicate control samples of urine, faeces, and plasma were included 
with no enzyme treatment to determine the extent of glucuronidation and/or sulfation. Urine, 
plasma and faecal levels of conjugated hop-derived bitter acids were calculated by 
subtracting the amount of free hop acid (no enzyme treatment) from the amount of total hop-
derived bitter acids (+ β-glucuronidase/sulfatase). 
 
 
LC-MS analysis of samples 
 
The extracted samples from the different biological media (urine, faeces, plasma) 
were analyzed using LC/MS analysis (Agilent 1200 LC-MS, Agilent, AT, Santa Clara, 
California, USA). The Agilent Chemstation software package (Rev.B.02.01) was used to 
control the analytical system as well as for data acquisition and processing. As stationary 
phase, an Xbridge C18 column (150 x 30 mm, 3.5 µm) (Waters, Zellik, Belgium) connected to 
a C18 guard column (20 x 3.0 mm; 3.5 µm) (Waters, Zellik, Belgium) was used. The mobile 
phase consisted of 10 mM ammonium acetate pH 9.75 + 20% MeOH (A) and 100% MeOH 
(B). The mobile phase was degassed by the integrated AT 1200 series vacuum degasser. 
The flow rate was 0.5 ml min-1 and the column temperature was 40 °C. The initial mobile 
phase, 27% B, was increased linearly to 60% B over 24 min, maintained for 5 min, and 
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further increased to 95% B in 5 min and maintained during 4 min. Finally, the mobile phase 
was re-adjusted to 27% B in 1 min and re-equilibrated at 27% B for 6 min prior to the next 
injection. UV-detection was performed at 314 nm for α-acids and β-acids and at 270 nm for 
iso-α-acids, dihydroiso-α-acids, and tetrahydroiso-α-acids.  MS analysis was performed 
using an AT multimode ionization source coupled to a single quadrupole detector (MSD), SL 
version. A standard APPI/APCI calibration mix was used for daily tuning of the MSD-source. 
The MS-parameters in the negative atmospheric pressure chemical ionization (APCI) mode 
were tuned to maximize formation of the deprotonated analyte. Interface settings were as 
following: N2 drying gas temperature 250 °C, N2 drying gas flow 5 l min
-1, APCI vaporizer 
temperature 150 °C, nebulizer pressure 105 Pa, capillary voltage 1000 V, corona current 6 
µA, and charging voltage 1000 V. In each analysis, qualitative identification was performed 
in the negative ion scan mode (m/z 150–700) and quantitative data were obtained by 
construction of the extracted ion chromatogram following measurement in the selected ion 
monitoring (SIM) mode. The [M - H](-) m/z-values, used for quantification of AA, BA, IAA, 
DHIAA, and THIAA, and the retention times of the different compounds are presented in 
Table 4.1. The quantitative data of the analysis of THIAA were assessed as an example to 
determine a possible difference in bioavailability between the cis- and trans-stereoisomers or 
between the different co- versus n-homologues. Calibration curves were established by 
linear-least-squares regression analysis using the ratio of the peak area of total AA, BA, IAA, 
DHIAA, or THIAA versus IS against the concentration of hop-derived acids in 6 standards 
(blank plasma medium) covering the range of 0.1 to 4.0 µg ml-1 (or 0.30 to 12 µM) in three 
replicates.  
Daily prepared calibration curves were constructed by injecting calibration standards 
at the beginning and at the end of each batch of samples.  
To evaluate the accuracy and precision of the method, recovery experiments were 
carried out on three consecutive days by adding different concentrations of AA, IAA, DHIAA, 
and THIAA (0.1 and 1.0 µg ml-1) to blank urine and plasma. The accuracy was expressed in 
terms of relative error, and the precision was evaluated in terms of the relative standard 
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deviation (RSD). The limit of detection (LOD) and the limit of quantification (LOQ) of the 
method were defined as the lowest concentration with a signal-to-noise ratio of 3 and 10, 
respectively, in spiked samples, where the noise data were taken from the analysis of blank 
matrices. 
 
Table 4.1 Molecular ions used for the selected ion monitoring (SIM) mode for the various hop 
acids in LC-MS analysis.  
 Compound   MW (g/mol)  m/z (-)  
α-acids  
cohumulone    AA1 
348  347  
adhumulone    AA2 362  361  
humulone    AA3 
β-acids  
colupulone    BA1 
400  399  
adlupulone    BA2 414  413  
lupulone    BA3 
iso-α-acids 
cis-isocohumulone    IAA1 348  347  
trans-isocohumulone    IAA2 
cis-isoadhumulone    IAA3 
362  361  trans-isoadhumulone    IAA4 
cis-isohumulone    IAA5 
trans-isohumulone    IAA6 
dihydroiso-α-acids 
cis-dihydroisocohumulone    DH1 350  349  
cis-dihydroisocohumulone    DH2 
cis-dihydro-isoadhumulone    DH3 
364  363  cis-dihydro-isoadhumulone    DH4 
cis-dihydro-isohumulone    DH5 
cis-dihydro-isohumulone    DH6 
tetrahydroiso-α-acids 
cis-tetrahydro-isocohumulone    TH1 352  351  
trans-tetrahydro-isocohumulone    TH2 
cis-tetrahydro-isoadhumulone   TH3 
366  365  trans-tetrahydro-isoadhumulone    TH4 
cis-tetrahydro-isohumulone TH5 
trans-tetrahydro-isohumulone    TH6 
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Pharmacokinetic calculations 
 
The plasma concentration-time profiles were analyzed by Win-NonLin® (version 
5.2.1, Pharsight Corporation, Mountain View, California, USA). The pharmacokinetic 
parameters were determined from the individual plasma concentration-time profiles by non-
compartmental analysis. According to the plasma concentration-time curves, the area-under-
curve (AUC0-t) was calculated by the linear trapezoidal rule from zero to the last time point 
showing a measurable concentration of the analyte. The terminal half-life (t1/2) was 
calculated as [ln(2)] λz
-1 and λz was the terminal elimination rate constant and was estimated 
from the slope of the terminal regression line.  The AUC0-∞ was calculated as AUC0-t + [Ct λz
-
1], where Ct is the last detectable plasma concentration and t is the time at which this 
concentration occurred. In all of the cases, the degree of extrapolation of AUC0-∞ was lower 
than 20%. The peak concentration (Cmax) and the time at which this occurred (tmax) were 
obtained from the observed data. The oral bioavailability (F) was determined by the ratio of 
the AUC0-∞ following oral and i.v. dosing. 
 
Statistical analysis 
 
SPSS release 17.0 for Windows (SPSS, Chicago, Illinois, USA) was used for all 
statistical analyses. The in vivo experiments had 3 independent observations for each test 
group (an identical dose of (AA + BA), IAA, DHIAA, and THIAA, respectively, was applied to 
3 rabbits), except for the oral plasma study in which 6 individual rabbits received an identical 
oral dose. Data were expressed as means ± standard deviation. The normality of distribution 
was investigated using the Shapiro-Wilk test and the homogeneity of variances was 
evaluated using Levene’s test. Comparison of means between more than 2 groups was 
performed using one-way analysis of variance (ANOVA) followed by Bonferroni post-hoc 
comparison of statistical significance. Results were considered to be statistically significant 
when P < 0.05. 
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4.1.3 Results 
 
Stability  
 
To investigate the short-term stability of the studied compounds in rabbit plasma and 
urine, control experiments with (AA + BA), IAA, DHIAA, and THIAA were carried out. Almost 
all (>95%) spiked hop-derived bitter acids were recovered unchanged from rabbit urine and 
plasma, indicating no significant degradation for (AA + BA), IAA, DHIAA, or THIAA. In 
addition, no inter-conversion of AA to IAA, or from the trans- to cis-form of IAA, DHIAA, and 
THIAA was observed. 
 
LC-MS Method for quantification of hop-derived bitter acids in plasma and urine 
 
For more details on the chromatographic LC-MS method used for separation of α-acids, β-
acids, iso-α-acids, dihydro-iso-α-acids, and tetrahydro-iso-α-acids, please refer to the 
previous chapter. The limits of detection (S/N = 3) for all compounds, both in urine and 
plasma, are listed in Table 4.2. In urine, the LODs ranged from 3.0 ng/ml to 40.1 ng/ml, and 
in plasma, from 4.0 ng/ml to 46.9 ng/ml. The limits of quantification were set as the lowest 
point of the calibration curves with a signal-to-noise ratio of at least 10. With regard to 
specificity, only a few small peaks were observed in the mass chromatograms of different 
blank urine and plasma samples. Since the present method also makes use of extracted 
ions for quantification, the background is further reduced and the sensitivity as well as 
specificity are increased. Moreover, simultaneous recording of characteristic retention times 
and UV spectra favored accurate identification and quantification of the target compounds. 
The linearity was tested in urine for the range of concentrations 0.1–4 µg/ml for all 
compounds.  Calibration curves showed linear responses for all analytes over the dynamic 
ranges and the corresponding regression correlation coefficients (r²) were all >0.995. 
Table 4.2 Limit of detection (LOD) in urine and plasma 
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 Plasma LOD (ng/ml) Urine LOD (ng/ml) 
AA 46.9 9.3 
BA 2.3 3.0 
IAA 4.0 31.0 
DHIAA 4.1 14.2 
THIAA 10.0 40.1 
 
The accuracy and precision, expressed as the percentage relative error (%RE) and 
relative standard deviation (RSD), was within the acceptable ranges of 15% for all 
compounds at all concentrations (Table 4.3), except for the α-acids in plasma (18.4% RSD). 
In urine, the accuracy ranged from 2.9% to 11.0% and, in plasma, from 5.3% to 10.0%. The 
intra-assay precision ranged from 3.4% to 5.3% and from 1.3% to 8.9% in urine and plasma, 
respectively. The inter-assay precision ranged from 4.9% to 13.2% and from 5.4% to 18.4% 
in urine and plasma, respectively.  Based on the data above, this method was considered 
suitable for our purpose. 
 
Table 4.3 Accuracy (%RE) and precision (RSD) (intra- and inter-assay) in urine and plasma 
 
Plasma  Urine   
accuracy precision accuracy precision 
intra-assay inter-assay intra-assay inter-assay 
AA 5.3 8.9 18.4 11.0 3.5 13.2 
BA 7.3 4.7 6.2 10.4 5.3 9.9 
IAA 4.9 1.3 8.9 6.5 4.5 4.9 
DHIAA 5.4 2.4 5.4 12.0 3.4 8.9 
THIAA 10.0 4.5 10.1 2.9 3.6 12.1 
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Pharmacokinetics of AA, BA, IAA and reduced derivatives 
 
In neither of the fractions (urine, plasma, fecal), no detectable amount of unchanged 
β-acids could be observed upon IV and oral dosing of β-acids. Therefore, results on 
bioavailability of β-acids have been left out in this work. 
Plasma concentration-time curves following i.v. and oral administration of AA, IAA, 
DHIAA, and THIAA are presented in Fig. 4.2 and Fig. 4.3, respectivelyThe corresponding 
pharmacokinetic parameters calculated from the non-compartmental analysis are shown in 
Table 4.4 and Table 4.5. After i.v. injection of 25 mg kg-1 of AA, IAA, DHIAA, and THIAA, the 
plasma levels of AA and IAA declined faster (clearance of AA and IAA was 707 ± 17, and 
931 ± 91 ml h-1, respectively) than those of DHIAA and THIAA, which showed both a similar 
elimination slope (Fig. 4.2). This is also illustrated by a half-life (t1/2) of 0.34 ± 0.02 h for AA 
and 0.32 ± 0.03 h for IAA versus 0.72 ± 0.10 h and 0.69 ± 0.07 h for DHIAA and THIAA, 
respectively. 
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Figure 4.2 Plasma concentration-time curves in rabbits following intravenous (0.5 – 60 min; n = 
3) administration of 17 mg/kg AA or 25 mg/kg IAA, DHIAA, and THIAA. Values represent the 
mean plasma concentration and error bars represent the standard deviation. AA: α-acids IAA: 
iso-α-acids; DHIAA: dihydroiso-α-acids; THIAA: tetrahydroiso-α-acids 
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Table 4.4 Non-compartmental analysis of pharmacokinetics of hop-derived bitter acids after a 
single intravenous (n=3) dose of 25 mg kg
-1
.(17 mg/kg for AA). Values are presented as mean 
values ± standard deviation. AA: α-acids; IAA: iso-α-acids; DHIAA: dihydroiso-α-acids; THIAA: 
tetrahydroiso-α-acids. Comparison of parameters following i.v. dosing between AA, IAA, 
DHIAA, and THIAA was performed using one-way analysis of variance (ANOVA) followed by 
Bonferroni post-hoc comparison of statistical significance. Statistically significant differences 
versus parameters between AA, IAA, DHIAA, and THIAA are indicated. 
 
 i.v. administration 
Parameter AA IAA DHIAA THIAA 
Cl (ml/h) 707 ± 17
a
 931 ± 91
b
 258 ± 67 300 ± 7 
t1/2 (h) 0.34 ± 0.02
c
 0.32 ± 0.03
d
 0.88 ± 0.29 0.69 ± 0.07 
AUC0-∞ (h*µg/ml)  71 ± 2
e
 81 ± 8
f
 252 ± 7 250 ± 6 
a
 Significant
 
difference in Cl of AA versus DHIAA and THIAA upon i.v. dosing. P < 0.05 
b
 Significant
 
difference in Cl of IAA versus DHIAA and THIAA upon i.v. dosing. P < 0.001 
c
 Significant
 
difference in t1/2 of AA versus DHIAA and THIAA upon i.v. dosing. P < 0.05 
d
 Significant
 
difference in t1/2 of IAA versus DHIAA and THIAA upon i.v. dosing. P < 0.05 
e
 Significant
 
difference in AUC0-∞  of AA versus DHIAA and THIAA upon i.v. dosing. P < 0.001 
f
 Significant
 
difference in AUC0-∞  of IAA versus DHIAA and THIAA upon i.v. dosing. P < 0.001 
 
 
When orally dosed, the plasma concentration-time profile of the individual rabbits (n 
= 6) was obtained, as shown in Fig. 4.3. Since large inter-individual variations were 
observed for the time to reach the absorption maximum, tmax was described as a range of 
values (Table 5.3).  For DHIAA, tmax ranged 4.0–12 h post-dosing, while tmax of IAA and 
THIAA varied 0.5–6 h after ingestion. The time to reach the maximum concentration for AA 
ranged 2.0-8.0 h post-dosing. For AA and IAA, a Cmax of 2.5 ± 1.6 µg ml
-1 (or equal to 6.9 
µM), and 3.7 ± 3.0 µg ml-1 (or equal to 10.3 µM), respectively, was determined, while for 
DHIAA, a maximum concentration was found, which was 2-3-fold higher than for AA or IAA 
(6.6 ± 3.8 µg ml-1 equaling 18.2 µM). Following oral dosing of THIAA, a Cmax of 7.7 ± 4.3 µg 
ml-1 (or equal to 21.2 µM) could be measured. The area-under-curve AUC0-∞ upon oral 
gavages for DHIAA and THIAA were 70.7 ± 48.4 µg h ml-1 and 57.4 ± 9.0 mg h ml-1, 
respectively. This was almost 6-7-fold higher than the value calculated for IAA, for which 
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AUC0-∞ was 10.6 ± 5.3 µg h ml
-1.  Also, for AA, a higher AUC0-∞ was found compared to IAA 
(18.2 ± 9.0 for AA versus 10.6 ± 5.3 µg h ml-1 for IAA), despite the lower dose (17 versus 25 
mg/kg).  
The lowest absolute bioavailability was determined for IAA, being 13.0 ± 6.5, while the AA 
and the reduced derivatives, however, reached higher absolute bioavailabilities of 25.6 ± 
13.2% for AA, 28.0 ± 19.4% for DHIAA and 23.0 ± 3.6% for THIAA.  
 
AA IAA DHIAA THIAA 
    
 
Figure 4.3 Individual plasma concentration-time profiles (log concentration (µg/ml) versus time 
(h) in rabbits following oral administration (0.5 – 24 h; n = 6) of 25 mg/kg AA, IAA, DHIAA, and 
THIAA. AA: α-acids; IAA: iso-α-acids; DHIAA: dihydroiso-α-acids; THIAA: tetrahydroiso-α-
acids 
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Table 4.5 Non-compartmental analysis of pharmacokinetics of hop-derived acids after a single 
oral (n=6) dose of 25 mg/kg. Values are presented as mean values ± standard deviation. Values 
for tmax are presented as ranging values of the individual rabbits. AA: α-acids; IAA: iso-α-acids; 
DHIAA: dihydroiso-α-acids; THIAA: tetrahydroiso-α-acids. Comparison of parameters 
(following i.v. dosing and oral dosing) between IAA, DHIAA, and THIAA was performed using 
one-way analysis of variance (ANOVA) followed by Bonferroni post-hoc comparison of 
statistical significance.  
 
 Oral administration 
Parameter AA IAA DHIAA THIAA 
AUC0-∞ (h*µg/ml) 18.2 ± 9.0 10.6 ± 5.3 71 ± 48 57 ± 9 
Cmax (µg/ml) 3.7 ± 3.0 2.5 ± 1.6 6.6 ± 3.8 7.7 ± 4.3  
tmax (h) [2.0 – 8.0] [0.5 – 6.0] [4.0 – 12.0] [0.5 – 6.0] 
F (%) 25.6 ± 13.2 13.0 ± 6.5 28.0 ± 19.4 23.0 ± 3.6 
 
 
To investigate possible phase-II metabolism of AA, IAA, DHIAA, and THIAA, 
enzymatic hydrolysis of plasma samples following oral treatment was carried out with a 
mixture of sulfatase and glucuronidase. The amounts of AA, IAA and THIAA, quantified after 
the enzymatic reactions, were not significantly different from the non-hydrolyzed levels; 
hence, the presence of conjugates could not be demonstrated in samples of AA, IAA and 
THIAA. However, enzymatic hydrolysis of plasma samples of DHIAA resulted in a value for 
AUC0-∞ of 140 ± 43 mg h ml
-1. From these results, the percentage of DHIAA being 
conjugated as a sulfate or a glucuronide could be estimated to be around 50%.  
The pharmacokinetic data of THIAA were assessed as a model to determine a 
possible difference in bioavailability between the cis- and trans-stereoisomers or between 
the different co- versus n-homologues (Table 4.6 and Table 4.7). The different side chain at 
C1 (isopentanoyl in n- and ad-, isobutyryl in co-analogues) resulted in a slightly higher 
bioavailability of the n-analogues compared to the co-analogues (25% versus 18%). On the 
other hand, in case of cis- and trans-tetrahydroisocohumulone there was no difference in 
bioavailability observed in favor of cis- (17%) compared to trans-analogue (19%).  
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Apparently, a higher grade of lipophilicity (of the n- versus co-analogue), and the presence of 
the side chains on different faces of the five-membered ring of the cis- and trans-analogues 
did not have substantial effect on the bioavailabilities. 
 
 
Table 4.6 Pharmacokinetic parameters of cis- versus trans-stereoisomers of THIAA after a 
single oral (n=6) dose of 25 mg/kg. Values are presented as mean values ± standard deviation. 
Comparison of the bioavailability (F) between cis- (cis-THIAA: cis-tetrahydroisocohumulone) 
versus trans-stereoisomers (trans-THIAA: trans-tetrahydroisocohumulone) homologues of 
THIAA was performed using one-way analysis of variance (ANOVA) followed by Bonferroni 
post-hoc comparison of statistical significance. 
 
 cis-THIAA trans-THIAA 
F (%) 17.0 ± 3.0 19.0 ± 4.0 
 
Table 4.7 Pharmacokinetic parameters of co- versus n-homologues of THIAA after a single oral 
(n=6) dose of 25 mg/kg. Values are presented as mean values ± standard deviation. 
Comparison of the bioavailability (F) between co- (co-THIAA: sum of cis-
tetrahydroisocohumulone and trans-tetrahydroisocohumulone) versus n- homologues (n-
THIAA: sum of cis-tetrahydroisohumulone and trans-tetrahydroisohumulone) of THIAA was 
performed using one-way analysis of variance (ANOVA) followed by Bonferroni post-hoc 
comparison of statistical significance. Statistically significant differences versus parameters 
between co- versus n-homologues are indicated.  
 
 co-THIAA n-THIAA 
F (%) 17.6 ± 2.6 25.1 ± 2.7 
 
 
 
Fractions excreted in urine and faeces 
 
The percentages of dose (%dose) of the compounds excreted unchanged in urine 
and faeces following oral and i.v. administration of AA, IAA, DHIAA, and THIAA are shown in 
Table 4.8. After oral gavage, the urinary %doses of intact IAA and AA were 0.13 ± 0.05% 
and 0.4 ± 0.2%, respectively.  
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This fraction was very small when compared with the levels of THIAA and DHIAA, for 
which the %dose was 1.0 ± 0.1% and 12.1 ± 4.8%, respectively. In the faeces, the %dose of 
intact THIAA following oral application was 25.6 ± 7.6%, while the %doses of DHIAA and 
IAA were 13.1 ± 1.1% and 6.0 ± 1.8%, respectively.  
 
Table 4.8 Percentages (% of dose) of IAA, DHIAA, and THIAA 24 h after dosing in urine and 
faeces upon a single oral and i.v. dose of 25 mg/kg; n=3. The unabsorbed fraction is calculated 
as the difference in the amounts in faecal samples following oral and i.v. dosing. Values are 
presented as mean values ± standard deviation. IAA: iso-α-acids; DHIAA: dihydroiso-α-acids; 
THIAA: tetrahydroiso-α-acids. Comparison of amounts (following i.v. dosing and oral dosing) 
between IAA, DHIAA, and THIAA was performed using one-way analysis of variance (ANOVA) 
followed by Bonferroni post-hoc comparison of statistical significance. Statistically significant 
differences versus amounts between IAA, DHIAA, and THIAA are indicated. 
 
Compound 
Intravenous Oral Fraction 
unabsorbed 
(% of dose) 
Urine Faeces Urine Faeces 
AA 0.3 ± 0.1 < LOD 0.4 ± 0.2 0.18 ± 0.05 - 
IAA 0.5 ± 0.2 0.9 ± 0.2b 0.13 ± 0.05 6.0 ± 1.8 5.1 ± 2.0 
DHIAA 15.4 ± 1.4a 8.4 ± 1.8 12.1 ± 4.8c 13.1 ± 1.1 4.7 ± 2.9 
THIAA 0.8 ± 0.2 10.1 ± 2.1 1.0 ± 0.1 25.6 ± 3.6 15.5 ± 4.9 
a
Significant
 
difference in urinary amount of DHIAA versus AA,  IAA and THIAA upon i.v. dosing.  P < 0.005 
b
Significant
 
difference in faecal amount of IAA versus DHIAA and THIAA upon i.v. dosing.  P < 0.05 
c
Significant
 
difference in urinary amount  of DHIAA versus AA, IAA and THIAA upon oral dosing.  P < 0.001 
 
Following i.v. administration, the urinary %dose of intact DHIAA was determined to 
be 15.4 ± 1.4%. The levels of AA, IAA, and THIAA were comparable: 0.3 ± 0.1 %, 0.50 ± 
0.2% and 0.8 ± 0.2%, respectively. The faecal %dose of intact IAA after i.v. dosing was 
again very low compared to the doses of the reduced derivatives: 0.9 ± 0.2%. No detectable 
amount could be determined for AA. For DHIAA and THIAA, comparable percentages were 
found: 8.4 ± 1.8% and 10.1 ± 2.1% for DHIAA and THIAA, respectively.  
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From these data, it was possible to calculate the non-absorbed fraction as the 
difference in the faecal %dose following oral and i.v. administration. This was around 5% of 
the ingested dose for IAA and DHIAA, in contrast with THIAA, for which a non-absorbed 
fraction of 15.5 ± 4.9% was calculated. Large differences between the different classes of 
hop-derived acids could be observed: the urinary excretion of DHIAA upon both oral and i.v. 
dosing exceeded the values of AA, IAA and THIAA, which were significantly lower. The 
differences in urinary excretion between IAA and THIAA (and AA versus THIAA) were not 
statistically significant. Samples of faeces and urine were also subjected to enzymatic 
hydrolysis with a mixture of sulfatase and glucuronidase to screen for the presence of 
possible phase-II conjugates of IAA, DHIAA, and THIAA. Subtracting the amounts upon 
enzymatic hydrolysis from the control samples (in the absence of enzyme treatment) showed 
no significant conjugation of AA, IAA or THIAA in urine or faeces. However, enzymatic 
hydrolysis of urine samples of DHIAA following oral ingestion showed that up to 22% of the 
excreted amount of DHIAA was conjugated as a sulfate or a glucuronide. 
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4.1.4 Discussion 
 
Hop-derived bitter acids, the main flavoring agents in beer, have been reported to 
show important bioactive properties, including anti-inflammatory, anti-angiogenic properties, 
lipid metabolism enhancement, and counteracting diabetes type 2. However, a review of the 
literature shows that data on the pharmacokinetics of these compounds are lacking. In this 
study, the pharmacokinetic parameters and oral bioavailability of hop-derived bitter acids (α-
acids, iso-α-acids and reduced iso-α-acids) were assessed. Quantities of hop-derived bitter 
acids up to 100 mg l-1 may be present in beer (depending on beer type and brand) equaling 
250 µM HBA.90  
The dose solutions used in the rabbit trials are diluted from commercially available 
Isohop®, Redihop® and Tetrahop Gold®, which are stable solutions of potassium salts of 
respectively IAA, DHIAA, and THIAA, respectively, at pH 8–10. For stability and solubility 
issues, the dose formulations were obtained by dilution with ammonium acetate buffer (pH 
10). Nevertheless, a potential influence on bioavailability by the use of non-physiological pH 
should be considered for further investigation. An animal dose of 25 mg kg-1 in the 
pharmacokinetic study could be translated to a human equivalent dose (HED) using the 
following formula: HED = 25 mg kg-1 x [Km factor (rabbit)] / [Km factor (human)], in which the 
Km factor (kg m
-2) is calculated from the ratio of the body weight (kg) and body surface area 
(m²) of a species. The FDA-draft guidelines report values of Km = 12 for rabbits and 37 for 
humans, based on the ratio of the body weight and the body surface area (BSA).301, 302 In 
this way, a HED of 8 mg kg-1 could be calculated, which would correspond with a dose of ± 
500 mg for a human weight of 60–70 kg. This is in the line with the amounts of hop-derived 
acids present in commercially available dietary supplements (usually 400 mg or more) and 
the doses (single or frequent dosing) used in clinical trials with animals 128, 152, 156 or 
humans.135, 229, 234 However, this dose is not conform to moderate beer consumption, since 
an amount of 400–500 mg hop-derived acids would require a beer intake of at least 5 liters. 
In all publications cited, no adverse effects were reported upon ingestion of these types of 
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compounds. In one report, Chappel et al. conducted a study to determine the effect 
associated with subchronic oral administration of THIAA (as well as hexahydroiso-α-acids) in 
the dog. Most materials were excreted in the faeces and the no-observed-adverse-effect 
level (NOAEL) of the compounds was 100 and 50 mg kg-1 body weight for THIAA and 
hexahydro-iso-α-acids, respectively. As for dogs, the observations showed that these 
compounds were generally well tolerated.227  
Also, an observational human trial to investigate the efficacy of a formula containing 
DHIAA (Meta050) (440 mg daily for eight weeks) on pain in patients with rheumatic disease 
did not result in clinically relevant changes in blood pressure, complete blood counts, or liver 
and kidney function. Furthermore, there was no negative impact on gastrointestinal markers 
normally affected by selective COX-2 enzyme inhibitors, as concluded from normal fecal 
calprotectin excretion. Similar data were obtained after administration of pure DHIAA (450 
mg daily for 2 weeks).228, 229 
 
We found that the absolute oral bioavailability of iso-α-acids was less than 15% in NZ 
white rabbits, while the bioavailabilities of the α-acids and reduced derivatives were higher 
(25.6% for AA, 23% for THIAA and 28% for DHIAA). However, differences in bioavailabilities 
were determined to be not statistically significant, because of large inter-individual variations 
in the animals. Factors limiting a high bioavailability can be diverse, but typically include 
inefficient absorption and rapid metabolism (i.e., the first-pass effect). 
In previous results in Caco-2 experiments studying intestinal absorption, the apparent 
permeability coefficients were determined for all compounds under investigation as > 1 x 10-6 
cm/s indicating efficient permeability of these compounds, which would result in efficient 
absorption. In correspondence, the calculated non-absorbed fractions (5% for IAA and 
DHIAA and 15% for THIAA) obtained from the amounts determined in the faeces upon oral 
and i.v. application suggest efficient absorption of IAA, DHIAA, and THIAA. However, this 
calculation of the non-absorbed fraction is likely an underestimated value, since a significant 
fraction of the administered compounds can be metabolized and/or degraded by the 
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microbiota into diverse metabolites which were not detected in the analysis. Nevertheless, 
absorption of hop-derived acids is suggested to be efficient in rabbits, indicated by 
substantial plasma concentrations in the µg ml-1 (or lower µM) scale. From the 
pharmacokinetic data of DHIAA obtained following oral application, an AUC0-8h of 30.6 h mg 
ml-1 could be determined, which is in accordance with the results published by Hall et al., 
taken into account an HED of 560 mg. Following oral application of a dose of 700 mg DHIAA 
administered to 2 healthy human subjects, an AUC0-8h of 26 mg h ml
-1 was calculated, which 
is in line with the results of our study.135 
Prior to absorption and introduction of a compound in the systemic circulation and 
exposure to liver enzymes, intestinal epithelial cells (enterocytes) provide the first site for 
CYP-catalyzed and phase-II metabolism,303 since the highest catalytic activity resides in the 
proximal region of the small intestine.254, 304, 305  Following oral dosing, only minor amounts of 
intact AA and IAA were determined in urine and faeces. In our study, the mass balance (a 
summed total of %dose in urine and faeces of intact and conjugated forms over 24 h) was 
lower than 6% for IAA and lower than 1% for AA, indicating that metabolism/degradation of 
AA and IAA are the most important paths of elimination. This seems consistent with the low 
levels recovered in urine and faeces after i.v. administration of IAA and AA. Previous 
experiments reported by Aniol et al. showed that hop α-acids and β-acids are totally 
degraded when incubated with peroxidase enzymes from plant extracts.306 This could 
suggest the involvement of P450-enzymes in the metabolism of α-acids and β-acids, which 
could explain the low levels of the unchanged α-acids found in urine and faeces. Also, the 
absence of detectable amounts of unchanged β-acids in plasma, urine, and faecal fractions 
could be caused by a fast biotransformation of the β-acids. Furthermore, two reports 
describe induction of quinine-reductase activity by AA and IAA and activation of CYP3A4, 
CYP2B6, and some multi-drug resistance (MDR1) levels in human hepatocytes indicating 
that these hop-derived acids can stimulate both elimination and metabolism detoxification 
processes.233, 239 In addition, recent reports of Intelmann and Hofmann on the identification of 
degradation products of IAA formed upon beer ageing confirm the proneness of IAA to 
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undergo oxidative degradation.71 Similar findings have been reported previously.72, 73, 307-311 
Next to phase-I metabolism of IAA, phase-II conjugation of IAA cannot be completely ruled 
out, but, in none of the plasma, urine, and faecal samples, proof for sulfation or 
glucuronidation could be demonstrated. The same situation was observed for THIAA. This 
also corresponds with previous results for enzymatic hydrolysis of Caco-2 monolayer 
samples. However, other possible phase-II metabolism reactions (conjugation of glutathione 
or amino acids) should be further investigated. 
Compared to IAA, the mass balance of the reduced derivatives following oral dosing 
was substantially higher, totaling 47% for DHIAA and 25% for THIAA of the dose 
administered, showing that a substantial part of orally administered DHIAA and THIAA 
escapes metabolism/degradation in vivo in rabbits. On the contrary, in the plasma and urine 
samples following DHIAA-ingestion, substantial sulfation or glucuronidation was evident. The 
presence of an accessible alcohol group in DHIAA explains the absence of conjugation for 
IAA and THIAA. The enolic group, present in the molecular structures of AA, IAA and THIAA, 
may be inactive for conjugation in view of its acidity or due to intramolecular hydrogen 
bonding with the adjacent carbonyl group in the acyl side chain. 
 
Conclusions 
 
In the study presented above, the bioavailabilities in rabbits of hop-derived bitter 
acids, which have been reported to show important bioactive properties, have been 
investigated. At least in rabbits, the maximum exposure levels reached for AA, IAA, DHIAA 
and THIAA are in the range of 2–8 µg ml-1 (or equal to 7–20 µM), which is in line with 
bioactive concentrations previously suggested elsewhere.135, 136, 152, 156 The bioavailabilities of 
AA and IAA were lower compared to those of the reduced derivatives (DHIAA, THIAA) and 
they are largely affected by phase-I metabolic interference. The bioavailabilities of DHIAA 
were influenced by substantial phase-II metabolism.  
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4.2 Metabolism of hop-derived bitter acids 
 
This subchapter is based on:  
 
Cattoor K.; Dresel M.; De Bock L.;, Boussery K.; Van Bocxlaer J.; Remon J.P.; De 
Keukeleire D.; Deforce D.; Hofmann T.; Heyerick A., Metabolism of Hop-Derived Bitter 
Acids, Journal of Agricultural and Food Science, Manuscript in revision 
 
 
4.2.1 Introduction 
 
In a previous study, it has been shown that pre-systemic breakdown or metabolism 
(either gastrointestinal or in hepatic tissues) was the most important factor influencing 
bioavailabilities of α-acids, iso-α-acids and reduced derivatives.312 Recently, induction of the 
quinone reductase activity by α-acids and iso-α-acids and activation of CYP3A4, CYP2B6, 
and some MDR1 levels in human hepatocytes have been reported.233, 239 It appears that hop 
acids stimulate both phase I and phase II detoxification processes.  
The present study focuses on the CYP-metabolism of the hop-derived bitter acids (α-
acids, β-acids, and iso-α-acids) present in beer and hop-based food supplements. Insights 
into the metabolism and/or degradation following ingestion of these substances are essential 
to understand their overall bioavailabilities, and related health effects, following intake of 
such preparations. Since CYPs are the major enzymes involved in drug metabolism and 
bioactivation, accounting for ∼75% of the total metabolism, phase-I metabolism catalyzed by 
cytochrome P450-enzymes was investigated by incubation of α-acids, β-acids, and iso-α-
acids with liver microsomes, isolated from New Zealand white rabbits. 
 The most common reaction catalyzed by cytochrome P450-enzymes is a mono-oxygenase 
reaction; therefore, especially the formation of oxidative breakdown products was 
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investigated by specific HPLC-MS and LC-MS/MS methods in order to identify metabolites of 
iso-α-acids, α-acids, and β-acids following microsomal incubations. 
 
 
4.2.2 Materials and methods 
 
Chemicals 
Hop α-acids and β-acids were obtained as pure solutions in methanol and iso-α-acids 
as an isomerized extract from Hopsteiner (Mainburg, Germany). International calibration 
standards for α-acids and β-acids (ICE-2), and iso-α-acids (DCHA-Iso, ICS-I3), were 
obtained from Labor Veritas (Zurich, Switzerland). Glucose 6-phosphate sodium salt, 
glucose 6-phosphate dehydrogenase from baker’s yeast (S. cerevisiae), β-nicotinamide 
adenine dinucleotide phosphate hydrate (β-NADP+) were purchased from Sigma-Aldrich 
(Bornem, Belgium). All other reagents were of analytical grade and used without further 
purification. Water (ULC/MS grade) and all other LC/MS solvents (LC/MS quality) were 
obtained from Biosolve (Valkenswaard, the Netherlands) and Merck (Darmstadt, Germany). 
Formic acid was obtained from Merck (Darmstadt, Germany). Hydrochloric acid (HCl) was 
purchased from Riedel-de-Haen (Seelze, Germany). De-ionized water used for 
chromatography was purified by means of a Mill-Q Gradient A10 system (Millipore, Billerica, 
Massachusetts, USA).  
Pure reference compounds (Figure 5.2) (1-17) used for identification by means of HPLC-
MS/MS Qtrap analysis, were obtained following the recently published protocols of 
Intelmann and Haseleu.40, 69-71  
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Animals   
The study protocol (approval number 2009/98) of the animal experiments was 
approved by the Ethics Committee of the Institute for Agricultural and Fisheries Research 
(ILVO) (Merelbeke, Belgium). New Zealand white rabbits (breeding approval number 
LA2400369) (3.0 ± 0.5 kg) were fasted 16 h prior to the experiment. Water was available ad 
libitum.  
 
Preparation of Rabbit Liver Microsomes   
Six rabbits (n=6) were anesthetized using CO2 and killed by asphyxiation. The livers 
were quickly removed, cut-up into smaller pieces (1 cm³), and frozen at -80°C before use. 
Aliquots of the liver of 6 different rabbits were washed with phosphate buffer containing 
1.15% KCl (0.25 mol/l, pH=7.25) to remove blood and the weight of one sample was 
adjusted to 3.1 ± 0.1 g. Then, all liver pieces in one sample were mixed with phosphate 
buffer (10 ml/g liver) containing 1.15% KCl (0.25M, pH=7.25) and homogenized using an IKA 
Ultra-Turrax® equipped with a Potter-Elvehjem tissue grinder (VWR International, West 
Chester, Pennsylvania, USA). The homogenate was centrifuged at 10.000 g for 25 min at 
4°C and the pellet (nuclei, mitochondria and debris) was discarded. The supernatant (S9 
fraction) was further centrifuged at 100.000 g for 80 min at 4°C in order to separate the S9 
fraction into a cytosolic fraction (supernatant) and a microsomal pellet. The microsomal 
pellet was resuspended in phosphate buffer (10 ml/g liver) containing 1.15% KCl (0.25 mol/l, 
pH=7.25), homogenized, and centrifuged again at 100.000 g for 80 min at 4°C. The final 
microsomal pellet was resuspended in phosphate buffer (1.5 ml/g liver) containing 1.15% 
KCl and 30 % glycerol (0.25 mol/l, pH=7.4) and microsomes were stored at -80°C until use. 
The protein concentration of liver microsomes was determined according to the method 
described by Bradford.313  
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In vitro Metabolism of Hop-derived Acids   
The microsomal fractions were thawed on ice on the day of the assay and diluted to 
the required protein concentration using ice-cold Tris-HCl buffer. A typical 0.5 ml 
biotransformation incubation mixture in Tris-HCl (0.1 mol/l, pH=7.4) consisted of 1 mg/ml of 
pooled liver microsomal protein (n= 6), a nicotinamide adenine dinucleotide phosphate 
(NADPH)-regenerating system (NRS) consisting of 1mM β-NADP+, 10 mM glucose-6-
phosphate (G6P), and 1 unit/ml glucose-6-phosphate dehydrogenase (G6PDH), 5 mM 
MgCl2, and 20 µM α-acids, β-acids, or iso-α-acids as substrate (this was a serial dilution in 
Tris-HCl of a 20 mM solution in methanol (MeOH) to the required concentrations). The final 
MeOH-concentration did not exceed 1% (v/v) in the mixture. After pre-incubation for 5 min, 
the reaction was initiated by the addition of NRS. Incubations were carried out at 37°C for 
120 min with continuous shaking in an Eppendorf Thermomixer (VWR International, West 
Chester, Pennsylvania, USA). Control incubations were performed without the addition of 
NRS or microsomes to ensure that metabolite formation was dependent of the presence of 
microsomes and NADPH. Reactions were terminated by acidification (pH 2) with H3PO4 (0.1 
mol/l, 2 volumes) to the incubation mixture (500 µl), followed by extraction with ethyl acetate 
(EtOAc; 4 volumes). The EtOAc-phase was evaporated to dryness under a nitrogen flow. 
The residues were reconstituted in 100 µl MeOH and stored at -20°C until analysis. 
Comparative studies with human liver microsomes (purchased from Celsis IVT, Chicago, 
Illinois, USA) were also included using the incubation protocol described above. 
 
LC-MS Analysis  
LC-MS analysis of samples from the different incubations and of urine was performed 
using an Agilent 1200 LC-MS system (SL) equipped with a dual ionization source (ESI/ 
APCI) and DAD detector (Agilent, Waldbronn, Germany). The Agilent Chemstation software 
package (Rev.B.02.01) was used to control the analytical system as well as for data 
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acquisition and processing. As stationary phase, an Xbridge 3.5 µm C-18 column (150 x 30 
mm) (Waters, Zellik, Belgium) was used. The mobile phase consisted of 10 mM ammonium 
acetate pH 9.75 + 20% MeOH (A) and MeOH (B). The flow rate was 0.5 ml/min and column 
temperature was maintained at 40°C. The initial mobile phase, 27% B, was increased 
linearly to 60% B over 24 min, maintained for 5 min, and further increased to 95% B in 5 min 
and maintained for 4 min. Finally, the mobile phase was re-adjusted to 27% B in 1 min and 
re-equilibrated for 6 min prior to the next injection.  UV/VIS detection was performed at 270 
nm (for iso-α-acids, dihydroiso-α-acids, and tetrahydroiso-α-acids) and 314 nm (for α-acids 
and β-acids). The MS parameters in the negative atomic pressure chemical ionization 
(APCI) mode were tuned to maximize formation of the deprotonated analyte. Interface 
settings were as follows: N2 drying gas temperature 250 °C, N2 drying gas flow 5 l/min, APCI 
vaporizer temperature 150 °C, nebulizer pressure 105 Pa, capillary voltage 1000 V, corona 
current 6 µA, and charging voltage 1000 V. In each analysis, qualitative identification was 
performed in the negative-ion scan mode (m/z 150–700) and quantitative data were obtained 
by reconstruction of the extracted-ion chromatogram following measurement in the selected 
ion monitoring (SIM) mode. The [M-H](-) m/z-values, used for quantification of α-acids, β-
acids, and iso-α-acids are presented in Table 4.8.78, 95, 96, 100  
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Table 4.8 Molecular ions used for the selected-ion monitoring (SIM) mode for the various hop 
acids in LC-MS analysis.  
 Compound   MW (g/mol)  m/z (-)  
α-acids  
cohumulone AA1 
348  347  
adhumulone AA2 362  361  
humulone AA3 
β-acids  
colupulone BA1 
400  399  
adlupulone BA2 414  413  
lupulone BA3 
iso-α-acids 
cis-isocohumulone IAA1 348  347  
trans-isocohumulone IAA2 
cis-isoadhumulone IAA3 
362  361  trans-isoadhumulone IAA4 
cis-isohumulone IAA5 
trans-isohumulone IAA6 
 
 
HPLC-MS/MS Q-Trap Analysis  
In order to identify hop acid metabolites, samples from microsomal incubations and 
urine were analyzed using an Agilent 1200 Series HPLC-system, consisting of pump, a 
degasser, and an autosampler (Agilent, Waldbronn, Germany) connected to an API 4000 Q-
TRAP mass spectrometer (AB Sciex Instruments, Darmstadt, Germany) which was 
equipped with an electrospray ionization (ESI) source and operated in the negative 
ionization mode.  Data processing and integration was performed by use of Analyst software 
version 1.5 (AB Sciex Instruments, Darmstadt, Germany). As stationary phase, a Synergi 4 
µm Hydro-RP column (150 x 2.0 mm) (Phenomenex, Aschaffenburg, Germany) was used. 
The mobile phase consisted of acetonitrile (MeCN) + 0.1 % formic acid (HCOOH) as solvent 
A and H2O + 0.1 % HCOOH as solvent B. Using a flow rate of 0.25 ml/min, chromatographic 
separation was achieved by gradient elution increasing solvent A from 20 to 60% within 20 
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min and further increased to 70% in 15 min, to 92% during 28 min, and, finally, to 100% 
within 2 min. This was maintained at 100% for 5 min, following by re-adjustment to 20% 
within 1 min, and re-equilibrated for 5 min prior to the next injection. MS/MS parameters 
settings were based on the methods described by Haseleu and co-workers.16 Qualitative 
analysis was performed by mean of multiple reaction monitoring (MRM) mode using the 
fragmentation parameters and retention times by mean of co-chromatography with authentic 
reference compounds, obtained using protocols reported by Intelmann and co-workers.16-18, 
25  
 
 
4.2.3 Results 
 
In vitro Metabolism of Hop-derived Acids   
In Figure 4.4, the percentage of compounds metabolized following incubation of 20 
µM of α-acids, β-acids, and iso-α-acids with liver microsomes isolated from rabbit liver and 
human microsomes are shown. Results show that, after 120 min, the total amount of the 
applied β-acids was metabolized. The percentage of α-acids metabolized was 77 ± 0.8%. 
Although the iso-α-acids proved to be more resistant to biotransformations, still a substantial 
amount of 48 ± 3% was metabolized. In studies with human liver microsomes (Fig. 5.1), 
highly comparable values were obtained. The percentages of α-acids, β-acids, and iso-α-
acids metabolized amounted to, 73 ± 3%, 95 ± 1%, and 48 ± 2%, respectively.  
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Figure 4.4 Phase-I metabolism of 20 µM hop α-acids, β-acids, and iso-α-acids following 2 h 
incubation with rabbit liver microsomes (RLM) and human liver microsomes (HLM). 
Experiments were applied in triplicate. Amounts are presented as the percentage metabolized 
of the administered amount ± standard deviation. IAA: iso-α-acids; AA: α-acids; BA: β-acids 
 
 
Initially, all incubation mixtures were analyzed by LC-MS (APCI; negative mode) both 
quantitative (see results above), as well as qualitative. Figures 4.5-4.7 illustrate a set of total 
ion chromatograms (TIC) and extracted ion chromatograms (EIC) of parent compounds and 
potential metabolites of respectively, α-acids (Figure 4.5), β-acids (Figure 4.6), and iso-α-
acids (Figure 4.7) following 120 min incubation with rabbit liver microsomes. Microsomal 
incubation of α-acids (Figure 4.5) resulted in a quite complex TIC (Figure 4.5A). In the EIC of 
the parent compounds (Figure 4.5B) with pseudo molecular ion [M-H]- m/z 347 and 361, 
some proof of conversion of α-acids into iso-α-acids could be observed.  Study of the full 
scan spectrum of potential metabolites of the α-acids revealed that the main 
biotransformation products had a pseudo molecular ion [M-H]-  m/z 363 and 377, in which 
the molecular mass of the parent compound was increased by 16 Da, suggesting mono-
oxygenation reaction (epoxidation, hydroxylation…) as the most important metabolism 
product (Figure 4.5C).  
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Figure 4.5 Representative HPLC-MS chromatogram following 2h incubation of α-acids (20 µM) 
in microsomes. In each chromatogram, the co-analogue and n+ad-analogues are respectively 
represented by a solid line, and a dotted line. A: TIC. B: EIC of parent compounds with m/z 347 
and 361. C: EIC of mono-oxygenated metabolites with m/z 363 and 377.  
 
 
Figure 4.6 represents an LC-MS chromatogram following microsomal incubation of iso-α-
acids. The most important metabolites formed (Figure 4.6C and Figure 4.6D), showed a 
molecular mass increase of the parent compound by 16 or 32 Da, showing the incorporation 
of one or two oxygen atoms as major microsomal biotransformation products of iso-α-acids. 
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Figure 4.6 Representative HPLC-MS chromatogram following 2h incubation of iso-α-acids 
(20µM) in microsomes. In each chromatogram, the co-analogue and n+ad-analogues are 
respectively represented by a solid line, and a dotted line. A: TIC. B: EIC of parent compounds 
with m/z 347 and 361. C: EIC of mono-oxygenated metabolites with m/z 363 and 377. D. EIC of 
di-oxygenated metabolites with m/z 379 and 393.  
 
The metabolism of β-acids by microsomal enzymes resulted in several distinct products 
(Figure 4.7). In the β-acids mixture used in this experiment, only trace amounts of 
n+adlupulone were present compared to colupulone. Therefore only signals related to 
colupulone (parent compound with m/z 399) were used as a model for the metabolism of all 
the β-acids. Among the several metabolites detected, formation of a product with pseudo 
molecular ion [M-H]- m/z 317 was observed (Figure 4.7C), which corresponded with the 
molar mass of hulupones (318 Da), a well-known oxidation product of β-acids.  Also, in 
correspondence with the metabolism of α-acids and iso-α-acids, mono- and di-oxygenated 
biotransformation products were determined, with detection of pseudo molecular ions [M-H]- 
161 
 
m/z 415 and 431 (Figure 4.7D and Figure 4.7E). Furthermore, a metabolite with pseudo 
molecular ion [M-H]-  m/z 397 was determined.  
 
 
Figure 4.7 Representative HPLC-MS chromatogram following 2h incubation of β-acids (20 µM) 
in microsomes. A: TIC. B: EIC of parent compound with m/z 399. C: EIC of metabolite with m/z 
317. D. EIC of mono-oxygenated metabolites with m/z 415. E. EIC of di-oxygenated metabolites 
with m/z 431. F. EIC of metabolite with m/z 397.  
 
Though, by the use of LC-MS analysis, little structural information could be obtained for the 
biotransformation products formed. Based on data of the metabolism pathway of other 
prenylated hop-derived constituents such as xanthohumol and 8-prenylnarigenin (8-PN), 
retention times, UV spectra, and molecular mass of the detected metabolites, it was only 
possible to make some suggestions on the molecular structure.  
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However, for the products described above, the molecular mass determined in the 
LC-MS analysis, correlate to a great extend with the oxidative degradation products of hop 
bitter acids in aged beer & wort mixtures, recently described by Intellmann et al.16-18, 25, 26 
Based on this assumption, more structural and (semi)-quantitative information on possible 
degradation products and/or metabolites was obtained by detailed LC-MS/MS analyses 
using recently optimized multiple reaction monitoring (MRM) methods for the analysis of hop 
bitter acids and these degradation products observed in oxidatively aged beer. Confirmation 
of the identified products was possible by co-chromatography with authentic reference 
compounds. In this way, it was possible to demonstrate similarity in phase-I metabolites of 
hop-derived bitter acids (α-acids, β-acids, and iso-α-acids) and products formed upon 
oxidative decomposition of these hop constituents during beer ageing. The corresponding 
representative chromatograms of the identified products ( for the co-congener) analyzed by 
LC-MS/MS operating in the MRM mode of products following microsomal incubation of α-
acids and β-acids, and iso-α-acids are presented in Figure 4.8. Analogous results were also 
obtained for the ad- and n-congeners. An overview of possible reaction routes for the 
biotransformation of hop-derived α-acids, β-acids, and iso-α-acids is shown in Figure 4.9.  
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Figure 4.8 Representative LC-MS/MS chromatograms (MRM transitions) of parent compounds 
and identified microsomal metabolites of hop-derived α-acids, β-acids, and iso-α-acids. In 
each of the cases, the co-congener has been shown as matter of example. 
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Figure 4.9 Reaction routes for the biotransformation of hop-derived α-acids (1-3), β-acids (4-6), 
trans- (7-9) and cis-iso-α-acids (10-12) leading to the formation of humulinones (13-15), 
hulupones (16-18), trans- (22-24), and cis-humulinic acids (31-33), epimeric pairs of tricyclic β-
acid cyclization products (40a/b-42a/b, 43a/b-45a/b, 46a/b-48a/b), trans- (25-27) and cis-
alloisohumulonehydroperoxides (28-30), trans- (34-36) and cis-alloisohumulonehydroxides 
(37-39), and tricyclohumols (19-21). 
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Upon incubation with rabbit liver microsomes, α-acids (1-3) were mainly conversed into 
trans- (7-9) and cis-iso-α-acids (10-12), together with also humulinones (13-15), and 
surprisingly, also hulupones (16-18). To the best of our knowledge, hulupones are a well-
known oxidation product exclusively formed from β-acids. Besides the conversion of β-acids 
(4-6) into hulupones (16-18), biotransformation products of β-acids also comprised a series 
of epimeric pairs of tricyclic cyclization products, named dehydrotricyclolupulones (43a/b-
45a/b), hydroxytricyclolupulones (49a/b-51a/b), and hydroperoxytricyclolupulones (46a/b-
48a/b), in resemblance with the products recently identified by Haseleu and co-workers.25, 26 
Microsomal metabolism of iso-α-acids (7-9, 10-12) resulted mainly in the formation of trans- 
(22-24) and cis-humulinic acids (31-33), in addition to trans- and cis- pairs of hydroperoxy- 
(25-27, 28-30) and hydroxylated-allo-iso-α-acids (34-36, 37-39). Furthermore, the 
conversion of iso-α-acids into cyclic degradation substances, including tricyclohumols (19-
21) was observed. 
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4.2.4 Discussion 
 
Studies on ADME of hop-derived bitter acids, showing promising multipotent 
bioactive activities, such as anti-inflammatory, anti-osteoporotic or anti-carcinogenic,235 are 
of great importance. In the study above, a first insight is gained into the possible metabolic 
pathways of hop-derived bitter acids. Several biotransformation products of α-acids, β-acids, 
and iso-α-acids were identified in microsomal mixtures. The discovery of an array of 
breakdown products of these compounds was in line with the preceding findings on the 
bioavailabilities of hop-derived bitter acids in rabbits. Results showed  a fast elimination for 
α-acids and iso-α-acids, as well as low amounts of unchanged products in urine indicating 
breakdown by gut related microorganisms or  phase I/II metabolism in gastrointestinal  or 
hepatic tissues.312   
 
Several previous investigations have been reported on the structures of (oxidative) 
degradation of hop-derived bitter acids as well as their underlying formation mechanisms.40, 
54, 59, 69-73, 84, 307-311, 314-330 In particular, the 3-methyl-2-butenyl side chains of α-acids, β-acids, 
and iso-α-acids and the isohexenoyl-side chain of iso-α-acids are very sensitive to oxidation, 
either at the double bounds or in the allylic positions. Most often, the native oxidized 
compounds can be oxidized further or undergo further (de-) hydration and cyclization 
reactions. However, the focus in the cited studies was mainly on their decomposition in beer. 
Although, physiological biotransformation conditions (including metabolism) are nothing like 
beer deterioration, these studies provided preliminary suggestion to possible structures of 
metabolites of these compounds.  
 
Upon microsomal incubation, the metabolism of α-acids showed biotransformation 
into humulinones, besides cis- and trans-iso-α-acids, and surprisingly, hulupones, which is a 
well-known oxidation product of β-acids. Isomerization of humulone is the most important 
reaction in the brewing process.35, 49, 53, 97, 331, 332 Interestingly, this conversion could also be 
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catalyzed by microsomal enzymes. As the results showed, among the microsomal 
bioconversion of β-acids, the formation of 2 main types of reaction products could be 
identified, namely hulupones and tricyclic degradation products. The identified metabolites of 
iso-α-acids comprised predominantly humulinic acids, and hydroxy-/peroxy-
alloisohumulones.  These findings indicate that liver oxidation catalyzed by cytochrome 
P450-enzymes could be an important metabolic pathway for α-acids, β-acids, and iso-α-
acids. Moreover, this suitability to microsomal breakdown could suggest a significant first-
pass effect upon oral ingestion of such compounds, resulting in a fast clearance following 
absorption. 
 
Recently, some oxidation products of iso-α-acids and β-acids were identified upon 
oxidative breakdown in beer by Intelmann40, 71 and Haseleu.43, 44 In these studies, the 
transformation of iso-α-acids in hydroxyl- and hydroperoxy-alloisohumulones and β-acids 
into tricyclic compounds, including nortricyclo-, dehydrotricyclo-, and tricyclolupulones is 
described. Despite the different reaction conditions (beer matrix versus microsomal 
enzymes), some interesting similarities could be drawn. In the beer ageing studies, the 
authors proposed a lipid peroxidation mechanism (oxidation of unsaturated fatty acids), 
which is based on the same principles used in cytochrome P450 enzymatic pathways. First a 
hydrogen atom is abstracted leading to a resonance-stabilized radical in the isohexenoyl 
side chain (iso-α-acids) followed by addition of oxygen and leading to the corresponding 
hydroperoxy- and hydroxy-alloisohumulones. For the β-acids, hydrogen abstraction is 
followed by cyclization steps and oxygenation, leading to nortricyclo-, dehydrotricyclo-, and 
tricyclolupulones by different reaction routes. CYP metabolism pathways include iron-oxo 
species which abstracts a hydrogen atom from the alkyl group of a substrate to give a radical 
that subsequently displaces the hydroxyl group from iron in a homolytic substitution reaction 
(hydrogen abstraction–oxygen rebound), utilizing two electrons that are provided by 
NADPH.60  
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Apart from transformation of iso-α-acids into the hydroperoxy- and hydroxy-
alloisohumulones, formation of cis-/trans-humulinic acids was observed. These compounds 
result from cleavage of the (un)modified hexenoyl side chain, directly from iso-α-acids, or 
from another intermediate (alloiso-α-acids, hydroxy-/hydroperoxy-alloiso-α-acids).  
Furthermore, also cyclic metabolites of iso-α-acids were identified such as tricyclohumols. 
These products have been previously identified by Intelmann et al. upon acid-catalyzed 
intramolecular cyclization of trans-iso-α-acids in aged beer.69, 71 Although, it is unclear 
whether these compounds were the result of microsomal conversion or were formed during 
the acidic extraction conditions throughout the processing of the samples. Intelmann and co-
workers showed that this reaction was strongly pH-dependent (at pH 1.0, the most rapid 
degradation was observed, whereas none of these compounds were formed at pH 6.0).70 
Besides, this kind of acid-catalyzed degradation might also occur in the stomach and/or 
intestinal zones with lower pH upon oral ingestion of iso-α-acids. Moreover, only trans-iso-α-
acids were affected, since only for these stereomers the interacting carbon atoms possessed 
the correct steric geometry that enabled an overlapping of the corresponding π-orbitals for 
bonding.  
 
Using the MRM-method in the LC-MS/MS analysis, it was also possible to detect 
transitions representative for substances with hydroxylated positions in the prenyl side 
chains of α-acids and β-acids, although exact assignment of the molecular structures 
requires further experiments including NMR spectroscopy confirmation of isolated 
compounds. However, the occurrence of metabolites with hydroxylated prenyl (or 3-methyl-
2-butenyl) side chains of α-acids and β-acids is in line with CYP-metabolites of another hop 
constituent, 8-prenylnaringenin, (8-PN). In a study conducted by Nikolic et al., the most 
abundant pathway of hepatic metabolism of 8-PN was hydroxylation of one of the terminal 
methyl’s of the prenyl group. Hydrogen abstraction at a terminal methyl group is favorable 
due to the formation of a stable allyl radical and these groups are readily accessible for 
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enzymatic attack.333 Moreover, in two recent studies Negri et al. and Lupinacci and 
coworkers have reported an oxidized α-acids product, formed upon oxidation of the prenyl 
side chains in humulinone (oxidation product of α-acids), followed by cyclization, resulting in 
a compound wherein 2 oxygen atoms were incorporation.179, 334 These examples suggest the 
susceptibility of the 3-methyl-2-butenyl side chains of hop-derived bitter acids for oxidation. 
The evaluation of formation of similar products among metabolites of α- and β-acids should 
be further investigated.  
The absence of a hexenoyl side chain in the molecular structure of dihydro-iso-α-
acids, and the absence of double bounds in the molecular structure of tetrahydroiso-α-acids, 
could suggest that these reduced derivatives resist to a great extent the types of 
biotransformation described above. To support this, additional investigations with reduced 
iso-α-acids are necessary to support this. In the study on the bioavailabilities of hop-derived 
iso-α-acids and reduced derivatives in rabbits (see section 4.1), a slower clearance and a 
higher unmodified amount excreted in urine and faeces was observed for the dihydro-iso-α-
acids and the tetrahydro-iso-α-acids.312 
In conclusion, HPLC-MS/MS operating in the MRM-mode allowed for the first time 
detection of biotransformation products of hop-derived α-acids, β-acids, and iso-α-acids in 
microsomal incubation mixtures. Interestingly, the identified metabolites showed similarity to 
products formed upon oxidative decomposition of these hop constituents during beer ageing. 
The findings show a first insight into the metabolites of hop-derived bitter acids. 
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V. General Conclusion and Future 
Perspectives 
 
The objective of this PhD research project was to gain insight in the different aspects 
influencing the bioavailability of hop-derived bitter acids. 
In Caco-2 cell culture experiments, fast and efficient absorption of hop α-acids, iso-α-
acids, and reduced derivatives could be demonstrated. On the basis of the low apparent 
permeability coefficient of β-acids, the in vivo absorption of orally administered β-acids is 
predicted to be low. The limiting factors in the epithelial absorption of β-acids across Caco-2 
monolayers could be the involvement of P-gp- and MRP-2-type efflux transporters and/or 
substantial phase-II metabolic reactions. It was also shown that the transport properties of 
dihydroiso-α-acids are influenced by phase-II metabolism.  
 
In rabbits, used as an in vivo animal model, the maximum exposure levels reached for 
AA, IAA, DHIAA and THIAA are in the range of 2–8 µg ml-1 (or equal to 7–20 µM), which is in 
line with bioactive concentrations previously reported.135, 136, 152, 156 and confirms the values 
found in the Caco-2 assays. Amounts of β-acids could not be detected, which should be due 
to gastrointestinal pre-systemic instability. In addition, the bioavailability of IAA was lower 
compared to those of their precursor AA and the reduced derivatives (DHIAA, THIAA) and 
was largely affected by microbial and/or metabolic breakdown. The bioavailability of DHIAA 
was influenced by substantial phase-II metabolism. Fast biotransformation was evident for α-
acids, β-acids, and iso-α-acids in microsomal incubations (isolated from rabbits and 
humans). Interestingly, metabolites show structural similarities to the compounds formed 
upon oxidative decomposition during beer ageing. As such, our findings should have 
significant practical implications. 
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Because of the limited predictive power of animal studies for humans, extrapolations 
from the pharmacokinetic rabbit data obtained in this PhD should be used with caution. To 
reach the maximum exposure levels found in this study (2-8 µg ml-1), a corresponding 
human intake of 400-500 mg of hop bitter acids can be estimated based on the calculated 
HED following the FDA-draft guidelines (for a human weight of 60-70 kg).301, 302 This is in the 
line with the amounts of hop-derived bitter acids present in commercially available dietary 
supplements (usually 400 mg or more) on the market. Metagenics Inc. produces food 
supplements and nutraceuticals containing hop bitter acids and pre-formulates (400-500 mg) 
predominantly reduced derivatives (DHIAA, THIAA) in their products, which showed higher 
bioavailabilities according to our results. In a study presented by Hall et al., following an oral 
dose of 700 mg DHIAA administered to 2 healthy human subjects,  maximum exposure 
levels of 2-4 µg ml-1 were found, which is in line with the results of our study.135 Additional 
human trials are necessary to draw conclusions about human bioavailability.  
With regard to the topic ‘health & beer’, a dose of 400-500 mg is not conform to 
moderate beer consumption, since such amount of hop-derived bitter acids would require a 
beer intake of at least 5 liters. In the beer brewing industry, mostly iso-α-acids are used as 
main bitter flavoring compounds. The ADME properties of the iso-α-acids determined in this 
study suggest a significant absorption, followed by a fast biotransformation and elimination, 
indicating that the possibility of reaching bioactive tissue concentrations of unchanged hop-
derived bitter acids is more likely for beers flavored with reduced iso-α-acids. In a non-
regulated trial we conducted, urine (12h post intake) was collected and analyzed from a 
series of healthy subjects following oral intake of 660 ml of beer. Results showed that, in 
none of samples, iso-α-acids could be recovered unchanged whereas for the reduced 
derivatives (DHIAA, THIAA), unchanged amounts could be determined in urine (data not 
shown).  
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Also, it might be important to assess the biological activity of the main metabolites of 
iso-α-acids, such as hydroxylated allo-iso-α-acids, humulinic acids, and unidentified forms. 
For example, microbial transformation in the colon may increase the biological activity of 
ingested compounds, a process that has been described for different phytoestrogens, such 
as prenylflavonoids from hops, for which the pseudo estrogenic activity is determined by 
intestinal bacterial activation followed by absorption of the microbial metabolites.335 
 
A number of aspects have been investigated in this research project on the 
bioavailabilities of hop-derived bitter acids. Nevertheless, further research is essential to 
enable full understanding of the real health-beneficial properties of iso-α-acids and 
derivatives as important beer constituents and as part of nutraceuticals. 
 
- A study on the intestinal microbial metabolism, since intestinal microbiota are 
capable to induce a multitude of transformations in the diet and may play an 
important role in bioavailabilities and biological effects of specific compounds. First, 
the in vitro stability of iso-α-acids and reduced derivatives in the stomach and the 
small intestine can be studied. In a next step, the target compounds can be 
incubated with human faecal samples to investigate inter-individual differences of 
intestinal metabolism. In a last phase, evaluation of microbial transformations over a 
longer period of time and under steady-state conditions of feeding can be envisaged. 
Besides the influence of microbiota on the target compounds, the effects (on 
composition & activity) of exposure of these microbiota to iso-α-acids and reduced 
derivatives should be evaluated. 
- Animal studies, in which administration of multiple doses (long term) of iso-α-acids or 
reduced derivatives is applied by oral gavage to determine steady-state 
concentrations in faeces, urine and blood.  
- Human studies, where healthy human volunteers will be asked to ingest a single 
dose of iso-α-acids and/or reduced derivatives. Fractionated urine samples and 
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blood samples could be used to establish the most important pharmacokinetic 
parameters. Next, multiple doses of iso-α-acids and/or reduced derivatives could be 
applied in order to establish steady-state concentrations in both urine and blood. On 
the practical side, the matrix effect, such as prevailing in beer, should be integrated in 
comprehensive future studies. 
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Summary 
 
In comparison to the continuously growing number of publications targeting the 
health-beneficial effects of hop bitter acids, very little is known on their ADME-characteristics 
(absorption, distribution, metabolism, excretion), which is highly relevant when assessing the 
usefulness of these compounds for either preventive of therapeutic use. The background on 
hop-derived bitter acids and the current situation on bioactivity of these target compounds 
are addressed in a literature review in Chapter 1.  Following a description of the history, 
chemistry, and analytical methods of hop constituents and beer, current data on bioactivity 
and toxicity of the target compounds is described.  
In Chapter 2, the current state-of-the-art and -until now known- data on the 
bioavailability aspects (ADME) of hop-derived bitter acids is outlined, followed by the 
description of the different objectives of this work. 
  As a first approach to study the bioavailability, in Chapter 3, the in vitro intestinal 
permeabilities of hop bitter acids using Caco-2 cell monolayers (a commonly used screening 
tool for the prediction of intestinal absorption) was studied, preceded by an introduction on 
Caco-2 cells, their properties and uses for studying intestinal transport. It appears that α-
acids are efficiently absorbed, while the permeability of β-acids is low. The limiting factors in 
the absorption of β-acids involve P-gp- and MRP-2-type efflux transporters. In addition, 
phase-II metabolic reactions may also contribute to the reduced permeability of β-acids 
versus α-acids. In the comparative Caco-2 study with iso-α-acids and its reduced derivatives 
(dihydroiso-α-acids, tetrahydroiso-α-acids), efficient absorption was evident for all 
compounds, but lower transport rates were determined for dihydroiso-α-acids, due to 
influences by phase-II metabolism.  
Chapter 4 describes the in vivo evaluation of various hop acids and derivatives (α-
acids (AA) and β-acids (BA), iso-α-acids (IAA), dihydroiso-α-acids (DHIAA), tetrahydroiso-α-
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acids (THIAA)) in rabbits (oral vs intravenous administration). The most important 
pharmacokinetic parameters (Cmax, tmax, half life, clearance, AUC0-∞) and the absolute 
bioavailabilities were determined for each class of hop acid. After oral and i.v. dosing to New 
Zealand white rabbits, the absolute bioavailability for IAA was determined to be 13.0%. The 
AA and reduced derivatives reached higher bioavailabilities with 25.6% for AA, 28.0% for 
DHIAA and 23.0% for THIAA. The area-under-curve AUC0-∞ upon oral gavage for DHIAA 
and THIAA was 70.7 ± 48.4 µg h ml-1 and 57.4 ± 9.0 mg h ml-1, respectively, while that for 
AA and IAA was 18.2 ± 9.0 and 10.6 ± 5.3 mg h ml-1, respectively. Gastrointestinal instability 
and/or metabolism were indicated as the main factors limiting the bioavailabilities of IAA. The 
bioavailability of DHIAA is mostly influenced by phase-II metabolism as shown by enzymatic 
hydrolysis of plasma samples upon administration of DHIAA. As a final part of the 
investigations, a second part of Chapter 4 highlights metabolism of α- acids, β-acids, and 
iso-α-acids. Iso-α-acids and α- and β-acids were incubated with microsomes, isolated from 
New Zealand (NZ) white rabbits, and fractions were subjected to LC-MS/MS analysis for 
identification of oxidative biotransformation products of α-acids, β-acids, and iso-α-acids. 
The metabolism of β-acids was characterized by conversion into hulupones, as well as by 
formation of a series of tricyclic degradation products, named dihydrotricyclolupulones, 
hydroxytricyclolupulones, and hydroperoxytricyclolupulones. The most important metabolites 
of α-acids were identified as humulinones and hulupones. Iso-α-acids, were found to be 
mainly metabolized into cis- and trans-humulinic acids, in addition to hydroperoxy and 
hydroxylated alloiso-α-acids. Interestingly, phase-I metabolites were highly analogous to 
oxidative degradation products in beer. 
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Samenvatting 
 
In vergelijking met het groeiend aantal publicaties over de gunstige effecten van 
hopzuren op de gezondheid is zeer weinig bekend over hun absorptie, distributie, 
metabolisme en eliminatie (ADME), die belangrijke aspecten bij de beoordeling van de 
effecten van deze verbindingen voor zowel preventief als therapeutisch gebruik.  
Een inleiding over hopbitterzuren en hun situering wordt beschreven in Hoofdstuk 1. 
Na een overzicht van de geschiedenis, de chemie en de analysemethoden van hop-
afgeleide verbindingen en bier, volgt een weergave van de bekende gegevens over de bio-
activiteiten, en toxiciteit van deze verbindingen. In Hoofdstuk 2 wordt een overzicht gegeven 
van de huidige - tot nu toe beperkte - kennis op het vlak van biologische beschikbaarheid 
van hopbitterzuren, gevolgd door de beschrijving van de verschillende doelstellingen van dit 
onderzoek. 
In een eerste benadering van de biologische beschikbaarheid werd de in vitro 
intestinale absorptie van hopbitterzuren bestudeerd aan de hand van Caco-2 celculturen 
(een veelgebruikt screeningmiddel voor de voorspelling van intestinale absorptie). In 
Hoofdstuk 3 wordt een inleiding gegeven over Caco-2 cellen, hun eigenschappen en hun 
gebruik voor het bestuderen van intestinaal transport, gevolgd door de studie die werd 
uitgevoerd om de absorptie van α-zuren, β-zuren, iso-α-zuren en derivaten te bepalen. De 
resultaten toonden aan dat de α-zuren efficiënt worden geabsorbeerd, terwijl de 
permeabiliteit van β-zuren laag is. De beperkende factoren in de absorptie van β-zuren 
houden verband met actief transport door P-gp- en MRP-2-type efflux pompen. Ook kunnen 
fase-II metabolische reacties bijdragen aan de verminderde permeabiliteit van β-zuren in 
vergelijking met α-zuren. In de vergelijkende Caco-2 studie met iso-α-zuren en derivaten 
(dihydroiso-α-zuren, tetrahydroiso-α-zuren) bleek efficiënte absorptie op te treden voor alle 
verbindingen, maar lagere transportsnelheden werden gevonden voor dihydro-iso-α-zuren, 
gezien hun transport beïnvloed weerd door fase-II metabolisme. 
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Hoofdstuk 4 beschrijft de in vivo evaluatie van verschillende hopzuren en derivaten 
(α-zuren (AA) en β-zuren (BA), iso-α-zuren (IAA), dihydro-iso-α-zuren (DHIAA), tetrahydro-
iso-α-zuren (THIAA)) bij konijnen (orale versus intraveneuze toediening). De belangrijkste 
farmacokinetische parameters (Cmax, tmax, half life, klaring, AUC0-∞) en de absolute 
biologische beschikbaarheden werden bepaald voor elke klasse hopzuur. Na orale en 
intraveneuze toediening aan konijnen werd een absolute biologische beschikbaarheid voor 
iso-α-zuren (IAA) van 13.0% bepaald. De α-zuren, dihydro- en tetrahydro-derivaten 
bereikten een hogere biologische beschikbaarheid van 25.6% voor AA, 28.0% voor DHIAA 
en 23.0% voor THIAA. Het oppervlak-onder-de-curve AUC0-∞ na orale toediening voor 
DHIAA en THIAA was 70.7 ± 48.4 µg h ml-1 en 57.4 ± 9.0 mg h ml-1, terwijl voor AA en IAA 
waarden van, respectievelijk, 18.2 ± 9.0 en 10.6 ± 5.3 mg h ml-1 bepaald werden. 
Gastrolintestinale instabiliteit en/of metabolisme werden aangegeven als de belangrijkste 
factoren die de biologische beschikbaarheid van IAA beperkt. De biologische 
beschikbaarheid van DHIAA wordt vooral beïnvloed door fase-II metabolisme zoals 
aangetoond door enzymatische hydrolyse van plasmastalen bij toediening van DHIAA. Het 
tweede deel van Hoofdstuk 4 stelt een laatste deel van het onderzoek voor, waarin 
metabolisme van α-zuren, β-zuren en iso-α-zuren werd bestudeerd. Iso-α-zuren en α-zuren 
en β-zuren werden geïncubeerd met microsomen, geïsoleerd uit witte Nieuw-Zeeland (NZ) 
konijnen en stalen werden onderworpen aan LC-MS/MS analyse voor de identificatie van 
oxidatieve biotransformatieproducten van α-zuren, β-zuren en iso-α-zuren. Het metabolisme 
van β-zuren werd gekenmerkt door omzetting tot huluponen, evenals door vorming van een 
reeks van tricyclische afbraakproducten, genaamd dihydrotricyclolupulonen, 
hydroxytricyclolupulonen en hydroperoxytricyclolupulonen. De belangrijkste metabolieten 
van α-zuren werden geïdentificeerd als humulinonen en huluponen. Iso-α-zuren bleken 
voornamelijk te worden gemetaboliseerd tot cis- en trans-humulinezuren, naast hydroperoxy 
en gehydroxyleerde allo-iso-α-zuren. Het is interessant te vermelden dat de fase-I 
metabolieten overeenkomsten vertonen met oxidatieve afbraakproducten in bier. 
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